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ABSTRACT
The worldwide prevalence of type 2 diabetes mellitus has reached epidemic proportions. 
The so-called traditional risk factors cannot fully explain the excessive cardiovascular 
disease (CVD) risk of type 2 diabetic patients. Numerous studies indicate that postprandial 
metabolic derangements, most notably hyperglycemia and hypertriglyceridemia, which 
are exaggerated and prolonged in type 2 diabetes, are important CVD risk factors since 
they induce oxidative stress and endothelial dysfunctions. Here we review the current 
evidence showing that postprandial dysmetabolism may indeed constitute an important 
CVD risk factor as well as the mechanisms underlying this association. Finally, some 
possible therapeutic options and recommendations for future research are discussed.
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INTRODUCTION 
The worldwide prevalence of type 2 diabetes mellitus is growing rapidly, reaching epidemic 
proportions.1 One of the major reasons of the increased prevalence in developing countries, 
is the adoption of the so-called Western lifestyle, i.e. a high intake of energy dense food and 
a low physical activity pattern. These life-style changes lead to one of the key abnormalities 
underlying type 2 diabetes mellitus, i.e. insulin resistance. Insulin resistance is associated 
with central obesity, hyperinsulinemia, polycystic ovary syndrome, hypertension and 
dyslipidemia.2,3 Hyperglycemia, the established diagnostic marker of diabetes mellitus, is 
the result of the second key feature, progressive pancreatic beta-cell failure. 
It is well recognized that type 2 diabetic patients have an excess risk of developing athe-
rosclerosis, resulting in high cardiovascular disease (CVD) morbidity and mortality.4 
Therefore, with the rise of the prevalence of diabetes, it may be expected that the global 
burden of CVD will also increase. Since the so-called traditional risk factors, such 
as high cholesterol, hypertension, smoking, and low HDL-cholesterol, cannot fully 
explain the excessive CVD risk of type 2 diabetic patients, other risk factors need to be 
identified.5 
Two important processes involved in the development of atherosclerosis, the underlying 
cause of CVD, are inflammation and coagulation activation.6 Although the exact 
mechanisms underlying atherogenesis are still not completely understood, vascular 
endothelial dysfunction is generally believed to be the starting point.6,7 Under normal 
conditions, the multiple functional characteristics of the endothelium, including 
regulation of the vascular tone, thrombogenesis, vascular wall permeability, and cell 
growth, collectively protect the vascular system.7 Adequate production of nitric oxide 
(NO) plays a pivotal role in the majority of these processes. Since endothelial functions 
cannot be measured directly, several indirect methods have been developed to estimate 
these functions. These include the assessment of plasma concentrations of endothelial-
cell derived proteins, including Van Willebrand factor (vWF) and vascular cell adhesion 
molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1),7 as well as the 
more complicated measurement of NO-dependent vasodilatation or flow-mediated 
dilatation (FMD) of the brachial artery by non-invasive ultrasound.8  Increased plasma 
concentrations of vWF, VCAM-1 and ICAM-1, and a decreased FMD have been associated 
with an increased risk of CVD.7,8 
Other CVD risk factors which have been recognized recently include hyperhomocystei-
nemia, elevated plasma levels of C-reactive protein (CRP), reflecting a low-grade inflam-
matory state, fibrinogen, representing a hypercoagulable state, and oxidized-low density 
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lipoprotein (ox-LDL), as an indicator of oxidative stress.9,10 However, only recently, the 
excessive and prolonged metabolic disturbances occurring in the postprandial state in type 
2 diabetic subjects, have regained interest as potential CVD risk factors.11
Already over 200 years ago, William Heberden made the first observation regarding a 
postprandial effect on the circulation of blood,12 and in the late seventies of the previous 
century, Zilversmit postulated that atherosclerosis is a postprandial phenomenon.13 Ever 
since, a large body of evidence has accumulated indicating a relation between postprandial 
dysmetabolism, especially hyperglycemia and hypertriglyceridemia, and the risk of 
CVD.11,14-17 
In this review we will briefly discuss the present evidence for postprandial dysmetabolism 
as a potential CVD risk factor, with special emphasis on postprandial glucose and lipid 
dysmetabolism. To this purpose, the association of postprandial dysmetabolism with the 
presence of (indicators of) atherosclerotic vascular disease and the possible underlying 
mechanisms will be reviewed.
Postprandial hyperglycemia
Various mechanisms keep the plasma glucose levels in healthy subjects between strict 
limits, even after a carbohydrate load. The insulin response following a meal regulates the 
glucose uptake from the blood into the peripheral tissues and inhibits gluconeogenesis and 
glycogenolysis in the liver. Beta-cell dysfunction (e.g. loss of the normal insulin secretion 
pattern) and insulin resistance contribute to glucose intolerance and both can be found 
very early in the disease process, finally leading to type 2 diabetes.2
In the United Kingdom Prospective Diabetes Study (UKPDS), lowering of glycated 
hemoglobin (HbA1c) mainly reduced long term microvascular complications of diabetes, 
whereas effects on macrovascular disease were less convincing.18 In apparent contrast, 
several epidemiological studies have shown an association between 2-hour glucose 
concentrations following a 75 g glucose load (2hPG) and the occurrence of CVD in 
the general population.19,20 A meta-analysis of 20 studies with more than 95 000 people 
demonstrated a continuous relationship between postload glucose levels and CVD risk 
extending into the non-diabetic range.19 The DECODE study demonstrated that the 2hPG 
concentrations, even in subjects with normal fasting glucose, was associated with mortality, 
independent of fasting plasma glucose concentrations.20 
Chronic hyperglycemia has been associated with impaired endothelial function.21 Recent 
studies in healthy and type 2 diabetic subjects indicate that acute hyperglycemia causes 
endothelial dysfunction as measured by FMD.22 Also, circulating ICAM-1 plasma levels 
13
Postprandial dysm
etabolism
 and CVD
 in type 2 diabetes
Chapter 1a
1a
significantly increased in both diabetic and normal subjects after an oral glucose tolerance 
test, suggesting endothelial cell activation.23
Ceriello and co-workers have shown that postprandial hyperglycemia is accompanied by 
several alterations of the coagulation system.24,25 An oral glucose load in both healthy and 
type 2 diabetes patients caused a shortening of the half-life of fibrinogen and an increase 
in plasma fibrinopeptide A and the fragments of prothrombin and factor VII. In addition, 
acute, short-term hyperglycemia resulted in a transient hyper-reactivity of platelets to 
high shear stress, combined with a significant rise of plasma vWF in patients with type 
2 diabetes.26 Taken together, these findings suggest that hyperglycemia may induce a 
hypercoagulable state.
In healthy and impaired glucose tolerance (IGT) subjects, consecutive pulses of intravenous 
glucose increased circulating cytokine concentrations (interleukin 6 (IL-6) and tumor 
necrosis factor α (TNFα)) to a greater extent than during similar blood glucose levels 
which were kept stable during a hyperglycemic clamp. This effect was more pronounced 
in subjects with IGT.27 The same investigators showed changes in IL-6 (but not TNFα) 
plasma concentrations in type 2 diabetic patients after a carbohydrate meal.28 Thus, blood 
glucose excursions may induce a pro-inflammatory response.
Numerous in vitro studies demonstrated cytotoxic effects of high glucose levels in various 
cell types.29-31 Of interest is the demonstration by Risso and colleagues that intermittent 
high glucose levels induced more apoptosis than constant corresponding glucose levels 
in human umbilical vein endothelial cells.30 
Four main molecular mechanisms underlying the hyperglycemia-induced vascular damage 
have recently been reviewed,31 all of which are the result of intracellular hyperglycemia. 
These include increased polyol pathway influx; increased advanced glycation end-product 
(AGE) formation; activation of protein kinase C (PKC) isoforms; and increased hexosamine 
pathway flux. These seemingly different mechanisms are the result of a single process, 
i.e. overproduction of superoxide by the mitochondrial electron-transport chain. This 
hyperglycemia-induced oxidative stress ultimately results in modification of intracellular 
proteins resulting in an altered function, DNA damage, activation of the transcription 
factor NF-κΒ, causing abnormal changes in gene expression, decreased production of 
NO, and increased expression of cytokines, growth factors and pro-coagulant and pro-
inflammatory molecules.31 
Taken together, postload or postprandial glucose levels are associated with enhanced 
risk of CVD. However, most epidemiological studies addressing the contribution of 
postload glucose levels to CVD risk, especially the early ones, did not take into account 
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the earlier mentioned classical risk factors, such as dyslipidemia. In studies investigating 
the relationship between postload glucose and CVD risk, adjustment for blood pressure, 
lipids and smoking, resulted in considerable attenuation of this association.32,33 These data 
indicate that postload glucose may not be an independent CVD risk factor but rather a risk 
marker, suggestive of underlying other metabolic disturbances, such as insulin resistance 
and dyslipidemia, that may have an even greater impact on CVD risk. 
In conclusion, evidence of postprandial hyperglycemia as an independent risk factor is 
not convincing. Therefore, the observed association between postload glucose excursions 
with CVD is at least partly explained by the presence of insulin resistance and related 
CVD risk factors. 
Postprandial hypertriglyceridemia
In the Western diet, more than 40 percent of the energy intake is derived from fats. Figure 
1a.1 demonstrates a schematic representation of the metabolic pathways of dietary fats 
leading to triglyceride-rich lipoproteins (TRL) and endogenous TRL production.34 In the 
insulin-resistant state the production of very-low density lipoprotein (VLDL) by the liver 
is inappropriately high. Together with a reduced lipoprotein lipase (LPL) activity this 
results, in high triglyceride (TG) concentrations, especially in the postprandial state. The 
large amount of TRLs and their prolonged residence time in the circulation may lead to 
increased exchange of the core lipid cholesteryl ester for TG between TRL and LDL and 
HDL particles mediated by cholesteryl-ester transfer protein (CETP). This process enriches 
LDL and HDL with TG, and these particles are subsequently more readily hydrolyzed by 
hepatic lipase resulting in smaller, denser LDL particles and lower concentrations of HDL. 
These abnormalities may explain the characteristic diabetic dyslipidemia, which is now 
recognized to be very atherogenic.34
Already in 1959 an association between plasma TG concentrations and incident coronary 
heart disease was reported.35 However, the known inverse association between TG and 
HDL cholesterol makes it difficult to show an independent association between plasma 
TG and atherosclerotic vascular disease. A recently performed meta-analysis including 
data of 57 000 subjects from 17 studies demonstrated that fasting TG concentrations 
were an independent risk factor for CVD, also when adjusted for HDL cholesterol.36 A 1 
mmol/l increase in plasma TG was associated with a relative risk of 1.3 for men and 1.8 for 
women.
In general practice, serum lipid concentrations including TG are measured in the mor-
ning after an overnight fast. However, the fasting value should be considered the nadir 
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Figure 1a.1 Lipid metabolism in vivo. Dietary fatty acids (FA) are absorbed from the gut and 
converted to triglycerides (TG) to be incorporated into chylomicrons in the intestinal epithelial cells. 
The TG-rich apoB48 containing chylomicrons enter the plasma via the intestinal lymph. Lipoprotein 
lipase (LPL) hydrolyses the TG in chylomicrons to FA, which are taken up by muscle cells for oxidation 
or adipocytes for storage. The remaining particles, the chylomicron remnants, are removed from the 
circulation by the liver through binding of their surface apo E to the LDL receptor or LDL-receptor-
related protein. Very low density lipoprotein (VLDL) particles are TG-rich apo B100 containing particles, 
synthesized by the liver. As with chylomicrons, VLDL TG are hydrolyzed by LPL. VLDL-remnants or 
intermediate-density lipoproteins (IDL) are taken up by liver receptors via apoE or converted to 
low-density lipoproteins (LDL). Chylomicrons, VLDL and their respective remnants (RLP, remnant 
lipoproteins) are termed TG-rich lipoproteins (TRL). Under physiological conditions, insulin, which 
is elevated in the postprandial state, suppresses lipolysis from adipose tissue and hepatic VLDL 
production, however, this insulin action is inappropriate in insulin-resistance and type 2 diabetes, 
resulting in high TRL concentrations. The large amount of TRL and their prolonged residence time in 
the circulation increase the exchange of esterified cholesterol from HDL and LDL to TRL and of TG to 
LDL and HDL particles, which is mediated by cholesterol-ester transfer protein (CETP). TG-enrichment 
of LDL particles renders them better substrates for hepatic lipase (HL), which hydrolyses TG from the 
core of LDL and turns them into smaller and denser particles. Small dense LDL are more atherogenic 
as they readily enter the subendothelial space and become oxidized (ox-LDL). TG-enriched HDL 
particles are smaller and are more rapidly catabolized, which may explain the observed low plasma 
HDL in insulin resistance and type 2 diabetes.36
Postprandial dysmetabolism and CVD in type 2 diabetesChapter 1a
16
of the 24-h TG profile and could therefore be misleadingly low. In the past few years 
several clinical studies have suggested that high postprandial TRL may be related to 
coronary heart and/or carotid artery disease in non-diabetic and diabetic subjects.37-39 
The Physician Health study, including 14 916 men aged 40 to 84 years, with a follow up 
of 7 years, showed that the non-fasting TG concentrations strongly predicted incident 
myocardial infarctions, with a RR of 1.40 (95% CI, 1.10-1.77) per 1.13 mmol/L increase.38 
This study suggests that random or postprandial TG concentrations, are an important 
indicator of CVD risk. Although fasting TG levels are the most important determinant of 
postprandial TG levels,40 it may be argued that in insulin resistant subjects with a delayed 
postprandial TRL clearance, non-fasting TG should be used to approximate overall TG 
exposure.
In male patients following a myocardial infarction, Karpe and co-workers found that 
the progression of coronary lesions over 5 years was related to the postprandial plasma 
levels of small chylomicron remnants (Sf 20-60 apolipoprotein B-48).41 Adjustment for 
the possible confounding effect of HDL and dense LDL apolipoprotein B concentrations 
did not substantially alter the strength of this association. In line with these findings are 
coronary angiography data described by Mero et al., which suggest that especially small 
chylomicron remnants are implicated in the progression of coronary artery disease.16 
In healthy and type 2 diabetic subjects, endothelial dysfunction, measured by ultrasound as 
FMD, has been associated with high TG excursions.42,43 Correlations between postprandial 
TRL, impaired FMD and oxidative stress markers have been demonstrated, suggesting 
that free radical production may be an underlying mechanism.42,43 Supportive of this 
hypothesis is the finding that in healthy subjects this effect could be attenuated by the 
antioxidant vitamin C.43
In vitro studies demonstrated increased adhesion molecule expression in endothelial cells 
after incubating with chylomicrons and VLDL.44,45 Using rat arterial rings, Lundman et 
al, showed impairment of endothelium-dependent relaxation following exposure to the 
TG-containing fat emulsion Intralipid, however, exposure to VLDL did not affect vascular 
function.45
Postprandial coagulation activation by TRL was demonstrated by several investigators, 
however the underlying mechanism(s) are not fully understood.46,47 An elegant study 
performed by Silveira et al. suggests an important role for the intrinsic coagulation pathway, 
based on in vivo activation of factor XI by TG.46 Other prothrombotic changes occurring 
with an oral fat load are increased PAI-1 activity and PAI-1 antigen.48 Postprandial lipemia 
enhanced platelet P-selectin expression without affecting other markers of platelet activation.49 
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The effect of a high fat meal (50 g of fat) on cytokine concentrations, reflecting the 
inflammatory state, was studied in healthy and type 2 diabetic patients.28 In healthy 
subjects, significant correlations were found between postprandial TG and TNFα levels, 
whereas in diabetic patients also a positive correlation between postprandial plasma 
TG and IL-6 concentrations was observed. Anti-oxidant supplementation lowered the 
rise of the cytokines, suggesting that the cytokine response to TG was mediated by 
oxidative stress. 
To summarize, historically, in diabetic patients, most emphasis was laid on hyperglycemia, 
whereas recent evidence demonstrate the importance of dyslipidemia, in particular 
hypertriglyceridemia, as a CVD risk factor. Although at present, epidemiological and 
long-term intervention studies are largely lacking, in vivo data convincingly show an 
association between postprandial TRL and indicators of CVD. Similar to postprandial 
hyperglycemia, both in vivo and in vitro studies indicate that (postprandial) TG elevations 
are proinflammatory, prothrombotic, and adversely affect several endothelial functions, 
by inducing oxidative stress (Figure 1a.2). Therefore, it is feasible, that prolonged 
postprandial hypertriglyceridemia leads to an atherogenic environment in vivo. However, 
as for postprandial hyperglycemia the evidence for postprandial hypertriglyceridemia as 
independent in cardiovascular disease is still scanty. More evidence, which can only be 
obtained from large prospective studies, is certainly required. 
Therapeutical interventions
Drugs that have been effective in reducing meal-related glucose excursions are the 
α-glucosidase inhibitors, the short acting insulin analogues and the meglitinides.50-52 
Recently, the STOP-NIDDM study showed a lower incidence of hypertension and 
myocardial infarction after treatment with the α-glucosidase inhibitor acarbose.53 These 
findings should be interpreted with some caution as the study was not designed to assess 
the effect of acarbose on CVD end-points. The prospectively predefined end-point was 
conversion to diabetes, however, in the final report ten different CVD end-points were 
mentioned, including angina and peripheral vascular disease. In addition, it can not be 
excluded that the reduction in CVD end-points is the result of lowering TG, since a TG 
lowering effect of acarbose is described.54 
Metformin is the only blood glucose-lowering drug that has been shown to lower diabetes-
related and CVD endpoints in obese type 2 diabetic patients. Based on the proposed 
working mechanism,55 an effect on meal-related glucose excursions can not be expected, 
but metformin was shown to reduce postprandial chylomicron concentrations.56 
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Correction of postprandial hyperglycemia, for example with insulin secretion enhancers, 
will not only affect glucose levels but probably also the postprandial lipid responses. 
However, recently the group of Taskinen demonstrated that nateglinide and glibenclamide 
increased postprandial insulin secretion and decreased postprandial glycemia, but neither 
drug attenuated postprandial lipemia in type 2 diabetic subjects with good glycemic 
control.57
Intensive insulin treatment may improve diabetic dyslipidemia to some extent, however, 
an entire correction of the atherogenic lipid profile, including postprandial hypertrigly-
ceridemia, may not be achieved.58 
Figure 1a.2 Insulin resistant states and type 2 diabetes are characterized by high circulating levels of 
atherogenic lipid particles due to an increased supply of fatty acids to the liver and defective hepatic 
clearance of lipoproteins. In the postprandial state, the lipid abnormalities are further exaggerated, 
with an additional adverse effect of meal-induced hyperglycaemia. These postprandial metabolic 
derangements increase the production of reactive oxygen species causing oxidative stress and 
functional abnormalities of the vascular endothelium at several levels, including impairment of 
vasoreactivity, increased coagulation and inflammation activation and increased vascular permeability. 
Collectively, postprandial dysmetabolism and the associated oxidative stress may link insulin resistance 
and type 2 diabetes to the disproportional incidence of CVD in these high-risk populations. 
Central obesity, insulin resistance, type 2 diabetes
(Postprandial) dysmetabolism
- hyperglycaemia
- hyperlipidaemia
Coagulation activation
Inflammation activation
Endothelial dysfunctions
Cardiovascular disease
Oxidative stress
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The lipid lowering drugs, i.e. hydroxymethylglutarylco-enzyme A (HMG-CoA) reductase 
inhibitors (statins), and peroxisome proliferator-activated receptor (PPAR) alpha agonists 
(fibrates), are established as most efficient agents that reduce CVD morbidity and mortality 
in various high-risk populations.59,60 Statins inhibit cholesterol synthesis and up-regulate 
the hepatic LDL receptor whereas fibrates increase LPL activity and limit hepatic VLDL 
secretion. Based on their respective working mechanisms, the most benefit on postprandial 
lipidemia may be expected from fibrates. Indeed, fibrate treatment reduced postprandial TG 
levels by 30-50%.61 The proposed beneficial effect of fibrates on postprandial endothelial 
function measured by FMD, however, is disappointing.61,62 Statins tend to induce a modest 
lowering of both fasting and postprandial TG.61,63 However, statin treatment showed a 
marked beneficial effect on postprandial induced oxidative stress and endothelial function.63 
Independently of their cholesterol-lowering action, statins seem to have anti-inflammatory 
and vasculoprotective effects (‘pleiotropic’ effects).64
We conclude that the high CVD morbidity and mortality associated with type 2 diabetes 
is at least partly due to a prolonged and exaggerated postprandial state in these patients. 
To date, however, controlled randomized intervention studies, showing that postprandial 
glucose- and TG lowering results in amelioration of clinically relevant endpoints are 
lacking. 
These conclusions should in no way distract from the therapeutic aim to achieve target 
HbA1c and lipid values in patients with type 2 diabetes.
Recommendations for future research and testing postload dysmetabolism
As discussed above, although the beneficial effect of therapy targeting postprandial 
dysmetabolism still needs to be established, studies assessing the true atherogenic exposure 
of the vascular system in high-risk patients should abandon the classical glucose-centered 
view and use physiological tests combining glucose and lipid loads. Most earlier-mentioned 
studies demonstrated the effects of postprandial dysmetabolism on a single and rather 
artificial challenge, like a liquid 75 g glucose or liquid fat load. In daily life, most meals 
consumed are mixed and of solid consistence. Ceriello and co-workers showed a cumulative 
adverse effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial 
function.63 The effect of a single component challenge possibly underestimates the real-
life postprandial dysmetabolic state and we therefore recommend the use of standardized 
mixed-meal containing of at least 75 g of carbohydrates and 50 g of fat in future postprandial 
(intervention) studies. 
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ABBREVIATIONS
2hPG: 2-hour glucose concentrations following a 75 g glucose load; AGE: Advanced 
glycation end-product; CETP: Cholesteryl-ester transfer protein; CRP: C- reactive protein; 
CVD: Cardiovascular disease; DECODE: Diabetes Epidemiology : Collaborative analysis 
Of Diagnostic criteria in Europe; FMD: Flow mediated dilatation; HbA1c: glycated 
hemoglobin; HDL: High density lipoprotein; HMG-CoA: Hydroxymethylglutarylco-
enzyme A; ICAM-1: intercellular adhesion molecule-1; IGT: Impaired glucose tolerance; 
IL-6: Interleukin-6; LPL: lipoprotein lipase; NF-κΒ: Nuclear factor-κΒ; NO: Nitric oxide; 
ox-LDL: Oxidized-low density lipoprotein; PAI-1: Plasmin activator inhibitor-1; PKC: 
Protein kinase C; PPAR: Peroxisome proliferator-activated receptor; TG: Triglyceride; 
TNFα: Tumor necrosis factor α; TRL: Triglyceride rich lipoprotein; UKPDS: United 
Kingdom Prospective Diabetes Study VCAM-1: Vascular cellular adhesion molecule-1; 
VLDL: Very low density lipoprotein; vWF: Van Willebrand factor.
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ABSTRACT
Microparticles are small membrane vesicles that are released from cells upon activation 
or during apoptosis. Cellular microparticles in body fluids constitute a heterogeneous 
population, differing in cellular origin, numbers, size, antigenic composition and 
functional properties. Microparticles support coagulation by exposure of negatively 
charged phospholipids and sometimes tissue factor, the initiator of coagulation in 
vivo. Microparticles may transfer bioactive molecules to other cells or microparticles, 
thereby stimulating cells to produce cytokines, cell adhesion molecules, growth factors 
and tissue factor, and modulate endothelial functions. Microparticles derived from 
various cells, most notably platelets but also leukocytes, lymphocytes, erythrocytes 
and endothelial cells, are present in the circulation of healthy subjects. Rare hereditary 
syndromes with disturbances in membrane vesiculation leading to decreased numbers 
of microparticles clinically present with a bleeding tendency. In contrast, elevated 
numbers of microparticles are encountered in patients with a great variety of diseases 
with vascular involvement and hypercoagulability, including disseminated intravascular 
coagulation, acute coronary syndromes, peripheral arterial disease, diabetes mellitus 
and systemic inflammatory disease. Finally, microparticles are a major component of 
human atherosclerotic plaques. 
In view of their functional properties, cell-derived microparticles may be an important 
intermediate in the cascade of cellular and plasmatic dysfunctions underlying the 
process of atherogenesis.
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INTRODUCTION 
Already in the 1940s it was known that human plasma and serum contained a subcellular 
factor that facilitated fibrin formation.1,2 It was not until 1967 when, using electron 
microscopic techniques, Wolf demonstrated that this subcellular factor consisted of small 
vesicles (“microparticles”), which were called “platelet dust”. These microparticles, showed 
procoagulant activity, comparable to that of intact platelets.3 Their procoagulant activity 
was designated as platelet factor 3 (PF3).4 Subsequently, it was shown that (platelet-derived) 
microparticles (PMP) were formed during the attachment of platelets to the vascular wall 
in vitro.5 In recent years, the interest for microparticles has substantially increased, not 
only because of their procoagulant properties but also because of their putative role in 
inflammatory processes and their ability to directly affect endothelial functions.6-9 Their 
suspected involvement in clinical disease was demonstrated for the first time in patients 
with idiopathic thrombocytopenic purpura (ITP).10 
The majority of in vivo microparticles in blood is derived from platelets,11 whereas 
microparticles from erythrocytes, granulocytes, monocytes, lymphocytes and endothelial 
cells usually circulate at lower numbers. Interestingly, significant differences exist between 
microparticle fractions or subpopulations found in the circulation of healthy subjects12,13 
and those found in patients suffering from various diseases with increased thromboembolic 
risk or vascular damage, such as atherosclerotic vascular disease, sepsis, diabetes mellitus, 
severe hypertension and end-stage renal failure.14-22 Also, microparticles constitute an 
important component of the human atherosclerotic plaque.23 
To summarize, microparticles are closely associated with the presence and the possible 
development of atherosclerotic and inflammatory vascular damage. In this review, we 
describe the structure, detection, pathogenesis and characteristics of microparticles. 
Finally, the possible clinical relevance of microparticles will be discussed in the context 
of various diseases.
Characterisation of microparticles: size and composition
Platelet activation plays a key role in the development of arterial thrombosis resulting in 
major clinical syndromes, such as acute myocardial infarction. During platelets activation, 
vesiculation of parts of the plasma membrane occurs leading to the formation of PMP, the 
size of which typically ranges from 0.1 to 1.0 μm. Platelets and other cells are surrounded by 
a plasma membrane that consists of a phospholipid bilayer, including phosphatidylserine 
(PS), phosphatidylethanolamine (PE), phosphatidylcholine (PC) en sphingomyeline 
(SM). In unstimulated cells, the distribution of these phospholipids within the bilayer is 
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asymmetrical. The neutral (uncharged) phospholipids PC and SM are primarily located 
in the outer (exoplasmic) membrane leaflet, while the negatively charged PS and PE 
are present within the inner (cytoplasmic) leaflet. The asymmetrical distribution of 
phospholipids in the plasma membrane is actively maintained by various enzymes, such 
as the aminophospholipid-translocase or flippase.24 During cell activation or apoptosis, the 
asymmetrical distribution of these phospholipids disappears. As a consequence, negatively 
charged phospholipids such as PS and PE become (surface) exposed. The intracellular 
mechanisms underlying the release of microparticles are as yet not fully understood, but 
they seem to be associated – among others – with the inducing stimulus leading to the 
actual vesiculation. It is now becoming apparent, that the formation of microparticles is 
a highly regulated process: the phospholipid composition of PMP shows characteristics 
from intracellular rather than from plasma membrane fractions and recent studies in 
endothelial cells showed that constitutively exposed proteins from these cells are hardly 
transmitted to endothelial cell-derived microparticles.25,26
Microparticles expose various antigens, notably those also exposed by their “parent”cells, 
i.e. the cells from which they are released. For instance, PMP expose glycoproteins GPIb 
(CD42b), platelet-endothelium adhesion molecule-1 (PECAM-1; CD31) and the fibrinogen 
receptor, the integrin αIIbβ3 (GPIIb-IIIa). In addition, PMP can expose activation markers 
Figure 1b.1 The cellular origin, structure and functional properties of microparticles.
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such as P-selectin (CD62P). Similarly, microparticles from other cells can be characterized: 
examples are microparticles from erythrocytes that stain for glycophorine A, granulocytic 
microparticles for CD66, monocytic microparticles for CD14, lymphocytic microparticles 
for CD4 and CD8 and endothelial cell-derived microparticles for CD31, CD34, CD51 
(vitronectin), CD62E, and CD146 (MUC18, S-Endo-1).13,14,17-22,26 All these microparticles 
can also expose activation markers that are characteristic of their respective “parent”cell. 
Detection of microparticles
Flowcytometry
Microparticles can be detected by flow cytometry in blood samples or fractions there 
from, as well as in other body fluids such as synovial fluid.6,27 Using labelled antibodies 
against 1) cell-specific antigens and/or activation markers and 2) annexin V, a protein that 
binds specifically to negatively charged phospholipids in the presence of calcium ions, 
microparticle fractions or subpopulations can be quantified and concurrently their cellular 
origin as well as their “activation status” can be established. To correct for autofluorescence 
and binding of antibodies to Fc-receptors, microparticles are also stained with a (labelled) 
control antibody plus annexin V, but without calcium ions. Of each event detected by the 
flowcytometer, the size (forward scatter, FSC) and density (sidescatter, SSC) are determined 
electronically, as well as the fluorescence in various channels. Fluorescence reflects the 
amount of antibody bound and therefore is an estimate for the amount of antigen exposed 
on the membrane surface. Figure 1b.2 illustrates the visualization of PMP by flow cytometry.
Electron microscopy
Figure 1b.3 shows scanning electron microscopy images of unstimulated cultured human 
umbilical vein endothelial cells (HUVECS) and the formation of microparticles upon 
stimulation with interleukin-1α. The diameter of the vesicles released by stimulated 
HUVECS ranges from 0.1 to 1.0 μm.
Enzyme-linked immunosorbent assay (ELISA)
One of the most frequently used ELISAs to quantify cell-derived microparticles employs 
a plate coated with annexin V.7,28,29 Upon addition of a (plasma) sample, microparticles 
present within this sample will bind to annexin V. After washing, a cell-specific antibody 
can be added to quantify numbers of cell-specific microparticles. Alternatively, after 
washing the procoagulant activity of the (bound) microparticles can be determined using 
a prothrombinase assay. 
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Figure 1b.2 Use of flow cytometry for microparticle analysis. Flowcytometric analysis of whole 
blood by size (forward scatter, FSC) and density (side scatter, SSC) predominantly yields erythrocytes 
(visible in the upper right of panel A); Events staining positive for (labelled) antibody directed against 
platelet-antigen are platelets in R(egion) 2 (B), whereas R3 contains larger events such as complexes 
of platelets or platelet-derived microparticles, and R1 contains events smaller than platelets, the PMP. 
In cell-free plasma, microparticles can be analysed after additional centrifugation (C-H). In panel D, 
the microparticles are stained with an anti-GPIIIa (CD61) monoclonal antibody, as compared to a 
control antibody (C). Almost all events bind annexin V in the presence of calcium ions (F), but not in 
the absence of such ions (E). Double staining of microparticles with anti-CD61 plus annexin V in the 
presence of calcium ions allows visualization of PMP exposing negatively charged phospholipids (H). 
As a control, microparticles are stained with annexin V in the absence of calcium ions and control 
IgG1 antibody (G; control).
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Mechanisms of microparticle formation: activation and apoptosis
It is generally accepted that all eucaryotic cells release microparticles. Microparticle 
formation in vitro occurs whenever a stimulus is applied that induces either cell activation or 
apoptosis. To date, however, it is unclear whether the mechanisms underlying microparticle 
formation are identical during these two conditions are identical. 
Cell activation
Platelets can be activated by different agonists that bind to specific receptors on the 
platelet membrane. Thus, stimuli such as thrombin, collagen and adenosine diphosphate 
(ADP) activate specific transmembrane receptors that transmit signals into the cell. These 
signals induce changes in second messenger concentrations that in turn modulate cellular 
responses.6,7 Stimulation of platelets by these agents not only leads to platelet aggregation 
and secretion, but also results in membrane vesiculation and the release of microparticles. 
Alternatively, agents, such as calcium ionophores, trigger microparticle release by directly 
changing the intracellular concentrations of second messenger molecules. PMP are also 
formed during prolonged storage of platelets, or when platelets are exposed to high 
shear-stress conditions in vitro.5 The latter conditions resemble those occurring in vivo at 
stenoses of the vascular tree.
Although the molecular mechanisms underlying microparticle formation are as yet 
unresolved, the increase in intracellular levels of calcium ions, resulting in the activation of 
enzymes such as calpain, play an important role.6,7 Calpain degrades cytoskeletal proteins, 
and its inhibition partly prevents collagen- and thrombin-induced microparticle formation.30
Figure 1b.3 Scanning electron microscope images showing unstimulated cultured human umbilical 
vein endothelial cells (A) and the formation of microparticles after stimulation of the cells with 
interleukin-1α (B).
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Apoptosis
Programmed cell-death or apoptosis is associated with the abolition of the phospholipid 
asymmetry of the plasma membrane and condensation of the nucleus, followed by DNA 
fragmentation and the release of apoptotic blebs or microparticles.8 The intracellular enzyme 
family of caspases plays an important role in apoptosis.8 The irreversible step in which 
procaspase 3 (CPP32) is converted into the active caspase-3 is regarded as fundamental in 
the apoptotic process. Caspase-3 activates rho-associated kinase (ROCK I) resulting in the 
release of apoptotic membrane vesicles, which can also contain DNA fragments.31
Functional characteristics of microparticles
The most frequently described characteristic of both in vitro and in vivo microparticles is 
their procoagulant activity. Recent observations, however, also suggest their involvement 
in inflammatory processes,27 in the transfer of bioactive molecules to other cells and 
microparticles9 and the inhibition of endothelium-dependent vasodilatation.32,33 Not all 
the properties of cellular microparticles should necessarily be regarded as noxious: specific 
microparticle subpopulations may even prevent vascular damage. Thus, in vitro generated 
PMP were shown to enhance the activation of protein C, thus facilitating the inhibition of 
coagulation factors Va and VIIa and preventing thrombin formation.34 Other microparticle 
fractions were reported to induce cellular growth, chemotaxis, apoptosis and the outgrowth 
of transplanted haematopoetic stem cells.35,36
The various functional characteristics of in vitro generated microparticles as well as of 
those isolated from the circulation of various patient populations will be discussed (see 
also Table 1b.1).
Microparticles and coagulation
Coagulation activation plays an essential role in the development of atherothrombosis. 
Subjects with a high risk of cardiovascular disease show various degrees of hypercoagu-
lability. Coagulation activation requires plasmatic coagulation factors, calcium ions and a 
procoagulant membrane surface. An essential characteristic of such a suitable surface is the 
exposure of negatively charged phospholipids. As previously stated, the exposure of such 
phospholipids is one of the characteristics of microparticles. Coagulation factors bind – 
via their negative Gla-domains – to the negatively charged phospholipids in the presence 
of calcium ions, thus forming tenase- and prothrombinase-complexes. PMP expose more 
binding sites for factors Va, VIIIa, and IXa per unit of membrane surface area than activa-
ted platelets. Thus, at least in vitro, thrombin formation is supported more efficiently by 
microparticle membranes than by platelet membranes when corrected for unit surface area. 
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The procoagulant activity of microparticles can be quantified using the thrombin generation 
test.13,14 In this assay, the conversion over time of a specific chromogenic substrate by 
thrombin is measured photospectrometrically. In this system, microparticles supply the 
procoagulant surface and a possible initiator of coagulation, e.g. tissue factor, and plasma 
provides the necessary coagulation factors. By adding calcium ions, (activated) coagulation 
factors can bind to the (microparticle) membranes to initiate and / or facilitate coagulation. 
In this assay, the generation of thrombin is completely dependent on the presence of 
microparticles, and in their absence no coagulation occurs. 
Table 1b.1 Characteristics of in vitro and in vivo generated microparticles
Characteristics
In vitro generated platelet microparticles:
• stimulate CD11b expression on leukocytes, leukocyte-leukocyte interactions, phagocytosis 
• induce CD11a/CD18 and CD11b/CD18 on monocytes, resulting in monocyte adhesion to endothelial cells
• induce ICAM-1 exposure on endothelial cells, resulting in monocyte adhesion to endothelial cells
• stimulate COX2-expression in monocytes and endothelial cells
• stimulate thrombocyte aggregation, intracellulair calcium flux, inositol phosphate formation
• stimulate protein kinase C, mitogen-activated protein (MAP) kinases and stress (JNK) kinases
• transcellular transfer of arachidonic acid, resulting in amplification and modulation of platelet activation
• transfer of various cytokine- and chemokine-receptors to haematopoetic and malignant cells
• transfer of CXCR4-receptors for HIV-1 virus to cells
• enhance engraftment of transplanted bone marrow cells
• enhance APC-catalyzed inactivation of Factor Va
• co-localise plasminogen-activator inhibitor-1 and vitronectin
In vivo circulating platelet microparticles:
• initiate and propagate coagulation / enhance thrombin formation
• expose P-selectin
• expose tissue factor 
• transfer tissue factor to other cells and cell-derived microparticles
In vitro generated endothelial cell microparticles:
• induce monocyte adhesion to endothelial cells
• activate neutrophils 
• initiate and propagate coagulation / enhance thrombin formation 
• expose matrix metalloproteinases-2 and -9, induce matrix degradation and angiogenesis 
In vivo circulating endothelial cells microparticles:
• inhibit endothelium-dependent vasodilation
• initiate and propagate coagulation / enhance thrombin formation
• are associated with type 1 diabetic microalbuminuria
In vitro generated leukocyte microparticles:
• expose tissue factor, transfer tissue factor to platelets and their microparticles
• activate endothelial cells and stimulate the secretion of IL-6 via stress-associated signal routes (JNK1)
In vivo circulating leukocyte microparticles:
• are present in human atherosclerotic plaques, in close association with tissue factor 
• are associated with type 2 diabetic microvascular damage
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In vivo, coagulation is initiated by tissue factor, a transmembrane protein that binds 
factor VII(a) and catalyses its autoactivation. In turn, the tissue factor/factor VIIa 
complex directly activates factor X to factor Xa. Factor Xa, in the presence of its cofactor 
Va, forms the prothrombinase complex that converts factor II (prothrombin) into IIa 
(thrombin). Alternatively, the tissue factor/factor VIIa complex activates factor IX into 
factor IXa. Together with its cofactor, factor VIIIa, factor IXa forms the tenase complex 
that subsequently activates factor X into factor Xa. In this system, there is an important 
role for coagulation factor XI. Minute quantities of thrombin can activate factor XI into 
factor XIa. Subsequently, factor XIa activates factor IX into factor IXa, thereby enhancing 
the formation of thrombin. 
In vitro, microparticles can both initiate and propagate coagulation.21,37,38 However, the 
mechanisms by which in vivo microparticles support coagulation ex vivo were highly 
dependent on the clinical conditions. For instance, thrombin formation by microparticles 
from blood of a patient with meningococcal sepsis and diffuse intravascular coagulation 
(DIC) was completely inhibited by antibodies directed against either tissue factor or factor 
VII.17 These antibodies also completely inhibited thrombin generation by microparticles 
from human pericardial blood, i.e. blood that collects in the pericardial cavity during 
coronary artery bypass grafting (CABG).16 In contrast, neither of these antibodies inhibited 
thrombin generation initiated by microparticles obtained from healthy subjects. Thrombin 
generation by these microparticles as well as thrombin generation by microparticles from 
patients with sepsis and multiple organ failure was mediated by factor XI and in some 
patients also by factor XII.13,18 Only recently it was discovered that also tissue factor-
independent mechanisms are able to initiate coagulation. One example is the binding of 
factor X to the monocytic protein Mac-1 (CD11b/CD18) and the subsequent activation 
of factor X into factor Xa by catepsin G.39 Possibly, microparticles may also use similar 
tissue factor-independent, mechanisms to initiate coagulation.
An important question is whether microparticles are procoagulant in vivo. This 
issue is not easily resolved, but several lines of evidence suggest that microparticle-
mediated coagulation is indeed clinically relevant. Firstly, microparticles from various 
patient populations support coagulation in vitro.13,16-18 Secondly, the presence of highly 
procoagulant, tissue-factor exposing microparticles in certain disease conditions 
coincided with strongly elevated levels of in vivo coagulation activation markers, such 
as prothrombin fragment F1+2 and thrombin-antithrombin complexes. Examples are 
microparticles from a patient with fullminant DIC and meningococcal septic shock, 
microparticles from pericardial cavity blood during CABG, and microparticles from 
synovial fluid from patients with rheumatoid arthritis.16,17,27 Thirdly, numerous studies 
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demonstrated an association between elevated numbers of microparticles and the 
increased risk of thromboembolic complications.10,19,21,40 Fourthly, an increased bleeding 
tendency and decreased levels of circulating microparticles have been described in several 
rare syndromes.41-43 Finally, direct infusion of artificial phospholipid vesicles in baboons 
caused severe DIC,44 and systemic administration of microparticles in rats resulted in 
thrombus formation.45
Microparticles and inflammation
Like coagulation, inflammatory processes underlie the pathogenesis of atherothrombotic 
vascular disease.46 Elevated plasma levels of acute phase reactants and other markers 
of inflammation occur in various high-risk patient populations.14,38 Microparticles can 
directly activate and stimulate cells to produce inflammatory substances mediators 
such as cytokines.47-49 In addition, at least in vitro microparticles mediate intercellular 
interactions.49-51 Finally, subpopulations of microparticles isolated from human plasma 
expose C1q, C3 and C4, strongly suggesting their direct involvement in activation of the 
complement system.52 Currently, the relation between cellular microparticles and C-reactive 
protein (CRP) is studied. This acute phase protein is known to bind to membranes and, in 
the membrane-bound form, may activate the classical pathway of the complement system, 
ultimately leading to vascular damage. 
Tabel 1.1 lists the reported cell-microparticle and microparticle-microparticle inter-
actions. At present, however, there is no direct evidence that microparticles are involved 
in inflammatory disease in vivo. Although elevated levels of microparticle subpopulations 
are present in the circulation of patients with inflammatory disease, both of infectious 
and autoimmune origin, a causal relationship between microparticles and inflammatory 
processes cannot readily be established, because cytokines trigger cells, thereby 
stimulating the release of microparticles, whereas microparticles trigger cells to produce 
and release cytokines.47 Therefore, it is as yet unclear whether cellular microparticles 
are a cause or consequence of inflammatory processes and the associated vascular 
damage.
Microparticles and endothelial cell functions
In vitro microparticles adhere to endothelial cells and subsequently stimulate these cells 
to produce cell-specific adhesion cell molecules, cytokines and tissue factor.9 Also, in 
vivo microparticles were found to influence endothelial functions ex vivo: microparticles 
from patients with acute coronary syndromes directly impaired endothelium-dependent 
vasodilatation in rat aorta-rings, presumably by inhibition of the nitric oxide (NO)-
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mediated signal transduction.32 Also microparticles from women with preeclampsia 
impaired the endothelium-dependent vasodilatation.33 Several studies also suggest a 
relationship between circulating microparticles and endothelial function. Patients with 
complicated diabetes mellitus, who were treated with a platelet aggregation inhibitor, 
lowered the numbers of circulating PMP and decreased plasma concentrations of vascular 
cell adhesion molecule-1 (VCAM-1) and intercellular cell adhesion molecule-1 (ICAM-
1).38 Conversely, stimulation of endothelial cells in vitro by TNFα induced the formation 
of microparticles exposing adhesion cell molecules, including ICAM-1, E-selectin, 
vitronectin-3 and platelet-endothelial cell adhesion molecule-1 (PECAM-1). In patients 
with various systemic and autoimmune diseases elevated levels of microparticles originating 
from endothelial cells were found.53-55 
Microparticles and signal transduction, growth, angiogenesis and metastasis
Microparticles may expose adhesion cell molecules, specifically adhere to e.g. endothelial 
cells and stimulate these cells to produce various intermediates, such as E-selectin and 
tissue factor.35,49,56 The actual “communication” between microparticles and cells may 
occur through transfer of bioactive molecules such as arachidonic acid. Thus, PMP treated 
with secretory phospholipase A2, an acute phase reactant, had elevated (intravesicular) 
concentrations of arachidonic acid and these PMP were shown to activate endothelial cells 
by the transfer of this arachidonic acid.9,48
In patients with type 2 diabetes we previously described elevated numbers of microparticles 
from platelets, granulocytes and lymphocytes that exposed tissue factor.14 Both in vitro and 
in vivo studies demonstrated the presence of tissue factor-positive PMP subpopulations that 
concurrently expose antigens originating from granulocytes, monocytes or lymphocytes, 
suggesting a possible transfer of tissue factor by, as well as to these PMP.
PMP have the ability to transfer the CXCR4 receptor from CXCR4-positive to CXCR4-
negative cells.57 This receptor is mandatory for the HIV-1 virus to enter cells, suggesting 
a role for PMP in the dissemination of HIV-1 particles. Also, microparticles transfer 
cytokine- and chemokine receptors to haematopoetic, but also to malignant cells, 
by which mechanism these vesicles may modulate cellular activation, proliferation, 
survival, apoptosis and chemotaxis.58 Adherence of PMP to transplanted bone marrow 
cells stimulated their outgrowth, which may be regarded as a beneficial effect of the 
PMP. Conversely, in addition to activated platelets, PMP are involved in paraneoplastic 
thromboembolic complications and metastasis. Only recently, matrix metalloproteinases 
-2 and -9, enzymes that play a role in matrix degradation and angiogenesis, were detected 
in microparticles of endothelial origin.59
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Taken together, cellular microparticles may be carriers of antigens and receptors, including 
tissue factor, E-selectin and VCAM-1, all of which were previously regarded as “soluble” 
in plasma. Plasma concentrations of these substances are widely used as measures of 
endothelial dysfunction in human. By assessing the co-localization of these proteins 
with cell-specific antigens on microparticles and by measuring the plasma levels of these 
substances before and after centrifugation (i.e. after removal of the microparticle fraction), 
it becomes possible to determine the real cellular origin of these antigens, which currently 
are all ascribed to endothelial cells.
Clinical relevance of cellular microparticles
The last 5 years a growing number of publications appeared reporting elevated numbers 
of microparticle subpopulations in association with various disease states as well as studies 
investigating the composition and functional characteristics of microparticles. To date, 
however, it is unclear whether microparticles are a cause or merely a consequence of 
metabolic and vascular disease.
Platelet-derived microparticles (PMP)
The clinical relevance of PMP may be illustrated by the rare hereditary Scott syndrome, a 
disease characterized by a bleeding tendency and a decreased formation of PMP.41,60 The 
diminished formation of PMP is caused by a signal transduction defect that diminishes 
the transmembrane migration and exposure of PS. Castaman’s disease and Glanzmann’s 
thrombastenia are other rare syndromes, in which an increased bleeding tendency is 
associated with a decreased release of PMP.42,43 Low numbers of circulating microparticles 
were found in patients with sepsis and these showed an inverse correlation with markers 
of in vivo coagulation.18 Conversely, elevated numbers of PMP were found in patients 
suffering from diseases associated with an increased risk of thromboembolic processes 
and vascular damage, including ITP,10 acute coronary syndromes,15,19 acute cerebrovascular 
disease,40 heparin-induced thrombopenia (HIT),37 peripheral arterial disease,61 complicated 
diabetes mellitus,38 severe hypertension,20 end-stage renal disease,21 multiple sclerosis,54 and 
malignancy.58 In some studies, also the procoagulant activity of the in vivo microparticles, 
predominantly PMP, was demonstrated. In patients with uncomplicated type 2 diabetes 
mellitus, we found elevated numbers of tissue-factor-exposing PMP.14 Unexpectedly, this 
microparticle-associated tissue factor did not show procoagulant activity and therefore 
it was hypothesized that this tissue factor may play a role in other processes, such as 
angiogenesis, growth and signal transduction. 
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Endothelial-cell microparticles
Increased numbers of microparticles from endothelial cells were reported in patients 
with acute coronary syndromes, but also in those with severe hypertension, thrombotic 
thrombocytopenic purpura, systemic lupus erythematosus (SLE) and multiple sclerosis 
(Table 1b.2). Decreased numbers of endothelial-cell microparticles were measured in 
subjects with sepsis and multi-organ failure. Some authors explain their occurrence by 
apoptosis whereas others regard these vesicles as a result of endothelial cell activation. 
In a recent study, increased levels of endothelial cell microparticles were associated 
with albuminuria in subjects with type 1 diabetes mellitus, but not in those with type 
2 diabetes.22 We found similar numbers of endothelial cell-derived microparticles in 
patients with uncomplicated type 2 diabetes and in healthy controls.14 To note, since 
in the studies published different endothelial cell markers were used in various study 
populations,13,14,19,22,26,53,55 the findings cannot be readily compared.
Table 1b.2 Circulating non-platelet microparticles in diseases with vascular involvement
Cellular origin Disorder Microparticle numbers
granulocytes sepsis / multi organ failure
type 2 diabetes mellitus*
preeclampsia
↑
↑ 
↑
monocytes atherosclerotic plaques
type 2 diabetes mellitus 
lung cancer
↑
↑
↑
endothelial cells systemic lupus erythematosus  
acute coronary syndromes
congestive heart failure
sepsis
thrombotic thrombocytopenic purpura
multiple sclerosis
type 1 diabetes mellitus 
severe hypertension
↑
↑
↑
↓
↑
↑
↑
↑
lymphocytes HIV
atherosclerotic plaques
type 2 diabetes mellitus*
preeclampsia
↑
↑
↑
↑
*The proportion of granulocyte- and lymphocyte-derived microparticles that exposed tissue factor.
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Granulocyte-, monocyte- and lymphocyte microparticles
There are but a few studies investigating the numbers of granulocyte-, monocyte- and 
lymphocyte microparticles in relation to human disease (Table 1b.2). A strong increase 
in granulocyte-derived microparticles was found in patients with meningococcal sepsis 
at admission, but after 2 days their number dropped and a concurrent increase in 
monocytic microparticles was observed.17 The subject with the most fullminant course 
of disease developed DIC, which was associated with an extraordinary high number of 
circulating microparticles of monocytic origin that exposed highly procoagulant tissue 
factor. High numbers of granulocyte microparticles were also detected in patients with 
multi organ failure. In patients with type 2 diabetes, monocyte-derived microparticles 
were associated with plasma E-selectin levels and the highest microparticle numbers were 
found in subjects with diabetic nephropathy.62 Women with preeclampsia had elevated 
numbers of microparticles from granulocytes and lymphocytes (CD4+, CD8+) compared 
to controls, and – as mentioned before – the microparticles from these patients impaired 
endothelium-dependent vasodilatation in vitro.33 In HIV-infected patients, elevated 
numbers of lymphocyte (CD4+) microparticles were measured, suggesting increased 
apoptosis of CD4-lymphocytes in these patients.28 An interesting finding is the presence 
of tissue factor in the vicinity of monocyte- and lymphocyte microparticles in human 
atherosclerotic plaques, indicating the importance of microparticles in the development 
of atherosclerosis.23
SUMMARY AND DISCUSSION
Microparticles from various cell types – but predominantly from thrombocytes – occur 
in the human circulation. Elevated numbers of circulating microparticles are found in 
patients who suffer from diseases associated with an increased thromboembolic risk 
and vascular damage. Microparticles initiate and propagate coagulation by exposing 
negatively charged phospholipids on their membrane surface. In addition, under certain 
conditions, microparticles also expose tissue factor, the initiator of coagulation. The 
clinical relevance of the presence of microparticles in the circulation of healthy subjects 
is as yet unclear, but it may be regarded as a reflection of the dynamics between resting, 
activated and apoptotic cells. In addition, the numbers of circulating microparticles 
also reflect the result of their production and clearance. In vascular disease states it still 
remains to be elucidated whether microparticles are a cause or a consequence of the 
condition, since disease-related factors such as infectious agents, cytokines and metabolic 
disturbances are known to trigger microparticle formation. Still, it may be assumed that 
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microparticles do contribute to the severity of disease, as they can disseminate procoagulant 
and proinflammatory activities throughout the body. Therefore, microparticles may be 
viewed as part of a cascade of reactions in response to a stimulus. This stimulus that led to 
their generation determines their numbers, size, biochemical composition and functional 
characteristics. 
Although microparticle formation may be regarded as an adaptive process, such as e.g. 
the classical inflammatory response, an overshoot of this response, i.e. an excessive 
release of microparticles, may become harmful to the organism and as such unwanted. 
Conversely, defective microparticle formation, in particular of PMP, may result in an 
increased bleeding tendency. Patients with a haemorrhagic trait due to congenital or 
acquired forms of platelet abnormalities can be treated with plasma cryoprecipitate. 
The therapeutic efficacy of cryoprecipitates is in part attributed to their content of high 
concentrations of PMP.63
Various anti-platelet drugs, including the GPIIb/IIIa receptor antagonist abciximab64 and 
the cAMP phosphodiesterase inhibitor cilostazol,38 offer therapeutic possibilities, as they 
reduce excessive PMP formation. Short-term administration of vitamin C at a high dose 
reduced the number of circulating endothelial-cell-derived microparticles in patients with 
congestive heart failure.65 The possible beneficial effect of anti-oxidants was recently also 
demonstrated by an anecdotal observation, in which consumption of a flavinoid-rich cocoa 
beverage reduced circulating numbers of PMP in healthy subjects.66 
Future research should provide insight into the factors that induce microparticle formation 
and the molecular mechanisms underlying the process of generation of these vesicles, 
i.e. activation and apoptosis. Collectively, the data obtained from these studies should 
provide answers to the question as to whether cellular microparticles play a causative 
role in the development of thromboembolic complications and vascular damage in 
humans. 
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The topic of this thesis focuses on the role of the postprandial state and cell-derived 
microparticles, and their interaction, in the development of cardiovascular disease (CVD), 
in particular in high-risk patients. 
As previously reviewed in Chapter 1a, clinical and epidemiological evidence indicates that 
postprandial plasma glucose- and triglyceride responses are associated with increased CVD 
risk. In particular, postprandial triglyceride-rich lipoproteins seem to lead to oxidative 
stress, endothelial dysfunction, coagulation activation and increased inflammation, all 
processes involved in atherogenesis. However, all of previously described postprandial 
studies investigated the effect of a single meal (or rather a single oral fat- or glucose load), 
with the subject kept fasted for the subsequent 8 h. Also, in some studies, the meals were 
rather artificial, including (ice-) cream, fluids and high-bulk carbohydrates, whereas in 
real life, humans consume on average 3 consecutive mixed meals a day. 
In view of their functional properties, microparticles may be an important intermediate in 
the cascade of cellular and plasmatic dysfunctions underlying the process of atherosclerosis, 
as described in Chapter 1b. 
The effect of prolonged (i.e. circadian) postprandial metabolic derangements on the 
physiochemical properties of lipids, on microparticles and concomitant changes in 
endothelial and vascular functions in subjects with the metabolic syndrome and patients 
with type 2 diabetes is unknown. We hypothesized that monitoring metabolic changes 
during a prolonged time period in healthy controls, subjects with the metabolic syndrome 
and patients with type 2 diabetes, given at least 2 consecutive high-fat mixed meals, thereby 
mimicking the real-life situation, will unmask abnormalities which are underestimated 
during fasting conditions or following a single meal. Furthermore, we postulated that 
these metabolic abnormalities may induce the formation of (specific subpopulations 
of) microparticle formation, may stimulate the production of inflammatory mediators 
and oxidative stress, as well as result in coagulation activation and impair endothelial 
function. By studying both subjects with the metabolic syndrome versus patients with type 
2 diabetes, this may reveal the impact of hyperglycemia on top of the other components 
of the metabolic syndrome. 
Since the liver is crucial in lipid metabolism and hepatic steatosis is acknowledged as a 
key feature of the metabolic syndrome, the amount of liver fat content may contribute to 
postprandial dyslipidemia. In Chapter 2, we studied the effect of 3 consecutive high fat 
meals on lipid and apolipoprotein responses and its association with liver fat content in 
males with type 2 diabetes and those with and without the metabolic syndrome. 
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In the postprandial state, not only derangements in lipid concentrations may occur, but also 
the physiochemical properties, i.e. composition, size and function of HDL and LDL particles 
may be affected, that could further promote atherogenesis. In Chapter 3 we describe the 
effects of 3 consecutive meals on the physiochemical properties of HDL and LDL particles 
in type 2 diabetic males and men with and without the metabolic syndrome. In addition, 
the contribution of liver fat accumulation to postprandial triglyceride-enrichment of HDL 
particles, and subsequent HDL dysfunction and endothelial dysfunction were studied in 
Chapter 4.  
The effect of consecutive meals and the associated metabolic derangements on the 
formation of microparticles and their possible effects on endothelial function and 
coagulation activation is unknown. Therefore, in Chapter 5 we first studied the effects of 
2 consecutive high-fat mixed-meals, consumed at an interval comparable to the real-life 
situation, on postprandial metabolic changes and their association with microparticle 
generation and endothelial function in healthy males. In addition, to which extent 
quantitative and qualitative characteristics of microparticles are associated with coagulation 
in the postprandial state is described in Chapter 6.  
Second, in Chapter 7 we describe the effects of exposing males with and without the 
metabolic syndrome to 3 consecutive high-fat mixed meals, given during a 24-h period, 
to disclose the full scope of their compromised metabolism and subsequent circulating 
microparticles and arterial stiffness. Furthermore, in Chapter 8, using the same study 
design, we assessed the effect of postprandial metabolic changes on the numbers and 
cellular origin of microparticles, and their association with endothelial dysfunction in 
patients with uncomplicated type 2 diabetes and healthy controls.    
In addition, in Chapter 9, we review not only the potentially harmful role microparticles 
may play in the development of CVD, but also present recent evidence regarding their 
involvement in the maintenance and preservation of cellular homeostasis. 
Finally, in Chapter 10 the results of the abovementioned studies and future directions 
are discussed. 
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ABSTRACT
Objective: Liver fat is associated with dyslipidemia following a fat load. Previous 
studies demonstrated that alimentary fat is temporarily retained within enterocytes 
and mobilized by subsequently ingested nutrients. As this potentially contributes to 
cumulative postprandial hyperlipidemia, we assessed postprandial lipoprotein changes 
and their association with liver fat following 3 consecutive meals during a 24h period 
in males with type 2 diabetes, and men with the metabolic syndrome (MetS).
Methods: Plasma lipids were measured in 14 type 2 diabetic, 14 MetS and 14 healthy 
age-matched males, following a standardized breakfast (t=0h), lunch (t=4h) and diner 
(t=8h). Blood samples were collected before and at t=2, 4, 6, 8, 12, 16, 20 and 24h fol-
lowing breakfast. Liver fat was measured by proton magnetic resonance-spectroscopy.
Results: Type 2 diabetic (mean age 55(4.2)yrs; HbA1c 7.2(1.1)%) and MetS men had 
similar BMI, waist, blood pressure and triglycerides. 24h-AUC triglycerides, ApoB, 
and cholesterol-rich-remnants, but not ApoB-48, differed significantly among groups 
(calculated by ANOVA, all P<0.05). Liver fat was independently associated with 
24h-AUC triglycerides, ApoB and cholesterol-rich-remnants (r=0.57, P<0.001, r=0.38, 
P=0.017; r=0.48, P=0.002, respectively), but not with 24h-AUC ApoB-48 (r=0.22, 
P=0.18).
Conclusions: In type 2 diabetes and the MetS exposure to 3 consecutive meals produced 
exaggerated 24h triglyceride, ApoB and cholesterol-rich-remnant concentrations, 
which were closely associated with liver fat. Instead, ApoB-48 peak was delayed in 
type 2 diabetes, but not related to liver fat. In addition to liver fat, other mechanisms, 
including local intestinal processes, determine atherogenic postprandial lipoprotein 
changes following 3 consecutive meals during 24h.
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INTRODUCTION 
Exaggerated postprandial elevation of plasma triglyceride-rich lipoproteins and the 
accumulation of cholesterol-rich-remnant particles in type 2 diabetes mellitus and insulin 
resistant states have been associated with increased atherogenesis and cardiovascular disease 
(CVD) risk.1-3 Both intestinal-derived apolipoprotein (apo) B-48 and liver-derived apoB-
100 containing chylomicrons contribute to the postprandial triglyceride-rich lipoprotein 
responses. 
Recently it was suggested that intestinal chylomicron production and release is actively 
controlled in the intestine and affected by insulin resistance.4,5 The production rate of apoB-
48 correlates with insulin levels6 and is actually increased in type 2 diabetes.7 Furthermore, 
in healthy subjects, the intestinal storage of dietary lipids originating from fat contained 
in the previous meal can be released by a subsequent glucose load, resulting in a peak of 
atherogenic lipid particles in the plasma.8 Whether this mechanism influences plasma 
apoB-48 concentrations following consecutive meals in insulin resistant states like type 2 
diabetes or the metabolic syndrome (MetS) is unclear. 
The liver plays an important role in (postprandial) lipid metabolism via the production of 
triglyceride-rich apoB-100-containing lipoproteins, and their (competitive) clearance by 
remnant receptors. Non-Alcoholic Fatty Liver Disease (NAFLD) is associated with hepatic 
insulin resistance, fasting hypertriglyceridemia, unsuppressed postprandial apoB-100 
production and VLDL output, and low HDL-cholesterol. In addition, NAFLD is closely 
related to the MetS and type 2 diabetes.9,10 Also, it has been demonstrated that postprandial 
triglyceride-rich lipoprotein concentrations, including apoB-48, following a single meal 
are associated with NAFLD.11 
The sequence of daylong meals produce sustained triglyceride increase in type 2 diabetes.12 
Our hypothesis is that the above mechanisms (increased assembly and production, 
postponed release or retainment, and/or impaired clearance of intestinal-derived 
triglyceride-rich lipoproteins) will delay apoB-48 peak after consecutive meals in insulin 
resistant subjects and patients with type 2 diabetes. As a consequence, the use of one single 
fat load as performed in most studies addressing mechanisms contributing to postprandial 
lipid responses in type 2 diabetes, will not be sufficient to fully unveil the 24-hour course 
of the various lipid fractions, and therefore not the full spectrum and/or potential of the 
atherogenicity of postprandial dyslipidemia.    
Using proton magnetic resonance spectroscopy (1H-MRS) and 3 consecutive high-fat 
mixed meals during 24 hours, we quantified liver fat content13 and the plasma triglyceride-
rich lipoproteins apoB-100 measured as total apoB, apoB-48 and cholesterol-remnants 
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responses, respectively, and assessed their associations in males with type 2 diabetes, males 
with the MetS and healthy controls. 
MATERIALS AND METHODS
Subjects
Forty-two Caucasian males, aged 40-65 years, with type 2 diabetes (n=14) and with the MetS 
(n=14), and 14 age-matched healthy males were recruited by advertisement and studied 
after obtaining written informed consent. Diet, sulphonylurea and/or metformin were 
the only glucose-lowering treatments allowed in the type 2 diabetic group. Males with the 
MetS had to meet 3 out of 5 inclusion criteria based on NCEP/ATP III-criteria,14 without 
having hyperglycemia during a 75g oral glucose tolerance test (OGTT). Claustrophobia, 
excess alcohol intake (>20 units/wk), history of hepatitis and/or pancreatitis, abnormal liver 
and renal function tests (>2 times upper limits of normal), recent (<3 months) changes in 
weight (≥5%) and/or medication, history or current use of glucocorticosteroids, insulin 
and/or thiazolidinediones, were exclusion criteria. Since it has been demonstrated that 
statins reduce postprandial lipid excursions in several patients groups, including the 
MetS,15 we excluded participants using statins or other lipid-lowering drugs. Subjects were 
instructed to omit their medication during the examination and to refrain from heavy 
physical activities during the previous 24-h. The local ethics committee approved the study 
and the investigation conformed to the principles outlined in the Declaration of Helsinki.
Study design
After an overnight fast, subjects were admitted in the research unit for a 24-h period and 
received 3 consecutive, isocaloric (900 kcal), mixed meals (75g carbohydrates, 50g fat (60% 
saturated), 35g protein), at time points 9.00 AM (breakfast), 1.00 PM (lunch), and 5.00 PM 
(diner). Breakfast consisted of an EggMcMuffin®, croissant with butter and marmalade, 
200 ml of milk, combined with 20 ml of cream, and 13 ml of syrup. The lunch consisted 
of a Quarterpounder®, croissant with butter, 200 ml of milk, and 16 ml of syrup. Diner 
consisted of a Quarterpounder®, 90 gr of French fries, 175 gr of salad and 200 ml of water. 
The subjects were instructed to consume each meal within 15 minutes. Blood samples were 
drawn before and 2, 4, 6, 8, 12, 16, 20 and 24 hours after breakfast. To avoid lipoprotein 
lipase (LPL) activation by physical activity, subjects remained in the semi-recumbent 
position during the whole testing day.
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Biochemical measurements
Plasma glucose concentrations were measured by hexokinase-based technique (Roche 
diagnostics, Mannheim, Germany) and insulin concentrations by immunoradiometric 
assay (Centaur, Bayer Diagnostics, Mijdrecht, The Netherlands). Plasma total cholesterol, 
HDL-cholesterol and triglycerides were determined by enzymatic methods (Modular, 
Hitachi, Japan). LDL-cholesterol was calculated by the Friedewald formula. Glycated 
hemoglobin (HbA1c) was measured with cation exchange chromatography (Menarini 
Diagnostics, Florence, Italy; reference values: 4.3-6.1%). Plasma cholesterol-remnants 
were determined with immunoseparation assay (Otsuka Pharmaceutical Co, Tokio, Japan). 
Whereas plasma total apoB-lipoprotein was measured by immunochemical method based 
on immunoprecipitation at 340 nm (Thermo Electron Ov, Vantaa, Finland), we determined 
plasma apoB-48 by using a sandwich ELISA method that uses monoclonal antibody raised 
against apoB-48 C-terminal decapeptide.16 The homeostasis model assessment of insulin 
resistance (HOMA-IR), was calculated as described by Matthews et al.17 as fasting insulin 
(μU/ml) x glucose (mmol/l)/22.5.
MR-spectroscopy
MR examinations were performed after an overnight fast, using a 1.5-T whole-body system 
(Sonata; Siemens, Erlangen, Germany) in the supine position with the body-array coil 
positioned at the upper abdominal region as previously described in detail.18 In brief, at 3 
positions in the liver (right anterior, right posterior and left anterior) a 15 cm3 volume-of-
interest (2.5 x 2.5 x 2.5 cm3) was positioned, avoiding major blood vessels, intra-hepatic 
bile ducts and the lateral margin of the liver. User-independent spectral quantification was 
performed with LCModel (version 6.1).19 Spectroscopic lipid content is expressed as the 
percentage of the area under the methyl and methylene peaks relative to that under the 
water peak. The coefficient of variation between two assessments of liver fat was 4.7%.18
Abdominal fat volumes
Visceral adipose tissue area (VAT) and subcutaneous abdominal adipose tissue area (SAT) 
were measured using MRI as described previously.18 Quantification of VAT and SAT was 
performed using an image-analysis program, running on a Sparc10 workstation (Sun 
Microsystems, Palo Alto, CA). Processing of MRI data and calculations of VAT and SAT 
were performed by a single experienced investigator, unaware of the metabolic state of 
the studied subject. 
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Statistical analysis
Results are presented as the means±SE or medians (interquartile range). Twenty four-
hour area under the curve (24h-AUC) were calculated according to the trapezoid rule. 
Differences between groups were calculated using ANOVA and post-hoc analyses 
(Bonferroni). Non-normally distributed data were log transformed. The association of 
liver fat content and postprandial lipidemia was assessed by univariate and multivariate 
linear regression analyses. A P<0.05 was considered statistically significant. 
EXPERIMENTAL RESULTS
The diabetic, MetS and healthy groups did not differ significantly with respect to age, 
total cholesterol, LDL-cholesterol and liver enzymes (calculated by ANOVA, Table 2.1). 
Diabetic males had higher HbA1c, fasting and 2h-postload plasma glucose concentrations, 
liver and visceral fat content, and were more insulin resistant than non-diabetic males. 
MetS and healthy controls were comparable regarding HbA1c and fasting and 2h-postload 
glucose concentrations, whereas males with the MetS did not significantly differ from the 
type 2 diabetic males with respect to BMI, waist, blood pressure, HDL-cholesterol and 
triglyceride concentrations (Table 2.1).   
Postprandial plasma glucose concentrations (including 24h-AUC) were similar (P=1.0) in 
both non-diabetic groups, but differed significantly from type 2 diabetic males (P<0.001) 
(Figure 2.1A). Males with the MetS and males with type 2 diabetes had identical 24h 
AUC insulin responses, that differed significantly from healthy controls (P<0.001) 
(Figure 2.1B).
Plasma triglycerides increased significantly after the meals, reaching the highest concen-
trations 6 hours after breakfast in all groups (3.4±0.3 mmol/L in diabetic males, 3.4±0.3 
mmol/L in males with the MetS and 2.2±0.3 mmol/L in controls, P<0.001 in all groups 
compared to baseline. Plasma triglycerides in the healthy subjects decreased after 6 hours; 
the third meal did not seem to affect plasma triglyceride levels (2.2±0.3 mmol/L at 6 hours 
versus 1.5±0.1 mmol/L at 12 hours, P<0.01). In contrast, these remained significantly 
elevated after 6 hours in the MetS and type 2 diabetes group (P<0.01, compared to 
controls). Plasma apoB lipoproteins and cholesterol-rich-remnants concentrations 
decreased significantly following the third meal in the control group (106.1 (8.3) to 104.3 
(7.9) mg/dl, P=0.027), but not in the MetS and diabetic males (Figure 2.1).
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Figure 2.1 The 24-h course of plasma glucose (A), insulin (B), triglycerides (C), cholesterol-rich-
remnants (D), apoB-48 lipoprotein (E) and total apoB lipoprotein (F) concentrations after 3 high-fat 
mixed meals in T2DM (open circles), MetS (asterisk) and healthy males (solid circles). Bars (black, 
healthy males; grey, metabolic syndrome (MetS); white, type 2 diabetes (T2DM)) in the insets represent 
respective 24h-AUC values. Meal intake is indicated by M. The P value given for 24h-AUC difference 
(ANOVA). Data are mean±SE.
P<0.001
A B
C D
E F
P<0.001
P<0.001 P<0.05
P=0.34 P=0.02
M M M M M M
M M M M M M
M M M M M M
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ApoB-48 concentrations were highest in type 2 diabetic males after the third meal (t=12h), 
compared to controls (16.8±2.8 versus 10.7±1.1 μg/dl, P<0.05).
Twenty four-hour AUCs of apoB lipoproteins and cholesterol-rich-remnants differed 
significantly (both P<0.05), whereas 24h-AUC of apoB-48 lipoproteins did not 
significantly differ (P=0.34, ANOVA) between groups. Interestingly, males with the 
MetS had the highest postprandial apoB concentrations (P=0.045, compared to controls). 
Twenty four-hour AUCs of apoB and apoB-48 correlated highly with each other (r=0.71, 
P<0.001), and with 24h-AUC of cholesterol-rich-remnants (r=0.67, P<0.001; r=0.64, 
P<0.001, respectively). 
Liver fat was higher in the diabetic than in the non-diabetic groups (Table 2.1). Posthoc 
analyses revealed a significant difference in liver fat between diabetic males and MetS 
males (P<0.05). A nearly significant difference was found in liver fat between MetS and 
controls, P=0.08. Liver fat content was positively associated with BMI (r=0.50, P=0.001), 
waist (r=0.49, P=0.001), VAT (r=0.30, P=0.048), fasting plasma glucose (r=0.39, P=0.001), 
2h-postload glucose (r=0.65, P=0.001), fasting insulin (r=0.66, P<0.001), triglycerides 
(r=0.55, P<0.001), apoB (r=0.36, P=0.019), cholesterol-rich-remnants (r=0.39, P=0.011), 
and HOMA-IR (r=0.70, P<0.001). Liver fat content was not associated with SAT, fasting 
total cholesterol, LDL-cholesterol and apoB-48 concentrations. Additional univariate 
analyses also showed an association of liver fat content with 24h-AUCs of triglycerides, 
apoB and cholesterol-rich-remnants (r=0.57, P<0.001, r=0.38, P=0.017; r=0.48, P=0.002, 
respectively), but not with 24h-AUC apoB-48 (r=0.22, P=0.18) (Figure 2.2). Since 
glucometabolic state did not affect the association of liver fat content and postprandial 
lipoproteins, as excluded by introducing an interaction term in the multivariate 
analysis, the data of the 3 groups were pooled for the calculation of the regression line 
(Figure 2.2). 
Univariate analyses performed in the 3 separate groups revealed a significant correlation 
of 24h-AUC of triglycerides with liver fat content in the MetS males only (r=0.583, 
P=0.047). Nearly significant associations with liver fat content in healthy controls and 
type 2 diabetic males were 24h-AUC cholesterol-rich-remnants (r=0.494, P=0.073 and 
r=0.473, P=0.087, respectively), and in type 2 diabetes 24h-AUC of triglycerides (0.476, 
P=0.086). No correlations of apoB-48 with liver fat content in the 3 separate groups could 
be detected.   
Multivariate analysis was performed in the pooled groups to study the independent 
association of liver fat content with postprandial lipidemia. Twenty four-hour AUC of 
triglycerides, apoB and cholesterol-rich-remnants were separately entered as a dependent 
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variable, and subsequently, liver fat content, metabolic state (type 2 diabetes, MetS, or 
control), age, BMI or VAT, and fasting glucose were entered as independent variables into 
the model (Table 2.2 for triglycerides). Adjustment for these variables did not change the 
association of liver fat with 24h-AUC triglycerides. Comparable results were found for 
apoB and cholesterol-rich-remnants (data not shown). Table 2.3 shows results of forward 
stepwise multivariate linear regression model. The independent variables in each model 
were liver fat, metabolic state, age, BMI, waist, VAT, HbA1c, HOMA-IR. Liver fat remained 
as a significant determinant of 24h-AUC triglycerides, apoB, and cholesterol-rich-remnants, 
but not of 24h-AUC of apoB-48. In contrast, 24h-AUC of apoB-48 was independently 
determined by HbA1c. 
Figure 2.2 Scatter plots representing the relationship between liver fat content and postprandial 
lipidemia, including triglycerides (A), lipoprotein total apoB (B), lipoprotein apoB-48 (C) and cholesterol-
rich-remnants (D) in the whole study population (T2DM (open circles), MetS (asterisk) and healthy 
males (solid circles)). Pearson correlation coefficients are shown.
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Table 2.2 Multivariate associations between liver fat content and 24-h AUC triglyceride
24h-AUC TG (95% CI) P R R2 P
Model 1 0.50 0.25 0.001
Liver fat content (log %) 25.910 (13.831 to 43.103) 0.001
Model 2 (Model 1 + metabolic state) 0.50 0.25 0.001
Liver fat content (log %) 25.910 (8.117 to 42.498) 0.005
Metabolic state 1.210 (-16.486 to 18.905) 0.891
Model 3 (Model 2 + age) 0.51 0.26 0.01
Liver fat content (log%) 24.921 (7.558 to 42.283) 0.006
Metabolic state 1.512 (-16.344 to 19.368) 0.865
Age 0.406 (-0.785 to 1.598) 0.494
Model 4 (Model 3 + VAT) 0.53 0.28 0.016
Liver fat content (log%) 24.381 (6.972 to 41.791) 0.007
Metabolic state 8.412 (-14.231 to 31.054) 0.456
Age 0.467 (-0.732 to 1.665) 0.435
VAT -0.001 (-0.002 to 0.001) 0.321
Model 5 (Model 3 + BMI) 0.52 0.27 0.023
Liver fat content (log%) 23.403 (4.903 to 41.903) 0.015
Metabolic state 0.179 (-18.588 to 18.945) 0.985
Age 0.393 (-0.812 to 1.599) 0.512
BMI 0.563 (-1.606 to 2.731) 0.602
Model 6 (Model 4 + HOMA-IR ) 0.57 0.33 0.013
Liver fat content (log%) 19.372 (1.143 to 37.600) 0.038
Metabolic state 2.073 (-21.556 to 25.702) 0.860
Age 0.464 (-0.711 to 1.639) 0.429
VAT -0.001 (-0.002 to 0.000) 0.185
HOMA-IR 4.915 (-1.362 to 11.193) 0.121
Table 2.3 Significant correlates of forward stepwise multivariate linear regression model
Dependent variable Independent correlate Coefficient Standard error Significance
24h-AUC TG Liver fat 0.883 0.234 0.001
24h-AUC RLP cholesterol Liver fat 2.650 1.000 0.012
24h-AUC apoB Liver fat 563.310 220.484 0.015
24h-AUC apoB-48 HbA1c 44.902 17.480 0.014
Variables excluded metabolic state, age, BMI, waist, VAT, (HbA1c), HOMA-IR. TG, triglyceride; BMI, body mass index; 
HOMA-IR, homeostasis model assessment of insulin resistance; RLP cholesterol, cholesterol-rich remnants; VAT, 
visceral adipose tissue area.
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DISCUSSION
This study demonstrates that the consecutive consumption of 3 fat-rich mixed meals by 
men with type 2 diabetes and men with the MetS results in exaggerated and prolonged 
postprandial dyslipidemia during 24 hours, as compared to the profile in healthy age-
matched controls. We demonstrate for the first time that postprandial 24h-AUC of 
atherogenic apoB and cholesterol-rich-remnant particles are independently associated 
with liver fat content, whereas no such associations were found with 24h-AUC of apoB-48. 
Another novel finding in the present study is that 3 sequential meals produce significant 
delay in plasma apoB-48 peak at 8–12 hours in type 2 diabetes as compared to healthy 
subjects in whom apoB-48 steadily decreased after a third meal.  
High levels of apoB-48-containing lipoproteins may contribute to the increase of 
apoB triglyceride-rich lipoproteins and cholesterol-remnants in the postprandial state, 
as these triglyceride-rich lipoproteins are cleared by the same pathways. ApoB-48 
triglyceride-rich lipoproteins have higher affinity for LPL than apoB-100 triglyceride-
rich lipoproteins.20 Thus when LPL-activity is reduced, as in insulin resistant states,21 in 
particular postprandial apoB-100 concentrations may become exaggerated and prolonged 
due to impaired clearance. Therefore, the high total apoB concentrations we found in 
the MetS males can be explained by the preferential hepatic clearance of apoB-48 that 
result in higher apoB-100 concentrations than can be expected on high liver fat content 
only. Furthermore, an increased production or retainment of apoB-48 chylomicrons by 
the intestine in type 2 diabetes will result in higher apoB-48 concentrations following 
consecutive meals. This is in line with the findings by Robertson et al., who showed that 
apoB-48 lipoproteins were temporarily retained within enterocytes following a fat load 
and were released after a subsequent glucose load in healthy subjects.8 Speculatively, 
the underlying mechanism of this phenomenon will be impaired in type 2 diabetes and 
result in an delayed release of apoB-48 lipoproteins from the intestine. Other possible 
intestinal mechanisms that may contribute to our findings are increased microsomal 
triglyceride transfer protein and diacylglycerol acyltransferase activity, expression of 
Niemann-Pick C1-like 1, and blunted incretin responses.22 Current findings agree well 
with the view that chylomicron metabolism is regulated by multiple steps at the level of the 
enterocytes.
Our finding that 24h-AUC apoB-48 is not associated with liver fat content seems in contrast 
to previous findings.11 However, the latter study separated lipoprotein fractions, but used 
only one high fat mixed meal, and results were calculated in subjects divided according 
to liver fat content, irrespective of the diabetic state. Furthermore, a direct comparison 
between our postprandial responses following breakfast only and the previous results is 
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not possible, since in our study the second meal was introduced 4 hours after breakfast 
and the largest postprandial differences occur after 4 hours. 
We confirmed previous findings showing a significant difference in liver fat content between 
normoglycemic males with the MetS compared to those with hyperglycemia (or type 2 
diabetes), despite identical BMI, waist and dyslipidemia. This finding is in line with previous 
observations showing that liver fat accumulation may be different in people with similar 
BMI and waist circumference.23 Furthermore, hyperglycemia contributes to liver fat content, 
by increasing malonyl-CoA that inhibits carnitine palmitoyltransferase-1 leading to a 
decrease in mitochondrial β-oxidation and shuttling long-chain acyl-CoA into intracellular 
triglyceride accumulation.24,25 Our findings are in accordance with the concept that fatty 
liver secretes high rates of VLDL particles,26 since liver fat correlated with both fasting and 
postprandial triglyceride, apoB and cholesterol-rich-remnant concentrations following 3 
consecutive meals. Multivariate regression analyses indicate the importance of glycemic 
control in postprandial apoB-48 metabolism. This finding is in line with recent results 
by Su et al., who demonstrated an altered postprandial apoB-48 metabolism following 
2 sequential meals in normolipidemic subjects with poorly controlled type 1 diabetes.27 
One of the limitations of the present study was that we did not measure LPL activity or 
specific apolipoproteins on chylomicrons. Furthermore, we determined total apoB and 
apoB-48 in plasma and not in lipoprotein fractions. Finally, our study included a relative 
small number of subjects, which may not allow generalization of the data.
In conclusion, we found that exposure of males with type 2 diabetes and males with the 
MetS without hyperglycemia to 3 consecutive meals results in exaggerated and prolonged 
postprandial dyslipidemia during 24 hours, compared to healthy controls. Since the study 
design closely resembles daily meal patterns, it underscores the significance of postprandial 
dyslipidemia being a CVD risk factor in the MetS and type 2 diabetes. Furthermore, 
1H-MRS-measured liver lipid content was positively and independently associated 
with postprandial elevations of triglycerides, total apoB and cholesterol-rich-remnants. 
Consecutive meals reveal a postponed peak response of apoB-48 containing particles in 
type 2 diabetic males, independently of hepatic fat content.
CONCLUSION
Our findings suggest that in addition to liver fat content, other mechanisms, speculatively 
intestinal insulin resistance, determine the quantity and quality of postprandial lipoprotein 
changes following 3 consecutive meals during 24 hours. Future studies should elucidate 
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possible mechanisms, including intestinal insulin resistance and local impaired intestinal 
hormone responses, that underlie our observations in order to positively effect postprandial 
lipidemia as a risk factor for atherogenesis. 
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ABSTRACT
Background/objectives: Postprandial hyperlipidemia, which is exaggerated and 
prolonged in insulin resistant individuals, has been associated with cardiovascular 
disease. The objective of the present study was to investigate whether and how 
the composition, size, and function of HDL and LDL particles are affected in the 
postprandial state among males with the metabolic syndrome (MetS) or type 2 diabetes 
(T2DM), compared to controls.
Subjects/methods: Fourteen males with T2DM, 14 with the MetS , and 14 age-matched 
controls were given 3 standardized high-fat mixed meals (900 kcal; 50g fat, 75g carbo-
hydrate, and 35g protein) as breakfast, lunch and dinner. Blood sampling was perfor-
med just before the meals, and 4 and 8 hours after the last meal. HDL and LDL were 
isolated by ultracentrifugation and analyzed for their composition, particle diameter, 
and physicochemical properties.
Results: Postprandial triglycerides levels in plasma, HDL and LDL particles increased 
significantly in all groups (P<0.01). Compared to the controls, patients with T2DM 
had smaller LDL particles, and in agreement, a lower cholesterol-to-protein content in 
both fasting and postprandial samples. A prolonged increase in susceptibility of LDL to 
oxidation was found in all subjects, but was most evident in T2DM. The postprandial 
effect on LDL oxidation was associated with an increase in LDL triglyceride (r=0.29, 
P<0.05). In T2DM the anti-oxidative capacity of HDL trended to impairment after the 
third meal.
Conclusions: Postprandial increases in triglycerides, especially in T2DM, are accom-
panied by pro-atherosclerotic functional changes in HDL and LDL particles.
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INTRODUCTION 
Postprandial hyperlipidemia is considered to be an important risk factor for atherosclero-
sis.1,2 In clinical practice, however, triglycerides are traditionally measured in the fasting 
state, typically the lowest triglyceride level of the day. Recent studies have shown that 
measurement of non-fasting triglycerides levels may be superior to fasting concentrations 
because the former are clearly associated with increased risk of cardiovascular disease 
(CVD) and mortality.3-5 Postprandial responses related to triglyceride metabolism may 
trigger a number of pro-atherosclerotic processes including leukocyte activation,6 up-
regulation of pro-inflammatory genes,7 decrease in circulating antioxidant defense,8 and 
oxidative stress.2,9,10 Furthermore, reactive oxygen species (ROS) peroxidize constituents 
of lipoproteins, leading to modifications, including oxidized LDL and HDL, that may 
alter their functional properties. Individuals with the metabolic syndrome (MetS) and 
particularly patients with type 2 diabetes mellitus (T2DM) have postprandial hyperli-
pidemia which is associated with an increased CVD risk. It is likely that the lipoprotein 
composition and physicochemical properties may become postprandially more affected in 
comparison to healthy normolipidemic subjects. The postprandial effects on lipoprotein 
metabolism have been described in literature, but in contrast to our study most studies used 
just one meal and no more than one or two study groups. To the best of our knowledge, 
the present study is the first to examine the influence of 3 consecutive meals on both LDL 
and HDL properties in men with the MetS or T2DM compared to controls. So, the aim 
of the present study was to investigate whether postprandial hypertriglyceridemia affects 
the physicochemical properties of HDL and LDL in individuals with T2DM and with the 
MetS, in comparison to controls. 
MATERIALS AND METHODS
Study design
In total 42 nonsmoking Caucasian male subjects were enrolled; 14 patients with uncom-
plicated T2DM, 14 subjects with the MetS, and 14 age-matched volunteers (i.e. ‘control 
group’). Diet, sulphonylurea and/or metformin were the only glucose-lowering treatments 
allowed in the T2DM group. Males with the MetS had to meet 3 out of 5 inclusion criteria 
based on NCEP/ATP III-criteria,11 without having hyperglycemia during a 75g oral glucose 
tolerance test (OGTT). Inclusion criteria for control males included a BMI >25 kg/m2, 
normoglycemia during a 75g OGTT, fasting triglycerides <1.7 mmol/l, and blood pressure 
<145/90 mmHg. Exclusion criteria for all were excess alcohol intake (>20 units/week), 
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history of hepatitis and/or pancreatitis, abnormal liver and renal function tests (>2 times 
upper limits of normal), recent (<3 months) changes in weight (≥5%) and/or medication, 
history or current use of glucocorticosteroids, insulin and/or thiazolidinediones. Since it 
has been demonstrated that statins reduce postprandial lipid excursions in several patients 
groups, including MetS,12 we excluded subjects using statins or other lipid-lowering drugs. 
Participants were instructed to omit their medication during the examination and to refrain 
from heavy physical activities during the previous 24-h. After an overnight fast, participants 
received 3 consecutive, isocaloric (900 kcal) mixed meals (75g carbohydrates, 50g fat [60% 
saturated], and 35g protein) at time points t=0-h (breakfast), 4-h (lunch), and 8-h (din-
ner) and were studied during a 16-h period.13 Venous blood collections were performed 
before and 4 hours following every single meal (t=0, 4, 8, 12, and 16-h) for measurements 
of plasma lipids, glucose, insulin and for measurement of the physicochemical properties 
of HDL and LDL. Plasma aliquots were obtained after centrifugation (1550g, 20 min at 
4°C), snap frozen in liquid nitrogen, and stored at -80°C until assay. Informed consent was 
obtained from all participants and the study was approved by the local ethics committee.
Routine biochemical analyses
Glucose was measured enzymatically (Roche, Mannheim, Germany) and insulin with a 
double-antibody radioimmunoassay (Linco Research, St. Louis, MO, USA). HbA1c was 
analyzed by ion-exchange high-performance liquid chromatography (Bio-Rad, Veenendaal, 
The Netherlands). Total-cholesterol, HDL-cholesterol and triglycerides were measured 
by standard enzymatic methods (Roche, Mannheim, Germany). LDL-cholesterol was 
calculated, but only in fasting plasma samples.14 The protein content of LDL and HDL 
was measured by the Lowry method, modified to allow measurement in lipoproteins as 
described by Markwell.15 The concentration of cholesterol and triglycerides in isolated 
lipoprotein fractions were measured by standard enzymatic methods (Roche, Mannheim, 
Germany).
HDL and LDL particle size and function
HDL and LDL were isolated by ultracentrifugation and afterwards the average particle size 
was determined by high performance gel-filtration chromatography, using fibrinogen (22.2 
nm), thyroglobulin (17.0 nm) and bovine serum albumin (7.1 nm) as calibrators of known 
diameter.16 Intra- and inter-assay CVs were 0.1% and 0.2%, respectively. The susceptibility 
of LDL to in vitro oxidation, expressed as lag time, was determined by monitoring the 
conjugated dienes formation using copper (II) ions as pro-oxidant at a final concentration 
of 18 μmol/L.17 Experiments were performed at 30°C on a HTS 7000 plate reader (Perkin 
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Elmer, Norwalk, CT, USA). The intra- and inter-assay CVs for lag time determination 
were 1.6% and 3.6%. The anti-oxidative function of HDL was assessed by monitoring its 
capacity to inhibit the oxidation of dichlorodihydrofluorescein (Invitrogen, Carlsbad, CA, 
USA) by oxidized 1-palmitoyl-2-arachidonoyl-sn-phosphatidylcholine (Avanti Lipids, 
Alabaster, AL, USA).18 Briefly, in a total volume of 790 μL phosphate buffered saline (pH 
7.4), 35 μL of a normal LDL solution (final concentration of 18 μmol/L cholesterol), 35 
μL of test HDL-cholesterol (final concentration of 11 μmol/L cholesterol), 20 μl oxidized 
1-palmitoyl-2-arachidonoyl-sn-phosphatidylcholine (final concentration of 50 μmol/L), 
and 10 μL of dichlorodihydrofluorescein solution (final concentration of 40 μmol/L) were 
incubated in glass tubes for 2 hours at 37°C. Afterwards the fluorescence intensity was 
determined with a HTS 7000 plate reader at 485 and 530 nm (excitation and emission 
wavelength, respectively). Values for fluorescence intensity at t=0 for each group were 
normalized to 1.0, and consequently HDL function >1.0 in postprandial samples may 
indicate dysfunctionality. The intra-assay CV was 3.4%.
Statistical analysis
Data are presented as mean (SD) or median (interquartile range). Non-normally distributed 
data were log transformed before analysis. Correlations were performed using Spearman’s 
rank correlation test and differences between groups were tested using ANOVA and 
Bonferroni post hoc analyses. To estimate the overall changes during 16-h, the area under 
curve (AUC) of metabolic parameters against time was calculated according to the linear 
trapezoidal method. In order to test whether the changes of the physicochemical properties 
of HDL and LDL over time are affected by group, i.e. controls, MetS and T2DM, we 
performed analysis of variance (ANOVA) for repeated measurements with the interaction-
term time x group. P<0.05 was considered to indicate statistical significance. All analyses 
were performed using SPSS software, version 15 (SPSS Inc, Chicago, IL, USA).
RESULTS
Baseline characteristics
Subject characteristics at baseline divided by group are illustrated in Table 3.1. No sig-
nificant differences between the groups were noted in age, fasting total cholesterol and 
LDL-cholesterol. Individuals with either MetS or T2DM had higher values for waist 
circumference, blood pressure, insulin and plasma triglycerides. BMI, fasting glucose and 
HbA1c were significantly higher in the T2DM group. HDL-cholesterol was significantly 
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lower in MetS and T2DM. Table 3.2 shows the physicochemical properties of HDL and 
LDL in the three study groups before the meals. The triglyceride content of lipoprotein 
particles was higher in the T2DM group, but reached statistical significance only in HDL. 
At baseline, T2DM patients, relative to controls, had smaller LDL particles (P<0.05) and 
in agreement a lower cholesterol-to-protein content in their LDL (P<0.05). Likewise, the 
cholesterol content of HDL was significantly lower in patients with MetS and T2DM (both 
P<0.001), but differences in fasting HDL particle size did not reach statistical significance 
(P=0.22 and P=0.08, respectively for MetS and T2DM compared to controls).
Effects of meals on plasma lipids, glucose, insulin and lipoprotein properties
The postprandial responses following 3 consecutive meals were shown in Figures 3.1 
and 3.2 and were also presented as AUC in Table 3.3. Plasma triglyceride peaked 4 hours 
(t=4-h) after the first meal in controls, whereas in MetS and T2DM the highest levels 
were observed just before dinner (t=8-h; Figure 3.1). The increase in plasma triglyceride 
Table 3.1 Baseline clinical and biochemical characteristics of the study population
Variable Controls MetS P valuea T2DM P valueb
N 14 14 14
Age, years 54.3 (7.5) 56.4 (6.5) NS 55.5 (4.0) NS
BMI, kg/m2 27.5 (2.9) 30.7 (3.2) NS 32.7 (4.1) <0.001
Waist circumference, cm 101.2 (8.4) 111.8 (9.8) 0.012 112.1 (9.2) 0.009
SBP, mmHg 121 (6) 139 (13) <0.001 136 (13) <0.001
DBP, mmHg 74 (5) 84 (6) <0.001 83 (4) <0.001
Fasting glucose, mmol/L 5.4 (0.2) 5.6 (0.4) NS 8.8 (2.2) <0.001
HbA1c, % 5.6 (0.4) 5.9 (0.4) NS 7.2 (1.1) <0.001
Insulin, pmol/L 27 (22-37) 51 (36-85) 0.007 66 (41-84) <0.001
Total cholesterol, mmol/L 5.1 (0.9) 5.4 (0.9) NS 5.1 (0.5) NS
HDL-cholesterol, mmol/L 1.49 (0.40) 1.10 (0.31) 0.006 1.06 (0.18) 0.002
LDL-cholesterol, mmol/L 3.1 (0.8) 3.2 (0.8) NS 3.1 (0.5) NS
Triglycerides, mmol/L 1.0 (07-1.2) 2.0 (1.7-2.6) 0.002 1.8 (1.3-2.7) 0.002
MetS, metabolic syndrome; T2DM, type 2 diabetes mellitus; BMI, body mass index; DPS, diastolic blood pressure; 
SBP, systolic blood pressure. Data are presented as mean (SD), or median (interquartile range). 
aMetS syndrome compared with control group
bT2DM compared with control group
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Table 3.2 Fasting lipoprotein properties of the study population
Variable Controls MetS P valuea T2DM P valueb
N 14 14 14
HDL constituents and size
Triglyceride-to-protein, mmol/g 0.07 (0.02) 0.08 (0.03) NS 0.09 (0.03) 0.018
Cholesterol-to-protein, mmol/g 0.93 (0.15) 0.70 (0.12) <0.001 0.67 (0.11) <0.001
Particle size, nm 8.61 (0.35) 8.42 (0.18) NS 8.38 (0.21) NS
LDL constituents, size and susceptibility to oxidation
Triglyceride-to-protein, mmol/g 0.27 (0.07) 0.25 (0.05) NS 0.30 (0.11) NS
Cholesterol-to-protein, mmol/g 4.31 (0.33) 4.06 (0.30) NS 3.93 (0.41) 0.018
Particle size, nm 21.23 (0.55) 20.59 (0.47) 0.016 20.69 (0.62 <0.05
Oxidisabilty, min 63.2 (7.4) 56.8 (7.6) NS 62.8 (8.7) NS
MetS, metabolic syndrome; T2DM, type 2 diabetes mellitus. Data are presented as mean (SD). 
aMetS syndrome compared with control group
bT2DM compared with control group
Table 3.3 Postprandial response of 3 consecutive meals on plasma lipids, glucose, insulin, lipoprotein 
properties, during a 16-h period expressed as area under the curve (AUC)
Variable Controls MetS P valuea T2DM P valueb
N 14 14 14
AUC plasma variables
Triglycerides, mmol/L 25.3 (11.3) 45.2 (13.6) 0.014 46.1 (24.8) 0.010
HDL-cholesterol, mmol/L 23.1 (6.4) 15.7 (4.1) <0.001 14.9 (2.6) <0.001
Glucose, mmol/L 88.2 (6.9) 91.2 (5.0) NS 145.8 (48.1) <0.001
Insulin, nmol/L 1.3 (0.7) 3.3 (2.4) <0.001 2.7 (0.7) <0.001
AUC HDL constituents and size:
Triglyceride-to-protein, mmol/g 1.4 (0.3) 1.7 (0.5) NS 1.8 (0.6) NS
Cholesterol-to-protein, mmol/g 14.6 (2.8) 10.8 (1.8) <0.001 10.2 (1.8) <0.001
Particle size, nm 145 (6) 142 (4) NS 142 (4) NS
AUC LDL constituents, size and oxidation
Triglyceride-to-protein, mmol/g 5.0 (1.1) 4.5 (1.0) NS 5.3 (1.8) NS
Cholesterol-to-protein, mmol/g 69.4 (5.1) 64.1 (5.1) NS 62.4 (7.1) 0.009
Particle size, nm 341 (8) 330 (7) 0.005 332 (10) 0.042
Oxidisabilty, min 987 (105) 898 (112) NS 951 (133) NS
AUC, area under the curve over a 16-h time period; MetS, metabolic syndrome; T2DM, type 2 diabetes mellitus. 
Data are presented as mean (SD). 
aMetS syndrome compared with control group
bT2DM diabetes compared with control group
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was similar in MetS and T2DM. Postprandially, plasma HDL-cholesterol decreased 
somewhat in all groups. In MetS and T2DM compared to the control group, AUCs for 
plasma triglycerides concentrations were higher, whereas AUCs for HDL-cholesterol 
were lower. Postprandial glucose increased in all groups at t=12-h, but a marked rise 
was observed only in T2DM. Insulin concentrations were elevated following each meal, 
reaching the highest concentrations after the third meal (t=12-h) in all groups, with the 
highest responses in MetS. 
HDL and LDL were postprandially enriched in triglyceride-to-protein ratio in all three 
study groups (Figure 3.2) reaching a maximum concentration between 8 and 12 hours 
after breakfast. The lipoprotein triglyceride responses, expressed as AUC, were similar 
amongst the groups (Table 3.3). Postprandial HDL and LDL particles derived from 
T2DM and MetS versus controls had a decreased cholesterol content when expressed as 
AUC (Table 3.3), reaching the lowest values 8-h after breakfast (Figure 3.2). Postprandial 
Figure 3.1 Time courses during 16-h of the postprandial response following 3 consecutive meals 
of plasma triglyceride, HDL-cholesterol, glucose, and insulin (mean ± SEM) in T2DM (open circles), 
MetS (asterisk) and healthy males (solid circles). Meal intake is indicated by M.
M???????????M M M???????????M M
M???????????M M M???????????M M
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Figure 3.2 Time courses during 16-h of the postprandial response following 3 consecutive meals 
of high-density lipoprotein and low-density lipoprotein constituents (triglyceride and cholesterol) 
and size and of the anti inflammatory function of high-density lipoprotein and the susceptibility of 
low-density lipoprotein to oxidation (mean ± SEM) in T2DM (open circles), MetS (asterisk) and healthy 
males (solid circles). Meal intake is indicated by M.
M???????????M M M???????????M M
M???????????M M M???????????M M
M???????????M M M???????????M M
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HDL and LDL particles, especially those from T2DM, were larger compared to fasting 
diameters (Figure 3.2). In the T2DM group, the HDL size peaked at t=8-h and LDL at 
t=12-h. Postprandial changes in HDL size correlated significantly to changes in LDL size 
(r=0.47; P<0.01; all groups). The anti-oxidative capacity of HDL was hardly effected in 
the postprandial state, except for an change towards impairment after the third meal in 
T2DM (t=12-h; Figure 3.2), compared to both other groups. Subsequently, at the next time-
point measured, HDL functionality returned to baseline level. The postprandial effect on 
HDL function was positively correlated to changes in HDL-cholesterol content and HDL 
particle size (r=0.50 and r=0.46, respectively; both P<0.01; all groups). LDL lag time was 
postprandially decreased in all groups after breakfast and subsequently returned toward 
baseline levels at t=4-h in controls, at t=8-h in MetS, and at t=12-h in T2DM. The most 
important correlate of postprandial changes in LDL lag time was the increase of plasma 
triglyceride concentration (r=0.29, P<0.05; all groups). 
The P values of the time x group interaction terms for the physicochemical properties of 
LDL and HDL were all statistically non-significant (all P>0.05), except for the triglyceride 
to protein ration in HDL (P<0.05). However the differences of the AUC of the triglyceride 
to protein ration in HDL was non-significant (all P>0.05). 
DISCUSSION
Our results show that plasma triglycerides increased significantly after breakfast and 
lunch, but remarkably no further increase was found after dinner. The prolonged 
hypertriglyceridemia following 3 consecutive meals in males with the MetS and patients 
with T2DM results in the formation of triglyceride-enriched HDL and LDL particles and 
an concomitant increased postprandial susceptibility of LDL to oxidation, especially in 
those with T2DM. Furthermore, enlarged lipoprotein particles and an impairment of the 
anti-oxidative capacity of HDL were postprandially observed in T2DM.
Insulin resistant states, including the MetS and T2DM, are associated with decreased plasma 
HDL-cholesterol concentration, whereas LDL-cholesterol concentration is usually normal. 
However, in T2DM the metabolism of LDL is modified, rendering the lipoprotein particles 
more atherogenic.19 Furthermore, it has been shown that high-fat intake is associated with 
oxidative stress. For example, monocytes polymorphic nuclear cells release more superoxide 
anion when they are exposed to plasma from patients with hypertriglyceridemia.20,21 In 
addition, whipping cream (75g of fat) resulted in an increase in nitrotyrosine, a marker of 
peroxinitrite and nitrosative stress generation, in normal subjects and T2DM patients.22 
The ensuing postprandial oxidative stress may trigger a number of atherogenic changes 
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including increases in inflammation, vasoconstriction and oxidation of LDL.2 In the 
present study we have focused on (oxidative) modifications to both HDL and LDL, like 
composition, function, and particle size. 
Lipoprotein particles have been demonstrated to be heterogeneous in size. Several studies 
measured LDL particle diameter using non-denaturing polyacrylamide gel electrophoresis 
in the postprandial state with inconsistent results. Small, but significant, reductions of 
LDL size of up to 0.1 nm were observed in myocardial infarction patients 6-h after an oral 
fat tolerance test,23 and in apparently healthy men 4-h after a breakfast with high-fat.24 A 
decrease in LDL size of 0.4 nm was observed in hypertriglyceridemic patients 6-h after 
an oral fat load.25 The group of Taskinen measured LDL size 6-h after a high-fat meal in 
patients with coronary artery disease,26 and 8-h after a mixed fat-rich meal in subjects with 
diabetes.27 In both studies, LDL particles size remained statistically unchanged. In contrast 
to these studies, but in agreement to our study, a significant increase in LDL size (0.73 nm; 
P<0.05) was found in patients with primary mixed hyperlipidemia after an oral fat-tolerance 
test.28 In the present study we used high-performance gel filtration chromatography for 
measurement of lipoprotein particle sizes, which is regarded as a very precise technique 
(CVs <0.2%),16 and as such, small changes in diameter will be easily detected. 
The mean size of HDL and LDL in T2DM was postprandially enlarged probably due to 
the increase in triglyceride content. Triglyceride in HDL and LDL is a good substrate for 
hepatic lipase, which hydrolyses triglycerides and thus ultimately converts lipoprotein 
particles smaller and denser. Since our follow-up duration was 16-h, it is possible that 
we have missed this latter part. Interestingly, HDL and LDL size peaked at different time 
points. In T2DM, HDL particle size peaked 8-h after breakfast and the largest mean LDL 
size was observed 4-h later, at t=12-h. These results suggest that the exchange in lipids, 
mediated by cholesterol-ester transfer protein (CETP), is faster in HDL than in LDL. 
T2DM and MetS are associated with low-grade inflammation and oxidative stress. 
Therefore, it is likely that the antioxidant and anti-inflammatory properties of HDL, 
in which both the protein and lipid components are involved, are altered especially in 
postprandial conditions. Although the postprandial anti oxidative properties of HDL 
derived from T2DM was somewhat impaired after 3 consecutive meals at t=12-h, the 
current study observed no significant changes between- and within groups. The anti-
inflammatory/oxidative properties of HDL in the postprandial state have been studied 
earlier in two relatively small studies with healthy subjects. Nicholls et al. showed that 
the anti-inflammatory potential of HDL was reduced after consumption of saturated fat 
and improved following the consumption of polyunsaturated fat.29 Patel and coworkers 
demonstrated an impaired anti-inflammatory capacity of HDL in response to 20% 
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Intralipid.30 In these studies, but in contrast to our study, the anti-inflammatory activity 
of HDL were measured using postprandial endothelial cells expression of intracellular cell 
adhesion molecules-1 (ICAM-1) and vascular cell adhesion molecules-1 (VCAM-1). It is 
currently not known whether this approach for HDL functionality is in agreement with 
the procedure that has been used in the present study.
LDL may become oxidized by an increase of free radical production (e.g. superoxide anion 
and hydroperoxyl radical) or nonradical oxidants (e.g. hydrogen peroxide and hypochorite). 
Oxidation of LDL is an important early event in the development of atherosclerosis. 
Oxidatively modified LDL is taken up by macrophages, which may become foam cells, 
leading to the formation of atherosclerotic plaques. In agreement with an earlier study,17 
fasting LDL lag times of T2DM and controls were not different, but interestingly the 
present study showed that postprandial LDL, especially derived from T2DM, is more 
susceptible to in vitro oxidation. Diwadkar et al. demonstrated that postprandial samples 
of diabetic subjects had a significantly shorter lag phase following one physiological meal 
(85g fat), but unfortunately they did not measure the lipid content of this lipoprotein 
class.31 Of note, we demonstrated that the postprandial increase of LDL towards oxidation 
was positively associated with the triglyceride-to-protein ratio in LDL. In agreement, the 
highest triglyceride content in LDL and the most pronounced change in LDL oxidation 
has been found in T2DM.
There are several limitations of this study. In each group a relatively small number of 
subjects was examined and because our study has been conducted in men, the results 
may require replication in women. In addition, the exact peak of the highest postprandial 
concentrations is not known because a 4-h interval was used. Finally, we did not measure 
systemic oxidative stress levels.
Altogether, in subjects with the MetS and in patients with T2DM, the exaggerated and 
prolonged postprandial concentrations of plasma triglycerides lead to an increased 
triglyceride lipoprotein. The HDL cholesterol-to-protein ratio and HDL particle size 
have been shown to be important correlates of the anti oxidative properties of HDL, 
whereas the LDL triglyceride content was a determinant of LDL susceptibility to in vitro 
oxidation. In both fasting and postprandial samples, subjects with MetS and T2DM had 
smaller HDL and LDL particles. A prolonged period of increased LDL oxidisability was 
seen in T2DM. In conclusion, our study demonstrated that the exposure to 3 high-fat 
mixed consecutive meals results into pro-atherosclerotic changes of lipoprotein particles, 
especially in T2DM.
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ABSTRACT
Background: A large body of evidence has accumulated indicating a relation between 
postprandial hyperglycemia and hypertriglyceridemia, and the risk of cardiovascular 
disease.
Objective: We studied possible mechanisms underlying the postprandial proatherogenic 
state by exposing healthy males to 2 consecutive high-fat mixed meals.
Patients/Methods: Seventeen healthy males (age 25.4±3 yrs, BMI 23.6±2 kg/m2) 
were studied during 2 randomized visits. During the meal visit, subjects consumed 
standardized meals (50 g fat, 55 g carbohydrates, 30 g proteins) as breakfast and 4 hours 
later as lunch. During the control visit, subjects remained fasted. Prior to each blood 
collection (before and every 2 hours following the first meal), flow mediated dilatation 
(FMD) of the brachial artery was measured.
Results: Although within the normal range, postprandial plasma glucose and 
triacylglycerol concentrations increased significantly, especially after the second meal, 
as compared to baseline (4.8±0.3 to 5.4±0.4, 0.8±0.2 to 1.7±0.7 mmol/L, respectively; 
both P<0.05) and the fasting visit. Following the second meal, FMD was significantly 
impaired (6.9% versus 3.7%, P<0.05) whereas oxidized-LDL/LDL cholesterol ratio and 
malondialdehyde concentrations were markedly elevated (both P<0.01). Finally, an 
increase in total microparticle numbers was observed during the meal visit (P<0.05).
Conclusions: Mild elevations in plasma glucose and triacylglycerol in healthy males 
following 2 consecutive fat-rich meals were paralleled by impaired FMD, increased 
markers of oxidative stress and circulating microparticles, in particular, following the 
second meal. These findings may have consequences for subjects with postprandial 
dysmetabolism, including those with type 2 diabetes.
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INTRODUCTION 
In the late seventies of the previous century, Zilversmit postulated atherosclerosis to 
be a postprandial phenomenon.1 Ever since, a large body of evidence has accumulated 
indicating a relation between postprandial hyperglycemia and hypertriglyceridemia, and 
the risk of cardiovascular disease (CVD).2-7 The mechanisms that may link postprandial 
dysmetabolism to the increased CVD risk include postprandial endothelial dysfunction, 
as described in both healthy subjects and in patients at increased CVD risk, meal-
induced oxidative stress, and inflammation.7-10 Indeed, the observed correlations among 
postprandial triacylglycerol-rich-lipoproteins, endothelial dysfunction and selected 
oxidative stress markers suggest that triacylglycerols may reduce nitric oxide (NO) 
bioavailability by inducing oxidative stress.8-10 
Oxidative stress is the common pathway by which many classic CVD risk factors adversely 
affect the vasculature and elevated levels of oxidative stress markers, such as oxidized 
low density lipoprotein (oxLDL), circulate in subjects at high risk of CVD.11,12 Although 
prolonged exposure to dietary high fat increased plasma oxLDL concentrations,13 no acute 
meal-induced elevations of oxLDL were reported in healthy subjects. 
In addition to oxidative stress, the observed meal-related increases in circulating proinflam-
matory cytokines have been implicated in postprandial vascular dysfunction.7,14,15 Some 
authors found postprandial elevations of proinflammatory molecules in patients with type 
2 diabetes or postprandial leukocyte activation even in healthy subjects,7,10 whereas others 
could not confirm these findings.15,16
Besides their previously reported procoagulant properties, adverse effects of cellular 
microparticles (MP) on endothelium-mediated vasodilation and their ability to induce 
cytokine production from endothelial cells in vitro, MP have recently also been suggested 
to reflect cellular stress.17 Indeed, increased numbers of MP of various cellular origin 
are present in the circulation of patients at risk of CVD,18-21 and the recently described 
meal-induced increase in circulating endothelial cell MP, in association with postprandial 
metabolic changes, seems in line with this hypothesis.22 Thus, cellular MP may be one of 
the mechanisms linking postprandial metabolic and vascular functional derangements. 
The main limitation of previous studies addressing postprandial dysmetabolism in 
relation to CVD risk was that only a single meal was given, while the subjects were fasted 
for the subsequent 8-10 hours. In fact, in many studies, artificial solid or liquid ‘meals’ 
were used which may not be compatible with the real-life situation. Thus, the metabolic 
responses following these artificial fat and/or glucose loads and the concomitant effects 
on the endothelium and blood cells elicited by the experimental condition may differ from 
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those occurring in real life. Therefore, in the present study, 17 healthy volunteers received 
2 consecutive fat-rich mixed meals, as breakfast and lunch, respectively. In addition to 
the meal-related metabolic and endothelial functional responses, we measured markers 
of oxidative stress and inflammation, and cellular MP as possible mechanisms linking 
metabolic and vascular changes in the postprandial state. 
SUBJECTS AND METHODS
Subjects
Seventeen healthy subjects were recruited from the VU University by billboard advertising 
and via advertisements at a local student-rowing club. Healthy males, Caucasian, aged 
between 20-35 years, having a body mass index (BMI) less than 27 kg/m2 and a blood 
pressure <145/90 mmHg were eligible. Current smoking, the use of drugs (including anti-
platelet drugs and NSAIDs) and the presence of CVD, hypertension, diabetes mellitus, or 
1st degree family history of aforementioned diseases were exclusion criteria. Subjects were 
initially studied during a screening visit after giving written informed consent. The local 
ethics committee approved the study and the investigation conformed to the principles 
outlined in the Declaration of Helsinki.
Study design
Each subject was studied at 2 occasions, following an overnight fast (from 8.00 p.m. the 
previous evening). Subjects had to refrain from heavy physical activities during 24 hours 
prior to each visit. The order of the visits was randomized and the time interval between 
the control and meal visits was less than 4 weeks. During the meal day, the subjects 
received 2 consecutive, isocaloric (900 kcal) test meals at time point t=0 (breakfast) and 
4 hours (lunch). Blood samples were collected before and at 2, 4, 6 and 8 hours following 
the first meal. Prior to each blood collection, vascular function was measured as FMD at 
the brachial artery (see below). During the control day, subjects were kept in the fasting 
state, only drinking water was allowed (maximum of 50 mL/hour to limit the effects on 
the autonomic nervous system due to gastric distension), and FMD and blood collection 
were performed similar to the meal day. Subjects remained in the supine position during 
both days in a quiet, temperature-controlled room.
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Test meals
At the meal visit, each subject received 2 standardized fat-rich mixed-meals at breakfast 
(8.30 a.m.) and lunch-time (12.30 p.m.). Each meal consisted of 50 g fat, of which 60% was 
saturated, 55 g carbohydrates and 30 g protein. The breakfast consisted of EggMcMuffin® 
(McDonald’s, affiliation Amsterdam-Sloten, The Netherlands), croissant with butter 
and marmalade, 200 mL of milk, combined with 20 ml of cream. The lunch consisted of 
Quarterpounder® (McDonald’s, affiliation Amsterdam-Sloten, The Netherlands), croissant 
with butter, and 200 mL of milk. The subjects were instructed to consume each meal 
within 15 minutes.
Blood sample collection
To avoid endothelial and platelet activation artifacts, no in-dwelling canula was used and 
a new blood collecting system (Microflex, size 1.0 mm - 19 G, Vygon, France) was used 
for each blood collection. Venous blood was collected from the left antecubital vein at 15 
minutes following each FMD measurement (which was invariably performed at the right 
arm), to avoid the effect of forearm occlusion on the parameters measured. The needle 
was placed at least 1 cm distal from the previous insertion and stasis was carefully avoided. 
Plasma was recovered after centrifugation (1550xg, 20 minutes, 20°C) and aliquots of 250 
μL were snap frozen in liquid nitrogen within 30 minutes after withdrawal and stored at 
-80°C until assay. All samples from one subject were analyzed in the same series.
Endothelial function
Changes in brachial artery diameter in response to reactive hyperemia (FMD) were 
measured non-invasively using a high-resolution ultrasonic wall-tracking system (Wall-
track System, PieMedical, Maastricht, The Netherlands). All individuals underwent the 
ultrasound examination according to the guidelines of the International Brachial Artery 
Reactivity Task Force.23 In brief, the right brachial artery (20 mm proximal to the antecubital 
fossa) was visualized in B-mode using an 7.5 MHz linear probe (AU-5, Esaote, Maastricht, 
The Netherlands) and the baseline diameter was recorded. Then, during 5 minutes, a 
blood pressure cuff (Hokanson EC-4) around the forearm was inflated to 200 mmHg. 
After deflation of the cuff, the change in diameter was recorded every 30 seconds (up to 5 
minutes after deflation). To avoid movement artifacts, we used a stereotactic probe-holding 
device with the subject’s arm immobilized in a foam cast. Ten minutes after the final blood 
collection a second baseline recording was performed. Subsequently, 400 μg Nitroglycerin 
(NTG, Nitrolingual Spray, Pohl-Boskamp, Germany) was administered sublingually and the 
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change in brachial artery diameter was recorded at various time points (up to 10 minutes 
after NTG administration). Data were analyzed off-line using the Wall-track System. FMD 
and NTG-induced vasodilation were expressed as percentage change in diameter relative to 
baseline diameter. All measurements were performed by one experienced observer (MT). 
Reproducibility of the measurements showed a coefficient of variation <2%.
Biochemical measurements
Plasma glucose was measured by a hexokinase-based technique (Roche diagnostics, 
Mannheim, Germany), HbA1c by HPLC. Insulin was measured by a commercially available 
immunoradiometric assay (Biosource/Medgenix Diagnostics, Fleurus, Belgium). Plasma 
total cholesterol, high-density lipoprotein cholesterol (HDL-C) and triacylglycerols were 
determined by enzymatic methods (Modular, Hitachi, Japan). Low-density lipoprotein 
cholesterol (LDL-C) was calculated by the Friedewald formula, insulin resistance 
according to the homeostasis model assessment of insulin resistance (HOMAIR; (plasma 
glucose*insulin)/22.5). Non-esterified fatty acids (NEFA) were assessed by ELISA (WAKO 
chemicals, Neuss, Germany). OxLDL was measured by a competitive ELISA (Mercodia, 
Uppsala, Sweden), with intra-assay and inter-assay coefficients of variation of 4.8% and 
7.8%, respectively. To obtain an estimate of the percentage of oxidized LDL particles, 
the oxLDL to LDL-C ratio (U/mmol) was calculated. Total malondialdehyde (MDA; 
μmol/L) was measured in EDTA-plasma, after reaction with thiobarbituric acid with an 
additional alkaline hydrolysis step as described previously.24 The within run and between 
run variations were 3.5% and 8.7%, respectively. Both interleukin-6 (IL-6; pg/mL) and 
high-sensitive C-reactive protein (hs-CRP; mg/L) were measured in duplicate using ELISA 
(Diaclone, Besançon, France and Sanguin, Amsterdam, The Netherlands,25 respectively).
Reagents and assays
All chemicals were of analytical quality. Phycoerythrin (PE)-labeled anti-glycophorin A 
(JC159, IgG1) and anti-CD61-PE (Y2/51, IgG1) were from Dako A/S (Glostrup, Denmark), 
anti-CD4-PE (CLB-T4/2,6D10, IgG1) and anti-CD66e-PE (CLB-gran/10, IH4Fc, IgG1) 
from the CLB (Amsterdam, The Netherlands), anti-CD8-PE (SK1, IgG1), anti-CD14-PE 
(MØP9, IgG2b), anti-CD20-PE (L27, IgG1), IgG1-PE (X40), IgG2b-PE (S2), and IgG1-
peridinin chlorophyll-a protein (PerCP; X40) from Becton Dickinson (San Jose, CA). 
Anti-CD62e-PE (1.2B6, IgG1) from Serotec Ltd (Oxford, England), anti-CD66b-PE (80H3, 
IgG1κ) and fluorescein isothiocyanate (FITC)-labeled anti-CD66b (0531) from Coulter/
Immunotech (Marseille, France). Allophycocyanin (APC)-labeled annexin V-APC from 
Pharmingen (San Jose, CA) and anti-CD106-FITC (B44498) was from Calbiochem-
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Novabiochem Corporation (San Diego, CA). Anti-CD144-FITC (BMS 158FI) was from 
Bender MedSystems Diagnostics GmbH (Vienna, Austria).
Flowcytometric analysis of MP
MP were isolated as previously described.19,20 The samples were analyzed in a FACScan 
flow cytometer with CellQuest software (Becton Dickinson, San Jose, CA). Fluorescence 
threshold were set using a calcium-containing buffer, annexin V and isotype-matched 
control antibody as described before.19,20 MP were identified on forward scatter (FSC) 
and sideward scatter (SSC) characteristics, by binding of annexin V and a monoclonal 
antibody (MoAb) directed against a cell type-specific antigen. MP numbers were calculated 
as described earlier.19,20
Statistical analysis
Continuous variables are expressed as mean±SD, unless otherwise stated. To estimate 
the overall metabolic responses and the changes in MP during both visits, area under 
incremental curve (ΔAUC) of these parameters plotted against time were calculated. We 
used repeated-measures ANOVA, with time of measurement as the within factor and visit 
type as the grouping factor. Non-parametrical tests were performed for non-normally 
distributed data. Pair wise comparisons (Wilcoxon-Signed-Ranks tests) were applied as 
post hoc tests only when ANOVA revealed overall significant differences. Correlations 
were performed using the Spearman’s test. A P<0.05 was considered statistically significant. 
Data were analyzed with SPSS for Windows, release 11.5.1.
RESULTS
The clinical and laboratory characteristics of the participants are depicted in Table 5.1. 
All participants were highly active, with an average physical training activity of 5.6±4 
hours/week.
During the meal visit, plasma glucose, triacylglycerol and insulin concentrations rose 
significantly, especially after the second meal, as compared to baseline and the fasting 
visit (both P<0.05, P<0.01, P<0.01, respectively; Figure 5.1). Mean glucose concentrations 
rose from 4.8±0.3 to 5.4±0.4 mmol/L (t=6 hours, P<0.001 compared to baseline) and 
triacylglycerols increased from 0.8±0.2 to maximum mean values of 1.7±0.7 mmol/L 
(t=6 hours). Following the meals (t=2 and 6 hours), insulin concentrations increased 
to 75.2±32.2 and 114.2±37.6 pmol/L, respectively. HDL-C decreased from 1.37±0.2 to 
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1.28±0.2 mmol/L (P<0.01) during the meal day (data not shown). During the control visit, 
glucose (from 4.9±0.3 to 4.6±0.3 mmol/L) and insulin (from 35.7±13.8 to 26.6±9.6 pmol/L) 
decreased significantly (both P<0.001 versus baseline). Triacylglycerol concentrations 
remained unchanged (Figure 5.1). Levels of NEFA remained low during the meal day 
with significant further lowering following both meals, suggesting insulin-mediated NEFA 
suppression (from 0.31±0.2 at baseline to 0.13±0.1 at t=2 hours after the first meal; and 
from 0.28±0.1 prior to the second meal to 0.20±0.1 mmol/L at t=2 hours after the second 
meal, respectively, both P<0.001). As expected, NEFA concentrations rose significantly 
during the fasting day from 0.32±0.1 to 0.78±0.2 mmol/L (at t=8 hours; P<0.001 versus 
baseline and meal day; Figure 5.1).
FMD showed a marked reduction following the second meal (6.9% versus 3.7%; P<0.05) 
as compared to baseline (Figure 5.2). The difference between FMD at t=6 hours between 
both days tended to be statistically significant (P=0.051). NTG-induced vasodilation 
measured at the end of both days did not differ (both 13.0%). Changes in FMD showed 
no significant correlation with the metabolic changes or MP numbers (r=-0.36, P=0.31, 
for FMD and total MP).
Table 5.1 Baseline characteristics of the study population
Healthy males (n=17)
Age, years 25.4±3
BMI, kg/m2 23.6±1.8
Waist, cm 87.6±5
Systolic blood pressure, mmHg 116±8
Diastolic blood pressure, mmHg 75±7
HbA1c, % 5.1±0.2
Glucose, mmol/L 4.8±0.3
Insulin, pmol/L 33±10
HOMAIR 1.0±0.3
Total-cholesterol, mmol/L 4.0±0.6
HDL-C, mmol/L 1.37±0.2
LDL-C, mmol/L 2.2±0.6
Triacylglycerols, mmol/L 0.8±0.3
Values are mean±SD. BMI indicates body mass index;  HOMAIR, homeostasis model assessment of insulin resistance; 
HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol.
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Figure 5.1 Plasma concentrations of glucose, insulin, triacylglycerols and NEFA during the meal- 
(solid circles) and fasting days (open circles) in healthy lean subjects. Data are mean±SD. *P<0.05.  
Figure 5.2 Changes in flow-mediated dilation (FMD) during the meal- (solid circles) and fasting 
days (open circles) in healthy lean subjects. Data are mean±SEM. *P<0.05. 
* 
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OxLDL and MDA concentrations were measured at baseline (t=0) and t=6 hours during 
both visits (i.e. 6 hours after the first meal on the meal day, and 6 hours after the first 
blood collection during the fasting visit). During the meal visit, the oxLDL/LDL-C ratio 
increased from 19.4±2.8 to 22.4±4.5 U/mmol (P=0.001 compared to baseline and fasting 
day; Figure 5.3). During the fasting visit, oxLDL/LDL-C remained constant (18.7±2.8 and 
18.1±2.3 U/mmol). Postprandial changes in oxLDL/LDL-C correlated with the changes 
in triacylglycerol levels (r=0.60, P=0.01) but not with changes in glucose concentrations. 
Similarly, MDA increased during the meal day from 7.2±0.6 to 7.8±0.8 μmol/L and 
decreased during the fasting day from 7.8±0.7 to 7.0±0.5 μmol/L (P=0.01 and P=0.001, 
respectively and P=0.001 meals versus fasting; Figure 5.3). Changes in MDA correlated with 
meal-induced changes in glucose concentrations (r=0.67, P=0.003) but not with increases 
in postprandial triacylglycerols. Postprandial MDA elevations tended to correlate inversely 
with FMD changes (r=-0.52, P=0.059; Figure 5.4).
Circulating numbers of MP from T helper, T suppressor, B cells, granulocytes, and 
endothelial cells were negligible (data not shown). Therefore, we only report MP from 
platelets, erythrocytes and monocytes, in addition to the total MP count. The total numbers 
of MP, of which the largest fraction is platelet-derived (88-98%), increased during the meal 
visit compared to the fasting visit (P<0.05; Figure 5.5A and 5.5B). The overall changes 
in platelet-derived MP (PMP), calculated as ΔAUC PMP, correlated with the percentile 
change in oxLDL/LDL during the meal day (r=0.59, P=0.042). The fraction of erythrocyte-
derived MP, comprising 2-3% of total MP numbers during fasting, increased to 3-11% after 
Figure 5.3 OxLDL/LDL-C ratios and malondialdehyde (MDA) concentrations at baseline (t=0 hours) 
and at t=6 hours during the meal- (black bars) and fasting (white bars) days. Data are mean±SD. 
†P<0.01.
† 
† 
† 
† 
† 
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consumption of both meals (P<0.001, versus baseline and fasting day). Finally, monocyte-
derived MP, constituting 0.3% of the total MP numbers, tended to increase during the meal 
visit only (P=0.07 versus baseline; data not shown). 
Plasma IL-6 concentrations followed an identical “U-shaped” curve on both days, with 
the lowest values after noon (t=4 hours after baseline, P<0.03). CRP remained unchanged 
during both days (Figure 5.6).
Figure 5.4 Scatter plot representing the relationship between postprandial percentual changes 
in flow mediated dilatation (FMD) and absolute changes in malondialdehyde (MDA) concentrations.
r=-0.52 
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Figure 5.5 Courses of plasma total microparticles (MP) concentrations during the meal (solid circles) 
and fasting (open circles) visit (A). The area under the incremental curve (ΔAUC) of total microparticle 
(MP) numbers during the meal visit (black bars) as compared to the fasting visit (white bars) (B). Data 
are mean±SEM. *P<0.05. 
* 
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DISCUSSION
The present study demonstrates that exposure of healthy, physically active, lean and insulin 
sensitive young males to two consecutive fat-rich mixed meals results in impaired endo-
thelium-dependent vasodilatation and acute elevation of oxLDL and MDA concentrations 
despite relatively mild metabolic changes. All postprandial changes were most marked 
following the second meal, and the meal-related increase in oxidative stress associated 
with postprandially elevated numbers of circulating PMP. 
Both in vivo and in vitro studies indicate that (postprandial) hypertriglyceridemia 
adversely affects several endothelial functions, including exposure of adhesion molecules 
and NO-mediated vasodilatation by inducing oxidative stress.7-9,26,27 In healthy subjects, 
postprandially impaired FMD correlated with meal-induced hypertriglyceridemia in 
some,9,28,29 but not in other studies.8,10 In our study, the decrease in FMD following the 
second meal was not correlated to the concomitant plasma triacylglycerol elevations, but 
rather tended to associate with the meal-related increase in levels of oxidative stress markers. 
There are several possible explanations for these seemingly discrepant observations. Firstly, 
the populations studied are not readily comparable (i.e. very physical active and therefore 
more insulin sensitive compared to persons with a more sedentary lifestyle), secondly, the 
postprandial metabolic changes found in our subjects were relatively mild, as compared 
to those observed in other studies,9,14,29 thirdly, the composition and consistency (liquid 
versus solid) of the test-meals differed in the various studies, and finally, the changes in 
the different parameters measured, in relation to time following meal ingestion, cannot 
easily be established. 
Figure 5.6 The course of plasma interleukin-6 (IL-6) and C-reactive protein (CRP) concentrations 
during the meal- (solid circles) and fasting (open circles) days in healthy lean subjects. Data are 
mean±SD. *P<0.05.
* 
* 
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We found lower baseline concentrations of oxLDL/LDL-C (19.4 U/mmol) compared to 
findings by others who reported oxLDL/LDL-C concentrations of 21.5 and 23.6 U/mmol 
in elderly control subjects and type 2 diabetic patients, respectively.12 These authors found 
a correlation between fasting plasma triacylglycerols and oxLDL/LDL-C.12 Our results 
extend these observations to the postprandial state. Although alterations in plasma oxLDL 
concentration by dietary changes have been described previously,13 these changes occurred 
only after exposure to a low vegetable diet for several weeks, rather than acutely in response 
to a meal. Previously, it was suggested that oxLDL can promote the shedding of PMP in 
vitro.21 Our present study shows that this association may also exist in vivo. In addition, we 
found a postprandial increase in plasma MDA concentrations, also suggesting oxidative 
stress, and this was associated with FMD. 
In contrast to Ferreira,22 we could not identify any MP from endothelial cells. A possible 
explanation is that we only used endothelial cell-specific antibodies (CD62e, CD106 and 
CD144), and that the postprandial increases in CD31-positive MP reported by these 
authors may be in part due to elevated PMP.30,31 
Because PMP have often been associated with procoagulant activity,18,19 we determined 
prothrombin fragment F1+2 and thrombin antithrombin complexes. However, no difference 
was found in these coagulation parameters between fasting and meal days (data not shown). 
PMPs, in addition to their procoagulant potential, were previously shown to also posses 
anti-coagulant activity.19 Thus, the simultaneous presence of these opposing properties 
may overall have resulted in no measurable effect on thrombin generation in our study. 
The lack of association between MP numbers and changes in FMD during meal days does 
not preclude that MP may directly impair NO-bioavailability in vivo, as was observed 
in vitro,32 since the association between circulating MP, representing the result of MP 
formation and clearance, and NO-mediated vasodilation may be difficult to assess due 
to the dynamic characteristics of both variables. However, the observed association 
between MP and oxLDL suggest that MP, albeit indirectly, may play a role in postprandial 
endothelium-dependent vasodilatation. 
Despite previously reported plasma IL-6 elevations following a meal and its association 
with postprandial hypertriglyceridemia,7,14 we found no postprandial changes in IL-6 
concentrations. Interestingly, similar to others, we found IL-6 tend to display a circadian 
rhythm.33 In accordance to Tsai et al., who gave one high-fat meal to healthy males, 
postprandial CRP remained unchanged in our subjects.10 Thus, in healthy, lean and insulin-
sensitive subjects, the postprandial metabolic changes do not elicit acute proinflammatory 
effects. 
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The present study suggests that even in young healthy subjects high-fat diets may be 
atherogenic due to oxidative stress-induced impairment of endothelium-dependent 
vasodilatation. We suggest that, in order to obtain a reliable impression of the total exposure 
of the vasculature to meal-related derangements, postprandial studies should use a real-life 
approach by giving several (consecutive) test meals, at regular intervals, during one day. 
Our findings may have consequences for insulin resistant and type 2 diabetic patients, 
who suffer from an impaired clearance and suppression of postprandial triacylglycerol-rich 
lipoproteins resulting in prolonged and exaggerated postprandial metabolic abnormalities.
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ABSTRACT
Evidence is present that the phospholipid composition of circulating cell-derived 
microparticles (MP) affects coagulation in vivo, and that postprandial metabolic 
alterations may be associated with hypercoagulable state. Our objective was to investigate 
whether postprandial metabolic responses affect the phospholipid composition of 
MP, and whether such changes are associated with coagulation activation. Therefore, 
12 healthy males were studied twice and randomly received 2 consecutive meals or 
remained fasted. Blood was collected before and at 2, 4, 6 and 8h following breakfast. 
The phospholipid composition of MP was determined by hpTLC. Numbers and cellular 
origin of MP were determined by flowcytometry. Plasma concentrations of prothrombin 
F1+2 and thrombin-antithrombin-complexes were measured. The in vitro procoagulant 
activity of MP was studied by fibrin generation. During the meal visit, plasma glucose, 
triglyceride and insulin levels increased, compared to baseline and the fasting visit (all 
P<0.05). Postprandially, the total numbers of MP increased in time compared to the 
fasting visit (P<0.05). Especially erythrocyte-derived MP increased (6-fold) during 
the meal visit, but remained constant on the fasting day (P<0.001). On the meal versus 
fasting day circulating MP contained increased phosphatidylcholine (P<0.05) and 
decreased sphingomyelin (P<0.05) amounts. The amount of phosphatidylserine did 
not change. Concentrations of plasma F1+2 and thrombin-antithrombin were similar on 
both days, as was the ability of MP to generate fibrin in vitro. Although the numbers, 
cellular origin and phospholipid composition of MP change during exposure to 2 
consecutive meals in healthy subjects, this does not lead to changes in the coagulation 
activation in vivo.
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INTRODUCTION 
Clinical and epidemiological evidence indicates that postprandial elevations of plasma 
glucose and triglyceride-rich lipoproteins are related to the risk of atherothrombotic 
disease.1 To which extent postprandial coagulation activation contributes to this risk is 
still under debate. Several investigators reported postprandial coagulation activation in 
healthy subjects and in patients suffering from cardiovascular disease, as measured by 
increased plasma concentrations of factor VIIa, prothrombin fragment F1+2 (F1+2) or 
thrombin-antihrombin complexes (TAT).2-11 Explanations for the underlying mechanism(s) 
of coagulation activation in the postprandial state, however, range from activation of factor 
VII (FVII) and XI (FXI) by triglycerides to increased activity of plasminogen activator 
inhibitor (PAI). Of interest, other investigators found that postprandial FVII activation 
was not associated with increased concentrations of F1+2 and TAT.12,13 Similarly, there is 
no consensus among investigators whether platelet activation occurs in the context of 
postprandial lipemia.14,15 
By exposing negatively charged phospholipids, mainly phosphatidylserine, but also by 
exposing tissue factor, cell-derived microparticles (MP) can propagate and even initiate 
coagulation.16-18 Therefore, MP have been associated with coagulation activation in health 
and disease, and elevated numbers of circulating MP are related with an increased risk of 
thromboembolic events as well as with disseminated intravascular coagulation.16-18 Recently, 
we demonstrated that the total number of MP in plasma from healthy males is elevated 
following consecutive meals, suggesting that the postprandial state induces the formation of 
MP.19 At present, it is unknown to which extent quantitative and qualitative characteristics 
of MP are associated with coagulation in the postprandial state. Therefore, we investigated 
whether the postprandial state affects not only the numbers but also the cellular origin 
and phospholipid composition of circulating MP, their procoagulant phenotype and the 
association with coagulation activation in vivo. 
MATERIALS AND METHODS
Subjects
Twelve healthy males, Caucasian, aged between 20-35 years, having a body mass index 
(BMI) less than 27 kg/m2 and a blood pressure <145/90 mmHg were included as previously 
described.19 Current smoking, the use of drugs (except for incidental analgesic agents) and 
the presence of CVD, hypertension, coagulation disorders, diabetes mellitus, or 1st degree 
family history of aforementioned diseases were exclusion criteria. Subjects were initially 
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studied during a screening visit after having given written informed consent. The local 
ethics committee approved the study and the investigation conformed to the principles 
outlined in the Declaration of Helsinki.
Study design
Each participant was studied at 2 occasions, following an overnight fast (from 8.00 PM the 
previous evening). Subjects had to refrain from heavy physical activities during 24 hours 
prior to each visit. During the meal day, the participants received 2 consecutive, isocaloric 
(900 kcal) test meals at time points t=0 (breakfast) and 4 hours (lunch). Blood samples 
were collected before and at 2, 4, 6 and 8 hours following the first meal. During the fasting 
day, blood samples were collected at similar times from 8.00 AM onwards and the subjects 
were only allowed water at libitum. The order of the visits was randomized and the time 
interval between the control and meal visits was less than 4 weeks.
Test meals
At the meal visit, each subject received 2 standardized fat-rich mixed-meals at breakfast 
(8.30 AM) and lunch-time (12.30 PM). Each meal consisted of 50 g fat, of which 60% was 
saturated, 55 g carbohydrates and 30 g protein. The breakfast consisted of EggMcMuffin® 
(McDonald’s, affiliation Amsterdam-Sloten, The Netherlands), croissant with butter 
and marmalade, 200 mL of milk, combined with 20 ml of cream. The lunch consisted of 
Quarterpounder® (McDonald’s, affiliation Amsterdam-Sloten, The Netherlands), croissant 
with butter, and 200 mL of milk. The participants were instructed to consume each meal 
within 15 minutes.
Blood sample collection
To avoid coagulation, endothelial, and platelet activation artifacts, no in-dwelling canula 
was used and a new blood collecting system (Microflex, size 1.0 mm - 19 G, Vygon, France) 
was used for each blood collection. Venous blood was collected from the left antecubital 
vein, the needle was placed at least 1 cm distal from the previous insertion and stasis was 
carefully avoided, into 0.1 volume of 105 mmol/L trisodium citrate. Plasma was recovered 
after centrifugation (1550g, 20 minutes, 20°C) and aliquots of 250 μL were snap frozen 
in liquid nitrogen within 30 minutes after withdrawal and stored at -80°C until assay. All 
samples from one subject were analyzed in the same series.
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Biochemical measurements
Plasma glucose was measured by a hexokinase-based technique (Roche diagnostics, 
Mannheim, Germany), HbA1c by HPLC. Insulin was measured by a commercially available 
immunoradiometric assay (Biosource/Medgenix Diagnostics, Fleurus, Belgium). Plasma 
total cholesterol, high-density lipoprotein cholesterol (HDL-C) and triglycerides were 
determined by enzymatic methods (Modular, Hitachi, Japan). Low-density lipoprotein 
cholesterol (LDL-C) was calculated by the Friedewald formula. Non-esterified fatty acids 
(NEFA) were assessed with an enzymatic colorimetric method (WAKO chemicals, Neuss, 
Germany). F1+2 and TAT were determined by ELISA (Dade Behring, Eschborn, Germany).
Reagents and assays
Phospholipid standards were obtained from Larodan (Malmö, Sweden): l-α-phosphati-
dylcholine, l-α-lyso-phosphatidylcholine, sphingomyelin, l-α-phosphatidylserine, l-α-
phosphati dylinositol, l-α-phosphatidylethanolamine. The l-α-lyso-phosphati dylethano-
lamine standard was obtained from Sigma (St. Louis, MO). Chloroform (analytical grade) 
and ethylacetate, acetone, methanol, ethanol, dichloromethane, isopropanol, acetic acid 
(all HPLC grade) and HPTLC plates (Cat. No. 1.05641; 20 x 10 cm, Silicagel 60Å pore size, 
particle size 5-17 μm, 0.2 mm layer thickness) were obtained from Merck (Darmstadt, 
Germany). All other chemicals were of analytical quality. Phycoerythrin (PE)-labelled 
anti-glycophorin A (JC159, IgG1) and anti-CD61-PE (Y2/51, IgG1) were from Dako A/S 
(Glostrup, Denmark), anti-CD4-PE (CLB-T4/2,6D10, IgG1), anti-CD66e-PE (CLB-gran/10, 
IH4Fc, IgG1) from Sanquin (Amsterdam, The Netherlands), anti-CD8-PE (SK1, IgG1), 
anti-CD14-PE (MØP9, IgG2b), anti-CD20-PE (L27, IgG1), IgG1-PE (X40), IgG2b-PE (S2) 
and IgG1-peridinin chlorophyll-a protein (PerCP; X40) from Becton Dickinson (San Jose, 
CA), anti-CD62e-PE (1.2B6, IgG1) from Serotec Ltd (Oxford, England), anti-CD66b-PE 
(80H3, IgG1κ) and fluoresceinisothiocyanate (FITC)-labeled anti-CD66b (0531) from 
Coulter/Immunotech (Marseille, France), and allophycocyanin (APC)-labelled annexin 
V-APC from Pharmingen (San Jose, CA), anti-CD106-FITC (B44498) from Calbiochem-
Novabiochem Corporation (San Diego, CA) and anti-CD144-FITC (BMS 158FI) from 
Bender MedSystems Diagnostics GmbH (Vienna, Austria).
Isolation of MP
Per time point, two 250 μl aliquots were thawed on melting ice, and centrifuged for 
30 minutes at 17,590g and 20°C. The supernatant (225 μl) was removed and 225 μl 
phosphate-buffered saline (PBS) containing 0.32% trisodium citrate (154 mmol/L NaCl, 
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1.4 mmol/L phosphate and 10.9 mmol/L trisodiumcitrate, pH 7.4) was added. The MP were 
resuspended and again centrifuged for 30 minutes at 17,590g and 20°C. For flowcytometry, 
225 μl supernatant was removed. Subsequently the MP were resuspended and diluted 4-fold 
with PBS/citrate buffer, of which 5 μl was used per incubation. For Bligh & Dyer extraction, 
the supernatant (225 μl) was removed and the pellet was washed once more. Finally, 225 
μl supernatant was removed and the MP were resuspended in the remaining 25 μl.
Flowcytometric analysis of MP
The samples were analyzed in a FACScan flowcytometer with CellQuest software (Becton 
Dickinson, San Jose, CA). Forward scatter (FSC) and sideward scatter (SSC) were set at 
logarithmic gain. To distinguish MP from events due to noise, MP were identified not only 
on FCS and SSC characteristics, but also by binding of annexin V and a MoAb directed 
against a celltype-specific antigen. To identify annexin V-positive MP, a threshold was 
placed in a MP sample prepared in the presence of annexin V without calcium to correct 
for autofluorescence. To identify MP that bind cell type-specific MoAbs, the MP were 
incubated with identical concentrations of isotype-matched control antibodies to set the 
threshold. FITC-fluorescence was measured in the FL-1 channel and PE-fluorescence in 
the FL-2 channel. 
To 35 μl of PBS/calcium buffer (154 mmol/L NaCl, 1.4 mmol/L phosphate and 2.5 
mmol/L CaCl2, pH 7.4), 5 μl annexin V-PE and 5 μl FITC-labeled cell-specific MoAbs or 
isotype-matched control antibody (IgG1-FITC) were added. MP (5 μl) were added, and the 
mixtures were incubated in the dark for 15 min at room temperature. For the CD66e-PE 
analysis an IgG1-PE control antibody was used. Subsequently, 900 μl PBS/calcium buffer 
was added to stop the labeling. All samples were analyzed for 1 minute during which the 
flowcytometer analyzed about 150 μl of the MP suspension. From the number of events 
(Nx) in the upper right (marker and annexin V-positive) quadrant of the flowcytometric 
analysis (FL-1 versus FL-2 corrected for isotype control and autofluorescence), the number 
of MP/L plasma was calculated: Number/L=Nx[100/5]x[950/60]x[106/250], in which 5 
(μL) is the volume of MP suspension, 100 is the total volume of washed MP suspension, 
950 is the total volume in the tube before analysis, 60 is the sample volume analyzed, 106 
is the number of μL/L, and 250 is the original volume of plasma.
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Phospholipid extraction
Phospholipids were extracted according to Bligh & Dyer.20,21 To improve the recovery for 
phosphatidylserine and phosphatidylinositol, the water phase was replaced by acetic acid 
(0.5%).  
For each time point the remaining 25 μl of the two 250 μl aliquots were pooled. To these 
50 μl samples, 3 ml methanol:chloroform (2:1) was added. The samples were thoroughly 
mixed for 30 s and 750 μl 0.5% acetic acid was added. Again the samples were mixed for 30 
s. Then, chloroform (1 ml) and 0.5% acetic acid (800 μl) were added. After each addition, 
the samples were mixed for 30 s. Subsequently the samples were centrifuged for 10 minutes 
at 1560g (20°C). The chloroform fraction (at the bottom) was isolated, and the aqueous 
fraction was washed twice with chloroform (1 mL). The three chloroform fractions were 
pooled and dried under nitrogen at 40°C. The samples were stored overnight in -20°C, 
and redissolved in methanol:chloroform (2:1) to be applied to hpTLC plates.
High performance Thin Layer Chromatography (hpTLC)
To analyze cholesterol and phospholipid contents of the samples, separate hpTLC plates 
were used, because the developing solvent mixtures differ as previously described.21 All 
hpTLC plates were prerun (full height) with methanol:ethylacetate (6:4) in a Camag 
horizontal developing chamber (Merck) to remove impurities. The plates were activated 
for 10 minutes at 130°C. The first plate was used for phospholipids analysis, whereas the 
second plate was used for cholesterol analysis.
The identification of phospholipids species was based upon a standard mixture of 
commercial phospholipid standards that was applied to each hpTLC plate. The density of 
these spots was analyzed by photodensitometric scanning by a GS-800 Calibrated Imaging 
Densitometer (Bio-Rad; Veenendaal, The Netherlands), quantified using Quantity One 
software version 4.2.2 (Bio-Rad; Veenendaal, The Netherlands) and expressed as arbitrary 
units. 
Since plasma contains (phospho-)lipids and cholesterol, especially in the postprandial 
state, and the (washed) MP fraction still contains 1% plasma (final concentration), the 
lipid composition of MP was corrected for this confounder. Therefore, 25 μl of supernatant 
from the first washing step was taken and 225 μl of PBS containing 0.32% trisodiumcitrate 
(pH 7.4) added. These samples were also washed twice, extracted and analyzed, exactly as 
described for the MP preparation.
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Fibrin generation test (FGT)
The ability of MP to generate fibrin was measured directly in plasma of the participants 
in the absence or presence of anti-human (coagulation) factor VII, anti-human factor 
XI or anti-human factor XII (all provided by Sanquin, Amsterdam, The Netherlands) as 
previously described.22 After pre-incubation for 5 minutes at 37°C, clotting of plasma was 
initiated by addition of CaCl2. Fibrin formation was determined by measuring the optical 
density (λ=405 nm) in duplicate on a spectrophotometer (SPECTRAmax microplate reader; 
Molecular Devices Corp., Sunnyvale, CA) at 37°C.
Statistical analysis
Continuous variables are expressed as mean±SE, unless otherwise stated. To estimate the 
overall metabolic responses and the changes in MP during both visits, area under the curve 
(AUC) of these parameters plotted against time were calculated. Non-parametrical tests 
were performed for non-normally distributed data. Correlations were performed using 
the Spearman’s test. A P<0.05 was considered statistically significant. Data were analyzed 
with SPSS for Windows, release 15.0.
Table 6.1 Baseline and fasting characteristics of the study population
Healthy males (n=12)
Age, yrs 26.0±0.9
BMI, kg/m2 23.9±0.4
Waist, cm 87.6±1.3
Systolic blood pressure, mmHg 116±2
Diastolic blood pressure, mmHg 72±2
HbA1c, % 5.2±0.1
Glucose, mmol/L 4.9±0.1
Insulin, pmol/L 34±3
Total-cholesterol, mmol/L 4.0±0.2
HDL-C, mmol/L 1.36±0.1
LDL-C, mmol/L 2.3±0.2
Triglycerides, mmol/L 0.8±0.1
Values are mean±SE. BMI indicates body mass index; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol.
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RESULTS
Postprandial metabolic changes
The clinical and baseline laboratory characteristics of the participants are depicted in 
Table 6.1. The baseline concentrations of all parameters did not differ between the two 
study days. During the meal visit, plasma glucose, triglyceride and insulin concentrations 
rose significantly, especially after the second meal, albeit all within the normal range, as 
compared to baseline and the fasting visit (both P<0.05, P<0.001, P<0.001, respectively; 
Figure 6.1). During the fasting visit, plasma concentrations of NEFA rose significantly 
from 0.29±0.1 to 0.74±0.1 mmol/L (P<0.001 versus baseline and meals day).
Figure 6.1 Plasma concentrations of glucose, triglycerides, insulin and NEFA during the meal (solid 
circles) and fasting days (open circles) in healthy males. Meal intake is indicated by M. Bars (black, 
meals; white, fasting) in the insets represent respective AUC values. The P value is given for AUC 
difference. Data are mean±SE.
M M M M
P<0.001 P<0.001
M M M M
P<0.05 P<0.001
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Postprandial changes in circulating MP
The total numbers of MP, of which the largest fraction is platelet-derived (88-98%), 
increased during the meal visit compared to the fasting visit (P<0.05; Figure 6.2). Mean 
concentrations of erythrocyte-derived MP increased to more than 6-fold after consumption 
of both meals (P<0.001, versus baseline and fasting day), and remained unaffected during 
the fasting day. Finally, monocyte-derived MP concentrations, constituting only 0.3% of 
the total numbers of circulating MP, slightly increased during the meal visit (P=0.07 versus 
fasting). MP from lymphocytes, granulocytes, and endothelial cells were not detectable. 
The numbers of erythrocyte-derived MP correlated significantly with the corresponding 
insulin concentrations measured on both days (r=0.65, P<0.001). 
Figure 6.2 The course of total MP, platelet-derived MP, erythrocyte-derived MP and monocyte-
derived MP numbers/L during the meal (solid circles) and fasting (open circles) days in healthy males. 
Meal intake is indicated by M. Bars (black, meals; white, fasting) in the insets represent respective 
AUC values. The P value is given for AUC difference. Data are mean±SE.
M M M M
P<0.05 P=0.14
M M M M
P<0.001 P=0.07
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Postprandial changes in the phospholipid composition of circulating MP
Table 6.2 summarizes the overall phospholipid compositions of MP during the meal (+) 
and fasting (-) day, expressed as percentage of total phospholipid (mol/mol) after cor-
rection for the amount of phospholipids in MP-free plasma (see Methods). Compared 
to the fasting day, the relative % of phosphatidylcholine increased, whereas concurrently 
sphingomyelin decreased. Furthermore, the amount of phosphatidylinositol increased 
following the first meal. The phospholipids phosphatidylserine, phosphatidylinositol and 
phosphatidylethanolamine were not detectable in plasma that had been depleted from MP.
The cholesterol : phospholipid ratio of MP during the meals day did not change significantly. 
During the fasting day, however, the cholesterol : phospholipid ratio increased significantly 
from 0.34±0.1 to 0.49±0.1 (P<0.05; Figure 6.3).
Postprandial coagulation in vivo and in vitro
There were no significant differences between the meal and fasting day for both F1+2 and 
TAT concentrations (Figure 6.4). Furthermore, Figure 6.5 shows the results of the fibrin 
generation test on MP-containing plasma performed at baseline and at time point t=6 hours 
(i.e. 6 hours after breakfast and 2 hours after lunch; these time intervals were chosen since 
Table 6.2 Phospholipid composition of MP during postprandial or fasting state
Time points (hours)
Phospholipid Meals 0 2 4 6 8
L-PC + 1.3±0.8 0.9±0.8 1.0±0.8 1.3±0.8 1.3±0.8
- 1.2±1.0 1.2±1.2 1.2±1.2 1.1±1.3 1.6±0.9
SM* + 27±9.4 21±3.6# 23±5.5 22±4.5 22±4.7
- 24±5.8 23±6.3 25±5.0 25±4.7 25±5.5
PC* + 46±6.8 47±7.8 46±8.5 49±10# 48±13
- 42±12 43±11 42±11 43±9.2 41±11
PS + 8.1±6.6 12±7.5 9.2±7.3 8.2±7.2 9.1±6.7
- 13±12 13±11 11±7.5 11±8.4 12±12
PI + 6.1±3.8 6.4±3.6 6.9±3.6# 6.2±4.1 6.6±4.9
- 5.7±4.0 6.9±3.8 8.4±7.3 6.6±3.3 6.7±3.1
PE + 11±5.1 13±2.8 14±4.5 13±5.4 13±5.6
- 13±6.5 12±5.0 13±8.3 14±5.0 13±3.9
Data expressed as % of total phospholipid (mol/mol) ±SE. *P<0.05 (area under the curve), #P<0.05 (individual 
time points). L-PC indicates lyso-phosphatidylcholine; SM, sphingomyelin; PC, phosphatidylcholine; PS, phos-
phatidylserine; PI, phosphatidylinositol; PE, phosphatidylethanolamine.
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Figure 6.3 The cholesterol : phospholipid (PL) ratio of MP during the meal (solid circles) and fasting 
(open circles) days in healthy males. Meal intake is indicated by M. Data are mean±SE.
M M 
Figure 6.4 Plasma concentrations of F1+2 and TAT during the meal (solid circles) and fasting days 
(open circles) in healthy males. Meal intake is indicated by M. Bars (black, meals; white, fasting) in the 
insets represent respective AUC values. The P value is given for AUC difference. Data are mean±SE.
M M M M 
P=0.84 P=0.25 
Figure 6.5 Fibrin generation tests (FGT) at baseline (t=0 hours) and at t=6 hours during the meal 
(black bars) and fasting (white bars) days. Data are mean±SE.
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the metabolic changes were maximally different from baseline). There were no significant 
differences between the two days in the ability of MP to trigger fibrin formation in plasma 
in the absence or presence of anti-human factor VII, factor XI or factor XII.
DISCUSSION
The present study demonstrates that not only the numbers and cellular origin but also the 
phospholipid composition of circulating cell-derived MP changes after consumption of 
two consecutive high-fat mixed meals in healthy males. These changes, however, do not 
lead to enhanced coagulation activation in vitro and in vivo, suggesting that these relatively 
minor alterations in circulating MP are insufficient to cause a procoagulant state and that, 
under these physiological conditions, MP do not affect coagulation.  
Surprisingly, in the postprandial state, the numbers of erythrocyte-derived MP markedly 
increased and these numbers were strongly associated with insulin concentrations. Since 
insulin induces a Ca2+-dependent hyperpolarization of erythrocyte membranes, we 
hypothesize that this may be an inducer for the shedding of MP which is known to be 
highly calcium dependent.23-25 Previously, we demonstrated that erythrocyte-derived MP 
are associated with factor XI-dependent coagulation in sickle cell disease, but we could not 
confirm this association in the present study. A possible explanation is that the changes 
in the phospholipid composition, especially the presence of oxidized and nonoxidized 
phospholipids, may differentially affect coagulation.26 
In healthy individuals, cell-derived MP originate predominantly from platelets and contain 
mostly phosphatidylcholine and sphingomyelin, with smaller amounts of phosphatidyl-
ethanolamine, phosphatidylserine, and phosphatidylinositol, and minute quantities of the 
lysophospholipids lyso-phosphatidylcholine, lyso-phosphatidylethanolamine and lyso-
phosphatidylserine. We showed that following 2 consecutive meals the relative amount 
of phosphatidylcholine increases, whereas concurrently sphingomyelin decreases in MP, 
compared to a fasting day. Furthermore, following a meal, the relative amount of phosp-
hatidylinositol in MP also increases. These findings confirm earlier studies showing that 
changes in the phospholipid composition of MP vary between cell types and depend on 
the activation status of the parental cell,21,27,28 e.g. platelet-derived MP originating from 
collagen-activated platelets contained less phosphatidylcholine and more sphingomyelin, 
phosphatidylethanolamine and phosphatidylserine than non-stimulated platelets.27 Fur-
thermore, the postprandial increase of phosphatidylinositol in MP following a high fat 
meal is in line with a previous finding showing that the amount of this phospholipid is 
increased in membranes from erythrocytes of diabetic patients.29 
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One of the important findings of the present study is that the total amount of phospha-
tidylserine present in MP fractions remained unaffected by fasting or meals in healthy 
subjects. Since phosphatidylserine exposed by MP or cells is believed to support the binding 
of (activated) coagulation factors and thus the formation of tenase and prothrombinase 
complexes, our present results may explain why we found neither differences in coagulation 
activation in vivo nor as coagulation activation potency in vitro. 
In the present study, the phospholipid composition of in vivo MP was corrected for the 
plasma background. We found this correction to be essential, since both MP and MP-
depleted plasma contained substantial quantities of phosphatidylcholine and sphingomy-
elin.30 In contrast, the quantities of phosphatidylserine, phosphatidylinositol and phos-
phatidylethanolamine were below the detection limit of our assay in MP-depleted plasma, 
whereas phosphatidylserine, phosphatidylinositol as well as phosphatidylethanolamine 
were clearly detectable in the corresponding fractions of MP. This finding implicates that 
determination of the concentrations of phosphatidylserine-exposing microparticles or their 
coagulant properties by capturing the MP from plasma by using ELISA plates coated with 
annexin V may be a suitable tool for MP detection and possibly quantification ex vivo. 
The observed increase in the cholesterol : phospholipid ratio of circulating MP during a 
prolonged episode of fasting and its association with plasma NEFA concentrations may be 
of interest. During the fasting day, the concentrations of NEFA in our healthy population 
increased almost 3-fold due to unsuppressed lipolysis, reaching levels that are found 
in fasting patients with type 2 diabetes.31 Previously, it was shown that the amount of 
cholesterol in membranes of erythrocytes and leukocytes is associated with plasma fatty 
acids in patients with type 2 diabetes.32 Furthermore, we demonstrated previously that 
MP released upon platelet activation have an increased cholesterol content.21 It has been 
shown in several studies that growing cells in media with an altered balance of specific 
lipids, particularly oligo-unsaturated fatty acids and sterols such as cholesterol, affect the 
lipid composition of the plasma membrane.33,34 Since cholesterol plays several structural 
and metabolic roles, particularly in membranes, cells may shed MP to cope with acute 
lipid changes in plasma to retain their membrane qualities.
In conclusion, the numbers, cellular origin and phospholipid composition of cell-derived 
MP change upon consumption of 2 consecutive high-fat mixed meals in healthy males. 
However, these changes do not seem to affect the ability of circulating MP to activate 
coagulation, both in vivo and in vitro. We therefore hypothesize that the observed 
differences in (phospho-)lipid composition of cell-derived MP on fasting and meal days 
reflect the ability to maintain membrane homeostasis, rather than to modify coagulation.
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INTRODUCTION 
Type 2 diabetes (T2DM) is associated with prolonged and exaggerated postprandial 
hyperglycemia and hypertriglyceridemia, endothelial dysfunction and cardiovascular disease 
(CVD).1-7 Endothelial dysfunction may link postprandial dysmetabolism to CVD.5-7 Since the 
postprandial state unveils the full scope of metabolic abnormalities in T2DM, previous studies 
in fasting subjects may have underestimated the true risk.1 Currently, endothelial functions 
can only be estimated from indirect measurements, such as flow-mediated dilation (FMD).6,8
Cell-derived microparticles (MP) are released by cells in response to stress. Increased 
numbers of MP of various cellular origin circulate in patients at risk of CVD.9,10 Recently, 
VE-Cadherin (CD144) positive MP were demonstrated in T2DM patients with coronary 
artery disease and patients with end-stage renal disease.11,12 Since VE-Cadherin is exclusively 
expressed by endothelial cells, CD144-positive MP may be regarded as endothelium-derived 
MP (EMP), directly reflecting endothelial damage. However, it is unknown whether 
circulating EMP are cause or consequence of CVD and whether their occurrence associates 
with CVD per se or rather with diabetes-related metabolic abnormalities. 
We hypothesize that exposure of patients with uncomplicated T2DM to 3 consecutive 
high-fat mixed meals, given during a 24-h period, will disclose the full scope of their 
compromised metabolism and subsequent endothelial dysfunction, measured as FMD 
and circulating EMP. 
RESEARCH DESIGN AND METHODS
After obtaining informed consent, 27 non-smoking Caucasian males (n=15 with uncom-
plicated T2DM, n=12 healthy age-matched volunteers) were studied during a 24-h period. 
No drug use other than sulfonylureas and/or metformin was allowed. After an overnight 
fast, subjects received 3 consecutive, isocaloric (900 kcal), mixed meals (75g carbohydrates, 
50g fat (60% saturated), 35g protein), at time points t=0 (breakfast), 4 hours (lunch), and 
8 hours (diner). The study was approved by the local ethics committee and conformed to 
the principles of the Declaration of Helsinki.
Venous blood samples were collected before and at fixed intervals following the first meal 
as described previously.13 To avoid artifacts, no in-dwelling canulae were used and for each 
blood collection a new collecting system (Microflex, size 1.0mm - 19G, Vygon, France) 
was employed. Plasma aliquots (250 μL) were obtained after centrifugation (1550g, 20 
minutes, 20°C) and snapfrozen in liquid nitrogen and stored at -80°C until assay. Glucose, 
HbA1c, insulin and lipids were measured as previously described.13
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MP were isolated and analyzed as described using a FACScan flow cytometer with 
CellQuest software (Becton Dickinson, San Jose, CA).9,13 MP were identified on forward 
scatter (FSC), sideward scatter (SSC), binding of annexin-V and a monoclonal antibody 
directed against a cell type-specific antigen, and quantified as described.9,13 Samples were 
analyzed by a blinded technician.
Before each blood collection, FMD was measured at the right brachial artery by a single 
observer (CV<2%) using ultrasound (Wall-track System, PieMedical, Maastricht, The 
Netherlands).8,13 
To estimate the overall changes during 24-h, the area under curve (AUC) of metabolic 
parameters, FMD and MP, plotted against time was calculated. Data were analyzed by 
repeated-measures ANOVA, with time of measurement as the within factor and group as 
the grouping factor. Non-normally distributed data were log transformed before analysis, 
otherwise, non-parametrical tests were performed. Post hoc tests were only performed 
when ANOVA revealed overall significant differences. Correlations were performed using 
the Spearman’s test. A P<0.05 was considered statistically significant.
RESULTS
At baseline, T2DM patients (mean age 55±2 yrs) had higher BMI, blood pressure, HbA1c 
(7.1±1.1%), plasma glucose, triglycerides and insulin levels, but lower HDL-C than controls 
(data not shown). 
Plasma glucose, triglyceride and insulin concentrations rose postprandially in patients, 
relative to baseline and healthy controls (Figure 8.1A; all P<0.05). AUC glucose, 
triglycerides and insulin concentrations were significantly higher in patients vs. controls 
(all P<0.02).  
At baseline, FMD was decreased in patients vs. controls (5.5% vs. 8.9%; P<0.01), and 
deteriorated postprandially in both groups (Figure 8.1B). FMD during 24-h was reduced in 
patients vs. controls (P<0.01) and was inversely associated with AUC glucose, triglycerides 
and insulin (r=-0.77, r=-0.52 and r=-0.59, all P<0.01, respectively).
Total MP at baseline and AUC of total MP were similar in patients and controls (3.2x109/L 
vs. 3.5x109/L, P=0.32). In patients, the CD144-EMP fraction at baseline was higher than in 
controls (1.9%±2.0 vs. 0.8%±1.1, P<0.05), and rose significantly to 2.2±4.6% (vs. controls: 
0.6±0.9%, P<0.05) at t=12h, i.e. after consumption of all 3 meals (Figure 8.1C).
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AUC CD144-EMP was positively correlated with AUC glucose, triglycerides and insulin 
(r=0.51, r=0.38 and r=0.57, all P<0.05, respectively) and negatively associated with FMD 
during 24-h (r=-0.60, p<0.01; Figure 8.1D).
When 5 subjects per group were additionally studied during a 10-h fast, no increase of 
CD144-EMP was found (data not shown). 
Figure 8.1 A: The 24-h course of plasma glucose, triglyceride, and insulin concentrations in T2DM 
(open circles) and healthy subjects (solid circles). B: Changes in flow-mediated dilation (FMD) in T2DM 
(open circles) and healthy subjects (solid circles) during the 24-hour study day. C: Representative FACS 
dot plots of endothelium-derived MP (EMP) of a T2DM patient before (left) and after (right panel) 3 
high-fat mixed meals and the 24-h course of EMP in T2DM (open circles) and healthy subjects (solid 
circles). Data in A, B and C are mean±SD. D: Scatter plot representing the relationship between FMD 
during 24-h and EMP in T2DM (open circles) and healthy subjects (solid circles).
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CONCLUSIONS
CD144-MP circulate in patients with uncomplicated T2DM and associate with postprandial 
metabolic derangements and impaired FMD. We mimicked a real-life situation by giving 
T2DM patients 3 consecutive meals to unveil the true burden of meal-induced metabolic 
disturbances during a 24-h period.1 These derangements coincided with the highest levels 
of CD144-MP, which are derived from endothelial cells only. Other investigators used CD31 
(i.e. PECAM-1) to identify EMP.14 However, CD31 is not only present on endothelial cells, 
but also on platelets and platelet-derived MP, the latter being the most abundant MP in the 
circulation.10,15 Therefore, previously reported EMP numbers may be an overestimation 
of the actual EMP. 
Under physiological conditions, the ability of cells to release MP may reflect their capacity 
to cope with stress.9,10 By shedding caspase 3-containing MP, cells may prevent apoptosis 
and maintain homeostasis.9 In disease, however, the ability to handle cell stress and to 
release MP may be altered. This may explain the difference between our present and 
earlier findings, showing that in well-trained young healthy males the total numbers of 
circulating MP rose postprandially, whereas in T2DM patients no diurnal changes in total 
MP were observed and only a trend towards total MP elevation was observed in controls 
(data not shown). Thus, in T2DM, the ability of (endothelial) cells to respond to excessive 
metabolic stress may be impaired.  
To summarize, in uncomplicated T2DM, consumption of high-fat meals results in 
dysmetabolic changes and subsequent endothelial stress and injury, thereby contributing 
to atherogenesis and CVD risk. The possible value of CD144-MP as a marker to quantify 
endothelial dysfunction and/or injury needs further exploration.
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ABSTRACT
Microparticles are ascribed important roles in coagulation, inflammation and endothelial 
function. Inasmuch as these processes are mandatory to safeguard the integrity of the 
organism, their derangements contribute to the development of atherosclerosis and 
cardiovascular disease. More recently, the presumed solely harmful role of microparticles 
has been challenged, as microparticles may also be involved in maintenance and 
preservation of cellular homeostasis, and in promoting defense mechanisms. Here, we 
summarize recent studies revealing these two faces of microparticles in cardiovascular 
disease.
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INTRODUCTION 
Cardiovascular disease (CVD) remains the leading cause of death in developed countries 
despite advances in treatment.1 Although assessment and treatment of traditional 
cardiovascular risk factors, including hypertension, diabetes and smoking, play a central 
role in primary and secondary disease prevention, even adequate treatment of these risk 
factors does not completely reduce the risk of CVD. Therefore, a quest for novel biomarkers 
or mediators is ongoing, which may help us to gain more insight into the mechanisms 
leading to the development of atherosclerosis, the underlying cause of CVD.2 Cumulating 
evidence suggests that microparticles, i.e. vesicles budded from the outer membrane of cells 
upon their activation or as part of the apoptosis of the cell, and other microvesicles, may 
provide such a mediator. Since their identification in the late 60s of the previous century, 
the scientific and clinical interest in cell-derived microparticles has increased substantially. 
This is not surprising, because microparticles affect not only coagulation and inflammation, 
but also endothelial function, cellular survival and intercellular communication.3-5  
The majority of microparticles in blood is derived from platelets, whereas microparticles 
from erythrocytes, granulocytes, monocytes, lymphocytes and endothelial cells are also 
present, albeit at much lower numbers. There are substantial differences between the 
fractions of microparticles or subpopulations in blood of healthy subjects and those 
present in patients suffering from diseases with increased thromboembolic risk or vascular 
damage, such as atherosclerotic vascular disease, sepsis, diabetes mellitus, chronic severe 
hypertension and preeclampsia.3-5 Accordingly, in patients with acute myocardial infarction 
elevated numbers of microparticles are present compared to healthy controls.3,6,7 Moreover, 
subtypes of microparticles differ between patients with stable angina and acute coronary 
syndromes or myocardial infarction.7,8 Earlier it was demonstrated that microparticles from 
patients with myocardial infarction cause endothelial dysfunction and might contribute 
to the general vasomotor dysfunction observed after myocardial infarction.9
The clinical relevance of the presence of microparticles in blood of healthy subjects is as yet 
unclear, but can be regarded as a reflection of the dynamics of their production by resting, 
activated and apoptotic cells, and their clearance. In vascular disease states it remains to 
be elucidated whether microparticles are a cause or a consequence of the condition, since 
disease-related factors such as infectious agents, cytokines and metabolic disturbances 
are all known to affect the release of microparticles.3-5 Still, it is likely that microparticles 
contribute to the severity of disease, as microparticles can disseminate procoagulant and 
proinflammatory activities. Therefore, microparticles may be viewed as part of a cascade 
of reactions in response to various stimuli. The stimulus that leads to their generation 
determines their numbers, size, biochemical composition and functional characteristics. 
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Microparticles are likely to be important and essential mediators of physiological and 
pathological conditions, and in this review we will focus on the clinical relevance of 
microparticles in CVD. 
MICROPARTICLES: FRIEND OR FOE?
All body fluids, ranging from blood and urine to lacrima and mother milk, and human 
atherosclerotic plaques contain cell-derived vesicles. Microparticles as outer membrane-
derived vesicles are one type of vesicles, as are exosomes, which are extruded from 
intracellular multivesicular bodies once these fuse with the outer membrane. Different 
types of vesicles originating from a variety of cells are concurrently present in our body 
fluids under physiological and pathological conditions. Most clinical studies thus far have 
focused on the presence of microparticles in blood, their cellular origin, composition and 
function in disease.3-5
Microparticles may have not only deleterious effects by promoting coagulation and 
inflammation, or by modifying endothelial function, which all contribute to development 
of CVD, but may also have beneficial effects. First, recent studies have shown that 
microparticles are efficient vectors that exchange biological information between cells 
(intercellular communication).3-5 Second, the release of microparticles protects cells against 
the consequences of external stimuli or stress. Endothelial cells escape from complement-
induced lysis by releasing microparticles carrying the lytic complement C5b-9 complex.10 
Similarly, the release of microparticles protects cells against an overshoot in (internal) 
cellular reactions triggered by external stressors. With regard to the latter, microparticles 
play a role in “cellular waste management”, as they contain increased (compared to the 
parent cell) concentrations of chemotherapeutics, oxidized phospholipids or caspase 3.3-5 
Microparticles of viable, non-apoptotic cells, including endothelial cells, contain caspase 
3 in vitro and in vivo.11-13 Endothelial cells accumulate caspase 3 and undergo apoptosis 
when the release of (caspase 3-containing) microparticles is inhibited,13 indicating that 
the release of microparticles is part of a protective mechanism to prevent the intracellular 
accumulation of caspase 3 at dangerously high levels. Possibly, caspase 3 facilitates its own 
removal from cells by cleaving several kinases, including Rho-associated kinase I (ROCK-I) 
and p21-activated kinase (PAK), which become constitutively active upon cleavage and 
promote membrane blebbing. Upon incubation of human endothelial cells with simvastatin 
at clinically relevant concentrations, the cells remain viable and seemingly unchanged, but 
a marked increase in caspase 3-containing microparticles is observed, suggesting that an 
increased release of caspase 3-containing microparticles is needed to help the cells to remain 
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healthy and viable.14 It should be mentioned that the effects of statins on the release of 
microparticles may depend on the cell types studied, the experimental conditions including 
the concentration and type of statin used, or the combined application of a statin with a 
pro-inflammatory or pro-apoptotic inducer, but it is beyond the scope of this brief review 
to elaborate on this topic. In line with our results are the findings that in patients with 
subclinical or less occlusive atherosclerosis, higher numbers of endothelial microparticles are 
present compared to patients with established or symptomatic atherosclerosis,8,15 suggesting 
that the ability of the endothelium to release microparticles depends on its integrity and 
viability. In other words, if the ability of the endothelium to release microparticles becomes 
impaired or inhibited, the integrity and viability of the cells may deteriorate.
Microparticles and coagulation
The most described and reviewed characteristic of circulating and atherosclerotic 
plaque-derived cell-derived microparticles is their procoagulant phenotype. By exposing 
phosphatidylserine and sometimes tissue factor (TF), microparticles can initiate 
and propagate coagulation.3-5 However, TF seems often to be exposed by circulating 
microparticles in a non-coagulant form, as shown in patients with type 2 diabetes.16 This 
inactive or encrypted TF may become pro-coagulant after the capturing of the TF-bearing 
microparticles in the developing thrombus.17 This is supported by the recent finding that 
those patients with acute ST-segment elevation myocardial infarction, who had the highest 
plasma level of TF-exposing microparticles, were characterized not only by a pro-coagulant 
phenotype as reflected by increased plasma levels of thrombin-antithrombin complexes, but 
also by an increased risk of fibrinolysis failure.18 Furthermore, microparticles accumulate 
in human atherosclerotic plaques, and these microparticles have an increased ability to 
initiate tissue factor-dependent coagulation compared to the plasma microparticles.19 
The capturing of TF-bearing microparticles in the developing thrombus, that finally 
results in arterial occlusion, is thought to be mediated by P-selectin and / or CD36 exposed 
on activated platelets.17,20 Important factors in de-encryption of the TF procoagulant 
activity are protein disulfide isomerases (PDI), believed to be released from platelets and 
endothelial cells. In addition, platelet microparticles can expose PDI.21 Very recently, it was 
demonstrated that fibrin generation in vivo required PDI released from endothelial cells, 
whereas platelet-derived PDI contributed only to the total amount of thrombus-associated 
PDI but was not required.22 
The relationship between microparticles and coagulation as well as other processes is 
very complex. For instance, under normal conditions a continuous low grade generation 
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of thrombin is essential for activation of protein C, which in turn efficiently inhibits 
additional thrombin generation by inactivating coagulation factors Va and VIIIa. Previously, 
we reported that plasma samples from healthy human individuals containing low levels 
of microparticles have relatively high concentrations of thrombin-antithrombin and 
prothrombin fragment 1+2, suggesting that in these subjects insufficient activation of 
protein C may occur.23-25 Under clinical conditions, where elevated levels of microparticles 
can be present and where microparticles may expose coagulant TF, this inverse correlation 
is no longer present and then microparticles are more directly associated with in vivo 
coagulation activation. 
Microparticles are now thought to contribute to acute thrombus formation via various 
mechanisms, but also to contribute to anti-coagulant responses to modulate an adequate 
and physiologic coagulation response. Additional research, however, is essential to better 
understand their contribution to coagulation in clinical conditions, including CVD.     
Microparticles and inflammation
Similar to coagulation, inflammatory processes contribute to the pathogenesis of athero-
thrombotic vascular disease.26 Patients with elevated plasma levels of inflammation markers, 
including C-reactive protein (CRP), are at a high-risk to develop CVD, including those 
with diabetes mellitus, the metabolic syndrome, as well as those with chronic systemic 
inflammatory or autoimmune disease such as patients with rheumatoid arthritis (RA).26,27 
Microparticles may contribute to inflammatory responses by various mechanisms.3-5 For 
example, microparticles from leukocytes stimulate the expression of proinflammatory 
genes in endothelial cells, leading to the production of cytokines and leukocyte-endothelial 
cell adhesion molecules in vitro.28 Furthermore, microparticles in plasma samples from 
high-risk patients expose complement components C1q, C3 and C4, as well as several 
complement activator molecules, including CRP in patients with RA and IgG but not CRP 
in patients with myocardial infarction.29,30   
But again, microparticles may also have a beneficial function in the inflammatory response. 
Microparticles from polymorphonuclear leukocytes contain the functionally active anti-
inflammatory protein annexin 1 (AnxA1), and AnxA1-containing microparticles inhibit 
the interaction between leukocytes and endothelial cells in vitro as well as in an animal 
model in vivo.31 So, in health, microparticles can affect both pro- and anti-inflammatory 
processes, thus assuring an appropriate inflammatory response. In diseases such as RA or 
atherosclerosis, their increased and prolonged presence, altered properties and activities 
may become harmful and contribute to overall vascular deterioration.
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Microparticles and endothelial functions
Under normal conditions, the multiple functional characteristics of the endothelium, that 
in addition to anti-inflammation and anti-coagulation include the regulation of the vascular 
tone, vascular wall permeability, and cell growth collectively protect the vascular system. 
An altered function of endothelial nitric oxide (NO) synthase (eNOS) and/or decreased 
bioavailability of NO are fundamental abnormalities that can lead to the pathophysiological 
manifestations of endothelial dysfunction.32 In vitro, microparticles from various cellular 
and/or disease origin induce endothelial dysfunction, especially by altering the balance 
between NO and reactive oxygen species (ROS) production and release.33-35 For example, 
microparticles from T-lymphocytes decrease the NO production and increase oxidative 
stress in endothelial cells.35 These effects are associated with a reduction of eNOS activity, 
which depends on phosphatidylinositol-3-kinase (PI3K), ERK½, and NF-кВ pathways. The 
increase of ROS production that is down-regulated by the PI3K pathway involves xanthine 
oxidase and NF-кВ pathways. Also, exposure to microparticles results in increased caveolin-1 
expression and decreased phosphorylation, respectively, these effects being independent of 
the PI3K and ERK½ cascade.35 In vivo, NO-associated vasodilatation following shear stress 
can be measured by ultrasound of the brachial artery (flow-mediated dilatation (FMD)), and 
is associated with the viability of the endothelium. Of interest, an impaired FMD has been 
associated with the presence of endothelial microparticles in various clinical conditions.36,37 
In contrast to the harmful role of microparticles, they may actually improve endothelial 
dysfunction. T-cell microparticles carrying the morphogen sonic hedgehog (Shh) induced 
NO production directly by the Shh pathways (involving PI3-kinase and Akt).38 Using a 
model of ischemia/reperfusion in mice, these Shh-presenting microparticles enhanced 
NO-mediated relaxation of mouse coronary arteries in vivo in response to acetylcholine, 
which was accompanied by an increase of NO production in tissues and blood even after 
ischemia/reperfusion. Moreover, microparticles, especially those of non-platelet origin, 
released during sepsis, the clinical condition that ultimately challenges the endothelium, 
were protective against vascular hypo-reactivity which accounts for hypotension in patients 
with septic shock.39 In agreement with these results, Soriano and coworkers have shown 
that elevated levels of endothelial and platelet microparticles predict a more favorable 
outcome in severe sepsis in terms of mortality rate and organ dysfunction.40 Evidently, 
microparticles are able to restore endothelial injury through their dual ability to increase 
NO and reduce ROS. In summary, microparticles can have both detrimental and beneficial 
effects on endothelial functions, especially by altering the balance between NO and ROS 
production and release. It seems that these effects are depending on the specific stimulus 
underlying the release of microparticles by their parent cells. 
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Finally, it should be mentioned that circulating as well as atherosclerotic plaque-
derived microparticles can affect angiogenesis. One characteristic feature of vulnerable 
atherosclerotic plaques is an increased number of vasa vasorum. Whereas in initial studies 
microparticles from platelets and endothelial cells were shown to promote and inhibit 
angiogenesis in vitro, respectively, more recently Leroyer and coworkers showed that 
microparticles isolated from human atherosclerotic plaques not only promote endothelial 
cell proliferation in vitro but also stimulate angiogenesis in vivo. Thus, microparticles 
may contribute to neovascularization of atherosclerotic plaques, thereby affecting the 
vulnerability of rupture.41-43
Microparticles and cardiovascular disease
In the light of the above-described pro-coagulant and pro-inflammatory properties of 
microparticles, together with the association between elevated numbers of microparticles 
and clinical CVD, the prevailing view is that circulating microparticles are harmful, 
contributing to CVD and risk thereof. However, as outlined above, besides their potentially 
harmful effects, cell-derived microparticles may also be beneficial and as such protect 
against cellular and vascular damage. This is summarized in Figure 9.1. Therefore, it 
is not surprising that both elevated as well as lower levels of circulating microparticles 
have been associated with (risk factors of) CVD. For example, cigarette smoking is a well 
established risk factor for CVD and has been reported to lead to haemostatic, platelet and 
endothelial abnormalities.44 Whereas the numbers of platelet microparticles tended to be 
lower in young males compared to non-smoking controls, levels of circulating endothelial 
microparticles were elevated upon secondhand smoke exposure, and exposure of human 
monocytes to smoke increased the release of (TF-exposing) microparticles.45-47 It is clear 
that smoking affects the release of microparticles, but this effect is likely to be cell-type, 
concentration and duration dependent.  
Interestingly, elevated platelet microparticles were described in patients with both type 1 
and 2 diabetes mellitus, those with hyperlipidemia, obesity / the metabolic syndrome and 
hypertension.3,5 Thus, in plasma samples from patients with chronic severe hypertension 
compared to patients with mild hypertension and controls, higher numbers of microparticles 
exposing PECAM-1 (CD31) but not glycoprotein Ib (CD42), i.e. microparticles presumably 
of endothelial and/or platelet origin, were found.48,49 In these patients, elevated numbers 
of microparticles are likely to reflect the cellular stress of endothelial cells and platelets. 
In addition, microparticles from plasma of hypertensive patients with albuminuria 
attenuated proliferation and migration of endothelial progenitor cells, and increased 
endothelial hydrogen peroxide production, cellular senescence and apoptosis compared 
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to microparticles from hypertensive patients with normoalbuminuria.50 This suggests that 
the release of microparticles contributes to the progression of endothelial damage and this 
could then result in a vicious circle. 
High numbers of circulating microparticles of different cellular origin have been associated 
with subclinical atherosclerosis, measured by carotid intima-media thickness (cIMT) and 
coronary artery calcifications, quantified by computer tomography, as described by several 
authors.8,15,51-53 Recently, it was proposed that circulating microparticles are the major factor 
associated with carotid artery remodeling, with high numbers of circulating microparticles 
preventing compensatory remodeling in vessels with increased cIMT.53 Moreover, 
T-cadherin-exposing endothelial microparticles were elevated in patients with subclinical 
atherosclerosis, not only compared to healthy subjects but also to patients with established 
coronary artery disease, suggesting that the shedding of T-cadherin-positive microparticles 
represents a protective mechanism that can shift the balance in cellular stress response to the 
pro-survival signaling branches, which is only later followed by deleterious and apoptotic 
Figure 9.1 Proposed model describing the role of microparticles in cardiovascular health and disease. 
Cells release microparticles (left, green) to ensure homeostasis. These microparticles contribute to 
the regulation of physiological processes including (anti)coagulation, inflammation and regulation 
of endothelial functions. Under abnormal (stress) conditions, cells release microparticles that differ 
in numbers, composition and function (right, red), thereby contributing to a procoagulant and 
proinflammatory phenotype, endothelial dysfunction, as part of the development of cardiovascular 
disease.
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phases.15 This indicates that the release of microparticles attenuates compensatory outward 
artery remodeling in patients with (subclinical) atherosclerosis. However, longitudinal 
rather than the presently available cross-sectional studies are required to definitively 
demonstrate the causative role of microparticles in arterial remodeling. 
An important clinical question is whether microparticles are markers of CVD risk 
and whether they can be used as independent predictors of CVD outcome in relevant 
populations. Recently, the associations of the Framingham Risk score and numbers of 
platelet-, leukocyte-, endothelial progenitor-cell- and endothelium-derived microparticles 
where reported.52,54-56 From these four studies, only one included a prospective investigation, 
in which 488 patients with various CVD risk factors were followed for a mean period of 
36 months.56 The addition of endothelial (CD144+)-microparticles to the Framingham 
risk model improved not only the classification of risk, but also appeared as a significant 
and independent predictor of future CVD events in a high-risk population.56 These 
results are promising and imply that more prospective studies are needed to further detail 
the prognostic value of cell-derived microparticles in individuals at high risk for CVD. 
The lack of large-scaled studies in which microparticles are measured routinely may 
be partly due to the fact that to date the measurement of microparticles is still complex 
and elaborate. The detection and characterization of (individual) microparticles and 
other vesicles remains difficult due to their small size and heterogeneity, which has lead 
to confusing and sometimes conflicting results between laboratories.57 In addition, the 
detection of rare microparticles, e.g. endothelial microparticles, remains a real challenge. 
Whereas some laboratories have used antibodies against specific endothelial proteins, 
other investigators have used non-endothelial specific antibodies or combinations 
thereof.57,58
CONCLUSION
Since their presence and role in various diseases has been recognized, the interest in cell-
derived microparticles, also as markers or as mediators in the development of CVD, has 
grown substantially. Over the past years, the role of microparticles in the development 
of CVD has changed from “platelet-dust” or artifacts to novel and possibly essential 
elements in cellular homeostasis and communication. Furthermore, the release of 
microparticles contributes to the activation of (intentionally protective) protein cascades 
such as coagulation, inflammation, and also endothelial dysfunction (Figure 9.1), which 
all facilitate atherogenesis. Therefore, microparticles may not only reflect the presence of 
CVD, but also play a causative role in the development of CVD. 
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On the other hand, the release of microparticles can protect cells from dangerous or 
redundant products, compounds or cellular waste that may accumulate in response to cell 
stress induced by e.g. CVD risk factors. Thus, microparticles can contribute to cellular 
homeostasis. Although the release of microparticles may be beneficial to the individual 
cell releasing these microparticles, this release can also have paracrine and even systemic 
effects, affecting the surrounding cells. Whether cell-derived microparticles are a cause 
and / or a consequence of CVD remains to be established. Large-scaled prospective 
studies rather than the presently available cross-sectional studies, are mandatory to more 
definitively demonstrate the interrelation of changes in occurrence, phenotype and function 
of microparticles and the incidence and progression of CVD in various populations.
FUTURE DIRECTIONS
Future research should focus on further characterisation of cell-derived microparticles as 
opposed to exosomes and possibly other cell-derived vesicles in various diseases. Moreover, 
multidisciplinary research should focus on further refinement and validation of detection 
methods of microparticles. These methodological investigations may contribute to more 
uniformity and validation of microparticle quantification, detection, identification of their 
parent cell and biochemical and functional characterisation. With a multidisciplinary 
approach and the proper verification studies in relevant patient populations, microparticles 
may prove out to be true biomarkers of disease state and progression.
REFERENCES
1. American Heart Association. Statistical Fact Sheet — Populations 2007 Update. Dallas, Texas: 
American Heart Association; 2007 (http://www.americanheart.org; September 1, 2010).
2. Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of 
cardiovascular risk: a review for clinicians. J Am Coll Cardiol 2009; 54: 1209-27.
3. Diamant M, Tushuizen ME, Sturk A, Nieuwland R. Microparticles: New players in the field of vascular 
disease? Eur J Clin Invest 2004;34:392-401. 
4. Boulanger CM, Amabile N, Tedgui A. Circulating microparticles: a potential prognostic marker for 
atherosclerotic vascular disease. Hypertension 2006;48:180-6.
5. Nomura S, Ozaki Y, Ikeda Y. Function and role of microparticles in various clinical settings. Thromb 
Res 2008;123:8-23.
6. Van der Zee PM, Biró E, Ko Y, de Winter RJ, Hack CE, Sturk A, Nieuwland R. P-selectin- and 
CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and 
myocardial infarction. Clin Chem 2006;52:657-64.
Cellular microparticles and vascular diseaseChapter 9
162
7. Bernal-Mizrachi L, Jy W, Jimenez JJ, Pastor J, Mauro LM, Horstman LL, De Marchena E, Ahn YS. 
High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am 
Heart J 2003;145:962-70. 
8. Bernal-Mizrachi L, Jy W, Fierro C, Macdonough R, Velazques HA, Purow J, Jimenez JJ, Horstman LL, 
Ferreira A, De Marchena E, Ahn YS. Endothelial microparticles correlate with high-risk angiographic 
lesions in acute coronary syndromes. Int J Cardiol 2004;439-46. 
9. Boulanger Cm, Scoazec A, Ebrahimian T, Henry P, Mathieu E, Tedgui A, Mallat Z. Circulating 
microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation 
2001;104:2649-52.
10. Sims PJ, Wiedmer T. Induction of cellular procoagulant activity by the membrane attack complex 
of complement. Semin Cell Biol 1995;6:275-82.
11. Abid-Hussein MN, Nieuwland R, Hau CM, Evers LM, Meesters EW, Sturk A. Cell-derived 
microparticles contain caspase 3 in vitro and in vivo. J Thromb Haemost 2005;3:888-96. 
12. Böing AN, Hau CM, Sturk A, Nieuwland R. Platelet microparticles contain active caspase 3. Platelets 
2008;19:96-103.
13. Abid-Hussein MN, Böing AN, Sturk A, Hau CM, Nieuwland R. Inhibition of microparticle release 
triggers endothelial cell apoptosis and detachment. Thromb Haemost 2007:98:1096-107. 
14. Diamant M, Tushuizen ME, Abid-Hussein MN, Hau CM, Böing AN, Sturk A, Nieuwland R. 
Simvastatin-induced endothelial cell detachment and microparticle release are prenylation dependent. 
Thromb Haemost 2008;100:489-97.
15. Philippova M, Suter Y, Toggweiler S, Schoenenberger AW, Joshi MB, Kyriakakis E, Erne P, Resink TJ. 
T-cadherin is present on endothelial microparticles and is elevated in plasma in early atherosclerosis. 
Eur Heart J 2010 Jun 28. [Epub ahead of print] 
16. Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JW, Radder JK. Elevated numbers of tissue-factor 
exposing microparticles correlate with components of the metabolic syndrome in uncomplicated 
type 2 diabetes mellitus. Circulation 2002;106:2442-7.
17. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008;359:938-49.
18. Huisse MG, Ajzenberg N, Feldman L, Guillin MC, Steg PG. Microparticle-linked tissue factor activity 
and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation 
myocardial infarction. Thromb Haemost 2009;101:734-40.
19. Leroyer AS, Isobe H, Leseche G, Castier Y, Wassef M, Mallat Z, Binder BR, Tedgui A, Boulanger CM. 
Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic 
plaques. J Am Coll Cardiol 2007;49:772-7.
20. Ghosh A, Li W, Febbraio M, Espinola RG, McCrae KR, Cockrell E, Siversteins RL. Platelet CD36 
mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in 
mice. J Clin Invest 2008;118:1934-43.
21. Chen K, Detwiler TC, Essex DW. Characterization of protein disulfide isomerase released from 
activated platelets. Br J Haematol 1995;90:425-31.
163
Cellular m
icroparticles and vascular disease
Chapter 9
9
22. Jasuja R, Furie B, Furie BC. Endothelium-derived but not platelet-derived protein disulfide isomerase 
is required for thrombus formation in vivo. Blood 2010 Jul 28. [Epub ahead of print]
23. Tans G, Rosing J, Thomassen MC, Heeb MJ, Zwaal RF, Griffin JH. Comparison of anticoagulant 
and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood 
1991;77:2641-8.
24. Perez-Casal M, Downey C, Fukudome K, Marx G, Toh CH. Activated protein C induces the release 
of microparticle-associated endothelial protein C receptor. Blood 2005;105:1515-22.
25. Berckmans RJ, Nieuwland R, Boing, AN, Romijn FP, Hack CD, Sturk A. Cell-derived microparticles 
circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001; 
85:639-46.
26. Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation 
in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009;54:2129-38.
27. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, McInnes IB, Haentzschel H, 
Gonzalez-Gay MA, Provan S, Semb A, Sidiropoulos P, Kitas G, Smulders YM, Soubrier M, Szekanecz 
Z, Sattar N, Nurmohamed MT. EULAR evidence-based recommendations for cardiovascular risk 
management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann 
Rheum Dis 2010;69:325-31.
28. Mesri M, Altieri DC. Endothelial cell activation by leukocyte microparticles. J Biol Chem 1999;274: 
2311-18.
29. Biró E, Nieuwland R, Tak PP, Pronk LM, Schaap MC, Sturk A, Hack CE. Activated complement 
components and complement activator molecules on the surface of cell-derived microparticles in 
patients with rheumatoid arthritis and healthy individuals. Ann Rheum Dis 2007;66:1085-92.
30. Van der Zee PM, Biró E, Trouw LA, Ko Y, de Winter RJ, Hack CE, Sturk A, Nieuwland R. C-reactive 
protein in myocardial infarction binds to circulating microparticles but is not associated with 
complement activation. Clin Immunol 2010;135:490-5.
31. Dalli J, Norling LV, Renshow D, Cooper D, Leung KY, Perretti M. Annexin 1 mediates the rapid 
anti-inflammatory effects of neutrophil-derived microparticles. Blood 2008;112:2512-19.
32. Widlansky ME, Gokce N, Keaney JF, Vita JA. The clinical implications of endothelial dysfunction. 
J Am Coll Cardiol 2003;42:1149-60.
33. Brodsky SV, Zhang F, Nasjletti A, Goligorsky MS. Endothelium-derived microparticles impair 
endothelial function in vitro. Am J Physiol Heart Circ Physiol 2004;286:H1910-5.
34. VanWijk MJ, Svedas E, Boer K, Nieuwland R, VanBavel E, Kublickiene KR. Isolated microparticles, 
but not whole plasma, from women with preeclampsia impair endothelium-dependent relaxation in 
isolated myometrial arteries from healthy pregnant women. Am J Obstet Gynaecol 2002;187:450-6. 
35. Mostefai HA, Agouni A, Carusio N, Mastronardi ML, Heymes C, Henrion D, Andriantsitohaina R, 
Martinez MC. Phosphatidylinositol 3-kinase and xanthine oxidase regulate nitric oxide and reactive 
oxygen species productions by apoptotic lymphocyte microparticles in endothelial cells. J Immunol 
2008; 180:5028-35.
Cellular microparticles and vascular diseaseChapter 9
164
36. Tushuizen ME, Nieuwland R, Rustemeijer C, Hensgens BE, Sturk A, Heine RJ, Diamant M. Elevated 
endothelial microparticles following consecutive meals are associated with vascular endothelial 
dysfunction in type 2 diabetes. Diabetes Care 2007;30:728-30.
37. Amabili N, Guérin AP, Leroyer A, Mallat Z, Nguyen C, Boddaert J, London GM, Tedgui, Boulanger 
CM. Circulating endothelial microparticles are associated with vascular dysfunction in patients with 
end-stage renal failure. J Am Soc Nephrol 2005;16:3381-8.
38. Agouni A, Mostefai HA, Porro C, Carusio N, Favre J, Richard V, Henrion D, Martinez MC, 
Andriantsitohaina R. Sonic hedgehog carried by microparticles corrects endothelial injury through 
nitric oxide release. FASEB J 2007;21:2735-41.
39. Mostefai HA, Meziani F, Mastronardi ML, Agouni A, Heymes C, Sargentini C, Asfar P, Martinez 
MC, Andriantsitohaina R. Circulating microparticles from patients with septic shock exert protective 
role in vascular function. Am J Respir Crit Care Med 2008;178:1148-55.
40. Soriano AO, Wenche J, Chirinos JA, Valdivia MA, Velasquez HS, Jimenez JJ, Horstman LL, Kett 
DH, Schein RM, Ahn YS. Levels of endothelial and platelet microparticles and their interaction with 
leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis. Crit 
Care Med 2005;33:2540-6.
41. Kim HK, Song KS, Chung JH, Lee KR, Lee SN. Platelet microparticles induce angiogenesis in vitro. 
Br J Haematol 2004;124:376-84.
42. Mezentsev A, Merks RM, O’Riordan E, Chen J, Mendelev N, Goligorsky MS, Brodsky SV. Endothelial 
microparticles affect angiogeneis in vitro: role of oxidative stress. Am J Physiol Heart Circ Physiol 
2005;289:H1106-14.
43. Leroyer AS, Rautou PE, Silvestre JS, Castier Y, Leseche G, Devue C, Duriez M, Brandes RP, Lutgens E, 
Tedgui A, Boulanger CM. CD40 ligand+ microparticles from human atherosclerotic plaques stimulate 
endothelial proliferation and angiogenesis: a potential mechanism for intraplaque neovascularisation. 
J Am Coll Cardiol 2008;52: 1302-11.
44. Leone A. Smoking, haemostatic factors, and cardiovascular risk. Curr Pharm Des 2007;13:1661-7.
45. Casey RG, Joyce M, Roche-Nagle G, Cox D, Bouchier-Hayes DJ. Young smokers have altered platelets 
and endothelium that precedes atherosclerosis. J Surg Res 2004;116:227-33.
46. Li M, Yu D, Williams KJ, Liu ML. Tobacco smoke induces the generation of procoagulant microvesicles 
from human monocytes/macrophages. Arterioscler Thromb Vasc Biol 2010; 30:1818-24.
47. Heiss C, Amabile N, Lee AC, Real WM, Schick SF, Lao D, Wong ML, Jahn S, Angeli FS, Minasi P, 
Springer ML, Hammond SK, Glantz SA, Grossman W, Balmes JR, Yeghiazarians Y. Brief secondhand 
smoke exposure depresses endothelial progenitor cells activity and endothelial function: sustained 
vascular injury and blunted nitro oxide production. J Am Coll Cardiol 2008; 51:1760-71.
48. Preston RA, Jy W, Jimenez JJ, Mauro LM, Horstman LL, Valle M, Aime G, Ahn YS. Effects of severe 
hypertension on endothelial and platelet microparticles. Hypertension 2003;41:211-7.
49. Pirro M, Schillaci G, Bagaglia F, Menecali C, Paltriccia R, Mannarino MR, Capanni M, Velardi 
A, Mannarino E. Microparticles derived from endothelial progenitor cells in patients at different 
cardiovascular risk. Atherosclerosis 2008;197:757-67.
165
Cellular m
icroparticles and vascular disease
Chapter 9
9
50. Huang PH, Huang SS, Chen YH, Lin CP, Chiang KH, Chen JS, Tsai HY, Lin FY, Chen JW, Lin 
SJ. Increased circulating CD31+/annexin V+ apoptotic microparticles and decreased circulating 
endothelial progenitor cells levels in hypertensive patients with microalbuminuria. J Hypertens 
2010;28:1655-65.
51. Jayachandran M, Litwiller RD, Owen WG, Heit JA, Behrenbeck T, Mulvagh SL, Araoz PA, Budoff MJ, 
Harman SM, Miller VM. Characterization of blood borne microparticles as markers of premature 
coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol 2008;295:H931-
8. 
52. Chironi GN, Simon A, Hugel B, Del Pino M, Gariepy J, Freyssinet JM, Tedgui A. Circulating 
leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. 
Arterioscler Thromb Vasc Biol 2006;26:2775-80.
53. Chironi GN, Simon A, Boulanger CM, Dignat-George F, Hugel B, Megnien J-L, Lefort M, Freyssinet 
JM, Tedgui A. Circulating microparticles may influence early carotid artery remodeling. J Hypertens 
2010;28:789-96.
54. Ueba T, Nomura S, Inami N, Nishikawa T, Kajiwara M, Iwata R, Yamashita K. Plasma levels of 
platelet-derived microparticles is associated with coronary heart disease risk score in healthy men. 
J Atheroscler Thromb 2010;17:342-9.
55. Pirro M, Schillaci G, Bagaglia F, Menecali C, Paltriccia R, Mannarino MR, Capanni M, Velardi 
A, Mannarino E. Microparticles derived from endothelial progenitor cells in patients at different 
cardiovascular risk. Atherosclerosis 2008;197:757-67.
56. Nozaki T, Sugiyama S, Koga H, Sugamura K, Ohba K, Matsuzawa Y, Sumida H, Matsui K, Jinnouchi 
H, Ogawa H. Significance of a multiple biomarkers strategy including endothelial dysfunction to 
improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. 
J Am Coll Cardiol 2009;54:601-8.
57. Jy W, Horstman LL, Jimenez JJ, Ahn YS, Biró E, Nieuwland R, Sturk A, Dignat-George F, Sabatier 
F, Camoin-Jau L, Sampol J, Hugel B, Zobairi F, Freyssinet JM, Nomura S, Shet AS, Key NS, Hebbel 
RP. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004;2:1842-51.
58. Abid-Hussein MN, Meesters EW, Osmanovic N, Romijn FPH, Nieuwland R, Sturk A. Antigenic 
characterization of endothelial cell-derived microparticles and their detection ex vivo. J Thromb 
Haemost 2003;1:2434-43.
Cellular microparticles and vascular diseaseChapter 9
166
10
General discussion and 
future perspectives
General discussion and future perspectivesChapter 10
168
The prevalence of obesity is reaching to pandemic proportions, mainly because of ageing, 
and global adopting of the so-called Western lifestyle, i.e. a high intake of energy dense 
food and a low physical activity pattern.1 These life-style changes lead to one of the key 
abnormalities underlying type 2 diabetes mellitus (T2DM), i.e. insulin resistance, which 
occurs often in the presence of central obesity, and the sequelae, i.e. hyperinsulinemia, 
hypertension and dyslipidemia. Collectively, these often concurring cardiometabolic 
derangements constitute the so-called metabolic syndrome (MetS).2 Separately, the 
features of the MetS are regarded as risk factors for the development of cardiovascular 
disease (CVD),3 and the CVD risk increases proportionally to the number of features 
present.4,5 In susceptible individuals with (genetically) compromised beta-cell function 
and/or beta-cell functional mass, the constant demand on the beta-cells will ultimately 
lead to beta-cell failure with ensuing hyperglycemia and T2DM. In insulin resistant 
individuals with T2DM, the metabolic abnormalities become even more pronounced 
upon challenge, such as in response to a meal, resulting in prolonged hyperglycemia, 
hypertriglyceridemia, elevated fatty acids and hyperinsulinemia. In these individuals, 
due to these prolonged and exaggerated metabolic derangements, all organ systems, 
including the heart and the vascular endothelium, are exposed to a pro-atherogenic, pro-
inflammatory and pro-thrombotic milieu for almost 24 hours a day. As the abnormal 
metabolic responses usually concur, it makes it more difficult to tease out their relative 
contribution to cardiovascular damage and to design studies focusing on the effects of a 
single factor. Furthermore, seemingly distinct mechanisms of action, when concurring, 
interact and produce synergistic increases in oxidative stress, protein kinase-C (PKC) 
activation and advanced glycation end-product receptor (RAGE) activation.6,7 Collectively, 
these derangements result in systemic and vascular inflammation, impaired endothelial 
function and ultimately, in CVD.8,9 Importantly, chronic inflammation and elevated 
oxidative stress are not only associated with the complications of obesity or diabetes, but 
have also been linked to insulin resistance in vitro and in vivo.10-12 
In this thesis, it is attempted to obtain a more detailed understanding of the previously 
reported relationship between the postprandial state and cardiovascular damage in high risk 
individuals. Accordingly, underlying mechanisms, including oxidative stress, endothelial 
function and quantitative and qualitative changes in cell-derived microparticles (MP), 
linking postprandial dysmetabolic alterations to vascular abnormalities were explored. Also, 
to this end, we as much as possible wanted to mimic a real life situation and to tease out 
the additional contribution of hyperglycemia to the cellular and vascular changes, relative 
to the clustered risk factors common to the insulin resistant states, i.e. hyperinsulinemia, 
hyperlipidemia and hypertension. In order to accomplish all these goals, both the choice of 
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the population and the study design were instrumental. Thus, in these mechanistic studies, 
we chose to investigate males only, in order to have a more homogeneous population: 
women, relative to men, once they develop T2DM have a disproportional increase in the 
relative risk of macrovascular disease,13,14 as well as different lipid profiles and importantly, 
care should be taken that all are postmenopausal to avoid further confounding of different 
hormonal states.15-17 Thus, males with the MetS (in whom the MetS feature of dysglycemia 
was an exclusion criterion), males with the MetS and additional hyperglycemia, i.e. T2DM, 
and healthy subjects in the postprandial state were studied. The real-life situation was 
mimicked by a 10-h or 24-h study period during which the participants were given 2 
(10-h period), or 3 (24-h period) consecutive standardized high-fat mixed meals, given 
as breakfast and lunch or as breakfast, lunch and dinner, respectively. 
Major findings
This thesis in fact has two parts, i.e. the first part in which we detail quantitative and 
qualitative aspects of postprandial changes, particular with respect to the pro-atherogenic 
lipid profile, in men with MetS and in those with T2DM, versus controls. Furthermore, 
we also studied the consequences of these unfavorable postprandial responses on (markers 
of) oxidative stress and inflammation as well as vascular (functional) changes, but also on 
causal factors leading to these postprandial derangements, such hepatic steatosis (Chapters 
2-4). In the second part, we focus on the role of MP, as potential mediators of the metabolic 
and vascular derangements, by detailing differences in their numbers, cellular origin, 
subpopulations and functional characteristics between those with MetS and T2DM and 
healthy individuals (Chapters 5-8). 
PART I
Abdominal, particularly visceral obesity, is strongly associated with hepatic steatosis or 
non-alcoholic fatty liver disease (NAFLD), both via increased delivery of free fatty acids 
to the liver and through increases of hepatic lipogenesis associated with hyperglycemia 
and hyperinsulinemia.18,19 In turn, the worsening insulin resistance associated with hepatic 
steatosis may lead to the development and/or exacerbation of the features of the MetS. 
The close associations among hepatic steatosis, obesity, and cardiometabolic risk factors 
have led to the suggestion that hepatic steatosis may be a novel component of the MetS,18 
whereas it may alternatively be regarded as key causal factor of the MetS. One mechanism 
that may partly explain the link between hepatic steatosis and CVD is the postprandial 
dysmetabolic state. Indeed, in males with T2DM and males with and without the MetS, 
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we demonstrated that the amount of liver fat is associated with pro-atherogenic changes 
within the postprandial lipid profile (Chapter 2). These results partly confirm and extend 
the observations by Matikainen et al., who found an elevated VLDL-TG output following 
a single meal in individuals with hepatic steatosis (with and without T2DM).20 In addition 
to these findings, our results suggest an increased production or retainment of apoB-48 
chylomicrons by the intestine in T2DM males following 3 consecutive meals. 
Furthermore, we showed that hepatic steatosis was related to triglyceride enrichment 
of HDL particles in the postprandial state, resulting in changes of the physiochemical 
properties of HDL (Chapter 4).This postprandial triglyceride-enrichment of HDL 
particles altered the anti-oxidative capacity of this lipoprotein class, which was paralleled 
by endothelial dysfunction measured by ultrasound as flow mediated dilatation (FMD). 
Our findings based on a physiological stimuli, confirm but rather extend recent results by 
Patel et al. who demonstrated that infusion of an artificial fat emulsion (Intralipid) results 
in HDL-TG-enrichment with impaired endothelial function, as assessed by inhibition of 
(in vitro) endothelial cell adhesion molecule expression, in young healthy males.21 
The pro-atherosclerotic functional changes in HDL and LDL particles during the postprandial 
state were studied in Chapter 3. We showed that prolonged hypertriglyceridemia, as 
observed in males with the MetS and patients with T2DM, following 3 consecutive 
meals, resulted in the formation of triglyceride-enriched HDL and LDL particles as well 
as concomitant increased postprandial susceptibility of LDL to oxidation. Furthermore, 
enlarged lipoprotein particles and impaired meal-related anti-oxidant capacity of HDL 
was specifically observed in T2DM. With these findings we confirm Diwadkar et al. 
demonstrating that postprandial LDL particles of diabetic subjects had a significantly 
shorter lag phase following one rather artificial meal, containing 85 g of fat,22 and extend 
these findings by showing the association with changes in triglyceride content. The anti-
inflammatory/oxidative properties of HDL in the postprandial state have been studied 
earlier in two relatively small studies with healthy subjects. Nicholls et al. showed that the 
anti-inflammatory potential of HDL was reduced after consumption of saturated fat and 
improved following the consumption of polyunsaturated fat.23 As described previously, 
Patel and coworkers demonstrated an impaired anti-inflammatory capacity of HDL in 
response to 20% Intralipid.21 We extend these findings by measuring endothelial function 
in vivo, using consecutive meals to mimic a more real-life situation and studying males 
with T2DM and males with MetS, compared to healthy males.
Taken together, our results show that the postprandial state is associated with changes in 
physiochemical properties of lipid particles, increased oxidative stress, and endothelial 
dysfunction, and that this is exaggerated and prolonged in dysmetabolic states like the MetS 
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and T2DM. In addition, increased liver fat accumulation contributes to these postprandial 
derangements. However, routine ultrasound examination of the abdomen for the screening 
of hepatic steatosis in combination with serologic tests for viral hepatitis infection may not 
be feasible in daily practice in most countries. Furthermore, in daily practice the availability 
of magnetic resonance spectroscopy (MRS) to measure liver fat content is scarce and 
expensive. In addition, performance of regular liver biopsies to survey liver fat content is 
not recommended because of its risks, discomfort and relative inaccuracy. Previously, we 
and others suggested alanine aminotransferase (ALT) as a marker of NAFLD. Accordingly, 
in the population-based Hoorn Study we showed that ALT levels in the high range of the 
normal distribution are associated with an increased 10-year risk of coronary heart disease 
in elderly individuals.24,25 This association was independent of classical CVD risk factors and 
components of the Adult Treatment Panel III–defined MetS, indicating that ALT may be a 
useful marker in the assessment of CVD risk in patients who may have NAFLD. Although the 
evidence that lowering the amount of liver fat content is associated with decreased incidence 
of CVD is lacking, it is known that body weight reduction as a result of a negative energy 
balance due to dietary interventions and/or increased physical activity results in decreases 
in liver fat. Thus, any benefit obtained from body weight loss may be in part mediated by 
the metabolic improvements associated with concomitant reduction in liver fat. Still, in the 
absence of direct evidence from appropriate long-term intervention trials, it seems that early 
identification of patients with NAFLD and the associated cardiometabolic derangements 
may be important, not only in terms of risk for progression of severe steatosis into NASH, 
but also for adequate preventive and therapeutic measures aimed at reduction of CVD risk.
PART II
A more recent mechanism proposed to constitute a link between cardiometabolic risk 
factors and cardiovascular damage is the formation of pro-inflammatory and pro-
coagulant MP. Elevated circulating numbers of these vesicles of various cellular origin 
and composition, have been described in many high-risk populations and associated 
with (markers of) cardiovascular damage and even cardiovascular events.26-28 However, 
most human studies have focused on quantitative (circulating numbers) rather than 
qualitative aspects of MP, that were mostly of platelet origin and had been isolated from 
a single plasma sample obtained in the fasting state. At the time of the initiation of our 
studies, no data were available regarding 1) numbers and characteristics of MP in humans 
with uncomplicated T2DM versus MetS versus controls; 2) the impact of meal-related 
metabolic changes on MP numbers, cellular origin, specific subpopulations, and functional 
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characteristics and 3) their association with markers of vascular function. Earlier, we had 
shown that specific MP subpopulations, i.e. those exposing tissue factor, were elevated in 
patients with uncomplicated T2DM and associated with features of the MetS.29 
In this thesis, we took these preliminary observations to the next level by using a real-
life study design, by studying carefully selected, sufficiently contrasting populations and 
by taking a “smart-phenotyping” approach. The latter involved an integrated detailed 
characterization of the cardiometabolic state and the diurnal and meal-related changes 
thereof in all participants. Other unique and novel aspects included the state-of-the-art 
characterization of ex vivo isolated MP, obtained at various time-points through-out a 10-h 
or 24-h period and the possibility to link various features of the MP to the cardiometabolic 
changes in the participants.  
Initially, in a set of proof-of-concept studies, we investigated postprandial metabolic and 
MP responses in healthy young males. This approach allowed us to avoid confounding 
of concomitant co-morbidities and to assess whether the relatively minor metabolic 
disturbances caused by the 2 consecutive high-fat mixed meals, that were expected to 
occur in young, insulin sensitive individuals, would already impact on MP and endothelial 
function (Chapters 5 and 6). In Chapter 5 we could demonstrate that already in these 
healthy, well-trained males, the postprandial state, which indeed showed mild elevations 
of glucose, insulin and triglycerides, but all within the normal range, increased oxidative 
stress and promoted endothelial dysfunction. In healthy subjects, postprandially impaired 
FMD correlated with meal-induced hypertriglyceridemia in some,30-32 but not in other 
studies.33,34 In our study, the decrease in FMD following the second meal was not correlated 
to the concomitant plasma triglyceride elevations, but rather tended to associate with 
the meal-related increase in levels of oxidative stress markers. However, there are some 
aspects to be measured. Firstly, the populations studied are not readily comparable (i.e. 
very physically active and therefore more insulin sensitive compared to persons with a 
more sedentary lifestyle). Secondly, the postprandial metabolic changes found in our 
subjects were relatively mild, as compared to those observed in other studies.30,31 Thirdly, 
the composition and consistency (liquid versus solid) of the test-meals differed in the 
various studies. Finally, the changes in the different parameters measured, in relation to 
time following meal ingestion, cannot easily be established. 
Concomitantly, circulating levels of total MP (mainly consisting of platelet-, erythrocyte- 
and monocyte-derived MP) increased in the postprandial state, compared with fasting 
conditions. Previously, a single meal-induced increase in circulating endothelial cell MP, 
in association with postprandial metabolic changes, was published and seemed in line 
with our results.35 In contrast to Ferreira,35 however, we could not identify any MP from 
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endothelial cells. A possible explanation is that we only used endothelial cell-specific 
antibodies (CD62e, CD106 and CD144), and that the postprandial increases in CD31-
positive MP reported by these authors may be in part due to elevated platelet-derived MP.36 
By exposing negatively charged phospholipids, mainly phosphatidylserine, but also 
by exposing tissue factor, MP can propagate and even initiate coagulation (reviewed 
in Chapter 1b). Since the postprandial state has been associated with coagulation 
activation, we assessed in vivo coagulation variables in the fasting and the postprandial 
state as well as the pro-coagulant properties of MP, isolated from fasting and post-meal 
plasma in Chapter 6. Although we found distinct changes in numbers, cellular origin 
and phospholipid composition of MP during exposure to 2 consecutive meals in healthy 
subjects, this did not lead to changes in the coagulation activation in vivo. Our group 
previously showed that patients with severe meningococcal sepsis have higher levels of MP 
that are procoagulant,37 in more “mild” diseases including T2DM, however, these findings 
were not confirmed.27,38,39 Therefore, our finding suggests that the observed differences 
in (phospho-)lipid composition of cell-derived MP during fasting and meal days reflect 
the ability to maintain membrane homeostasis, rather than to modify coagulation. These 
findings confirm earlier studies showing that changes in the phospholipid composition 
of MP vary between cell types and depend on the activation status of the parental cell.39-41 
In Chapter 7, we extended the above-mentioned findings in young healthy males by 
describing the postprandial changes in MP levels in middle-aged males with and without 
the MetS following exposure to 3 consecutive high-fat mixed meals, given during a 24-h 
period. We demonstrated that changes in numbers of subpopulations of MP occur in the 
postprandial state and associate with metabolic changes and arterial stiffness. We found 
that especially MP derived from erythrocytes, activated granulocytes and platelets are 
elevated in the MetS during 24 hours, compared to healthy males. Moreover, we confirm 
and extend previous findings that increased levels of specific subpopulations of MP have 
been associated with impaired systemic artery elasticity in healthy subjects.42 Of interest 
is our finding that higher platelet-derived MP levels during the test day associates with 
decreased arterial stiffness support and confirm the more recent ideas that the release of 
MP is not necessarily solely deleterious (see also Chapter 9).  
Of note, using the same study design, we show that elevated levels of endothelial cell-
derived (CD144+) MP circulate in patients with uncomplicated T2DM and associate 
with postprandial metabolic derangements and impaired FMD (Chapter 8). Although 
the correlation of (presumably) endothelium-derived (CD31+/CD42-) MP with FMD was 
described before in fasting patients with end-stage renal failure, we extend these findings 
by using an antibody that is solely expressed by endothelial cells.43 Moreover, others have 
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described high levels of CD144+-MP in T2DM, especially in patients with accompanying 
CVD-complications.44-46 The relevance of this finding was demonstrated by Nozaki et 
al., who added the CD144+-MP levels to the Framingham risk model thereby not only 
improving risk classification, but also showing that CD144+-MP were an independent 
predictor of future CVD events in a high-risk population.47
Finally, in Chapter 9, recent studies reporting both deleterious as well as beneficial aspects 
of MP in the context of CVD risk are summarized. In the light of previously described 
properties of MP, together with the association between elevated numbers of MP and 
clinical CVD, the prevailing view is that circulating MP are harmful, contributing to CVD 
and risk thereof. However, the release of vesicles may protect cells from accumulation 
of dangerous or redundant compounds, acting as ‘dust-bags’, and in this manner may 
contribute to cellular wellbeing and even survival.  
In summary, humans with MetS and T2DM, compared to healthy individuals, are 
characterized by prolonged and exaggerated postprandial derangements, most notably 
pro-atherogenic changes in the lipid profile in both these groups, which may partly result 
from liver steatosis, as well as additional hyperglycemia in T2DM. This postprandial 
dysmetabolism leads to the increased production of reactive oxygen species causing 
oxidative stress and functional abnormalities of the vascular endothelium at several 
levels, including impairment of (NO-mediated) vasoreactivity, increased coagulation and 
inflammation activation and post or propter the release of MP (Figure 10.1). Collectively, 
postprandial dysmetabolism and the associated oxidative stress may link insulin resistance 
and T2DM to the disproportional incidence of CVD in these high-risk populations.  
In the first chapter of this thesis we reviewed the literature, available at that time, to 
provide a background and justification to the studies described in this thesis. In addition 
to Chapter 1a and in line with our own studies, we now review some of the more recent 
literature and speculate on possible therapeutic options for postprandial dysmetabolism 
as a CVD risk factor.   
Interventions improving postprandial glucose
More than 15 observational studies involving over 100,000 subjects have been published 
demonstrating that elevated postprandial glucose values, even in the high nondiabetic 
impaired glucose tolerance (IGT) range, contribute to an approximately threefold increase 
in the risk of developing coronary heart disease or a CVD event.48 The observational and 
therefore not causal associations have led to the hypothesis that specifically targeting 
postprandial glucose or glucose excursions / variability, would reduce CVD risk and 
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eventually also outcome. Small mechanistic studies showed that the mediating mechanisms 
linking glucose variability to vascular damage could be an increase in oxidative stress,49,50 
thus replicating the seminal experimental work by Michael Brownlee and co-workers.51 
However, several others were not able to reproduce these findings, suggesting that rather 
overall hyperglycemia, represented by HbA1c levels, should be regarded as culprit to 
diabetes-related complications, including macrovascular disease.52-55
Most established blood-glucose lowering agents lower both fasting and postprandial glucose, 
however, the respective effect size may differ and may depend on factors such as concomitant 
insulin resistance, residual beta-cell function, the extent to which glucose toxicity is lowered, 
Figure 10.1 Insulin resistant states and type 2 diabetes are characterized by higher circulating 
numbers of specific MP, levels of atherogenic lipid particles, and oxidative stress. In the postprandial 
state, the numbers of MP subtypes change and the lipid abnormalities and oxidative stress are further 
exaggerated, with an additional adverse effect of meal-induced hyperglycemia. These postprandial 
derangements cause functional abnormalities of the vascular endothelium at several levels, including 
shedding of MP, impairment of vasoreactivity, increased coagulation and inflammation activation and 
increased vascular permeability. Collectively, postprandial dysmetabolism and the associated changes 
in MP, physiochemical properties of lipids and oxidative stress may link insulin resistance and type 2 
diabetes to the disproportional incidence of CVD in these high-risk populations.
Environment Genetics
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Cell-derived microparticles
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etc. To date, the few studies that indeed succeeded to preferentially lower glucose excursions 
have not showed benefit beyond lowering of other glycemic measures such as fasting glucose, 
average glucose and HbA1c.56,57 In addition, the presumed causative role of postprandial 
glucose and glucose excursions as well as glucose variability, as opposed to other measures of 
glycemia, in the development of diabetes-related complications is still under debate.58 In spite 
of this controversy, several years ago, the International Diabetes Federation has commissioned 
a group of experts to write guidelines addressing the link between postprandial glucose and 
CVD and possible therapeutic approaches.59 Many pharmaceutical companies, however, 
in the quest of increasing the sales of their products, have successfully used the concept of 
postprandial glycemia as culprit and thus as treatment target in their marketing campaigns.
Life style
Not only do lifestyle interventions prevent or delay the onset of T2DM in high-risk 
populations, exercise has been shown to acutely and chronically lower (fasting and) 
postprandial glycemia.60-66 Hostmark et al. demonstrated an acute blood glucose reducing 
effect during 30 min of bicycling following the consumption of a carbohydrate-rich meal.65 
More recently it was shown that blood glucose responses were reduced by slow postmeal 
walking for less than one hour.66
Metformin
Metformin is now established as a first-line blood glucose lowering therapy for the 
management of T2DM. It has also been shown to reduce the risk of to develop T2DM and 
reduce micro- and macrovascular complications in T2DM.64,67,68 Although not prescribed 
primarily for this action, in addition to lowering fasting and mean blood glucose levels, 
resulting in HbA1c lowering, metformin has been shown to reduce postprandial glucose 
peaks,69 possibly by indirect effects like reducing insulin resistance and hepatic fat content.70 
Sulfonylureas
Sulfonylureas act by binding to sulfonylurea receptors on pancreatic beta-cells, leading to 
increased secretion of insulin with their glucose lowering potency similar to metformin.71,72 
Moreover, not only do they lower postload glucose concentrations, they have also shown 
to lower overall glycemia, i.e. fasting, postload and HbA1c, and have a beneficial effect 
on the so-called metabolic memory of glycemic legacy.73 The most common members of 
this class are glibenclamide (gliburide), glipizide, gliclazide and glimepiride. The main 
side effects are weight gain and severe hypoglycemia, particularly in elderly people treated 
with long acting sulfonylureas. 
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Meglitinides
Meglitinide analogues are a class of oral hypoglycemic agents that increase insulin 
secretion, in particular, during the early phase of insulin release.74,75 This property, 
along with clinical trial evidence, supports the potential role of meglitinide analogues in 
augmenting the early phase insulin release and, therefore, postprandial glucose control. 
Two analogues are currently available for clinical use: repaglinide and nateglinide, both 
with a rapid rise in insulin concentrations after dosing and a short half-life. Early trial 
evidence supports their effect in reduction of postprandial glucose and reduction in 
hypoglycemic episodes.74
Acarbose
The α-glucosidase inhibitor acarbose inhibits postprandial glucose concentrations by 
inhibition of α-amylase and α-glucosidase activities. Although acarbose has been shown 
to delay conversion to T2DM76 and to have beneficial effects on 2-hour postload glucose 
concentrations, there was no improvement of beta-cell function.77  
Thiazolidinediones
Peroxisome-proliferator activated receptors (PPAR)-γ agonists (or thiazolidinediones), 
such as pioglitazone and rosiglitazone, ameliorate insulin resistance, among others by 
decreasing lipotoxicity and stimulating growth of small insulin sensitive adipocytes, 
lower blood glucose and improve diabetic dyslipidemia.78 In diabetic subjects with poor 
glycemic control, pioglitazone improves oral glucose tolerance mainly by enhancing the 
suppression of endogenous glucose production and improving beta-cell function.79 The 
suppression of endogenous glucose production by pioglitazone is closely related to the 
reduction in hepatic fat content.80
Insulins
There is evidence to show that patients who added a prandial insulin-based regimen to 
oral therapy have better glycated hemoglobin (HbA1c) than patients who add a basal 
insulin-based regimen.81
Pramlintide
Pramlintide is a synthetic analogue of amylin, a neuroendocrine hormone that is co-
secreted with insulin from pancreatic beta-cells in response to nutrient intake.82 It plays 
an important role in the maintenance of postprandial glucose homeostasis by regulating 
the rate of glucose appearance into the circulation through three primary mechanisms: 
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regulation of gastric emptying, reduction of postprandial glucagon secretion, and 
regulation of food intake. Through these same mechanisms, pramlintide significantly 
reduces postprandial glucose concentrations when used as an adjunct to mealtime 
insulin in both T1DM and T2DM.83,84 To date, there are no outcome studies reported 
for pramlintide.
Incretin-based therapies
Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that, in a glucose-
dependent manner, stimulates meal-related insulin secretion (and production) and 
suppresses glucagon secretion, slows down gastric emptying, and reduces appetite 
and food intake.85 In a 6-week intervention study, in which GLP-1 was administered 
continuously via a subcutaneous insulin-pump delivery system in T2DM patients, the 
incretin hormone was shown to reduce body weight.86 Thus, since GLP-1 addresses several 
of the pathophysiological defects of the T2DM phenotype, it was regarded as an ideal 
approach for the treatment of T2DM. However, native GLP-1 is readily degraded by the 
ubiquitous enzyme dipeptidyl peptidase-4 (DPP-4) and consequently has a circulating 
half-life time of 1-2 minutes. Therefore, two different strategies were followed in order to 
enhance incretin action and harness GLP-1 as a therapeutic option for T2DM, including 
the development of injectable degradation-resistant GLP-1 receptor agonists (GLP-1RA; 
e.g. exenatide, liraglutide) and oral inhibitors of DPP-4 activity (DDP-4i; e.g. sitagliptin, 
vildagliptin and saxagliptin). All of these incretin-based therapies have been shown to 
decrease postprandial glucose concentrations.87-89
Interventions improving postprandial lipemia
Since the pro-atherogenic postprandial involves both glucose and lipids and their 
interaction, (see also Chapter 1a), therapeutic strategies that affect plasma glucose levels, 
may also influence postprandial lipids and lipoproteins. 
Life style
There is a large body of evidence showing that postprandial lipemia can be attenuated 
by exercise, both before and following a meal.90-95 For example, for physically inactive 
individuals with the MetS, exercising at moderate intensity for 45 min attenuates 
postprandial hypertriglyceridemia and improve insulin action.95  
179
G
eneral discussion and future perspectives
Chapter 10
10
Fibrates – statins
Fibrates, drugs in the class of amphiphatic carboxylic acids, have multiple blood lipid 
modifying actions due to their ability to bind and activate the transcription factor PPARα. 
Treatment with fibrates did not only show a reduction in postprandial hypertriglyceridemia, 
also the postprandial increase of larger-sized VLDL and smaller-sized LDL particles, 
oxidized fatty acids and oxLDL was abrogated by fenofibrate.96-101 Recently, the triglyceride 
lowering actions in the postprandial state of fenofibrate include alterations in triglyceride 
and fatty acid metabolism in the small intestine of high-fat fed mice.101 
The most important action of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors 
(statins) have been proved highly effective in reducing CVD event risk, both in primary and 
secondary prevention trials.102-104 Moreover, statins have been shown to reduce postprandial 
lipemia,96,105-107 although not as effective as fibrates.100  
Metformin
Although mainly known for improving glycemic control in T2DM, metformin also has 
favorable effects on postprandial lipid metabolism.108-110 Moreover, in non-obese T2DM 
patients, fasting and integrated 6-h postprandial measures of plasma glucose, cholesterol, 
triglycerides and serum FFA decreased equally after 4 months of metformin versus 
repaglinide treatment.110
Sulfonylureas
Data on the effect of sulfonylureas on postprandial lipid metabolism are inconsistent 
and conflicting.111-116 However, most of the studies suggest that sulfonylureas improve 
postprandial lipemia ameliorating the postprandial increase in FFAs, chylomicrons and 
VLDL triglycerides. This effect is possibly due to the increased activity of lipoprotein lipase 
(LPL) and hepatic lipase (HL) by hyperinsulinemia and to the reduction of glycemia and 
FFAs postprandially. 
Meglitinides
Although meglitinides increase postprandial insulin secretion and decrease postprandial 
glycemia, most of the available studies show a rather disappointing impact on postprandial 
lipemia in patients with T2DM.116-118
General discussion and future perspectivesChapter 10
180
Acarbose
Already in the late 1970s the (dose-dependent) effectiveness of acarbose in the reduction 
of postprandial hypertriglyceridemia was shown.119 More recently, it was demonstrated 
that acarbose attenuates the postprandial increase of total triglycerides, chylomicrons, 
VLDL and lipoprotein remnants concentrations.120-122 It may contribute to the regulation 
of LPL activity by modifying apoC-II and apoC-III levels.   
Thiazolidinediones
Remarkable differences exists between the effects of rosiglitazone and pioglitazone 
on postprandial lipemia in several study populations.80,115,123-128 Despite metabolic 
improvements (insulin sensitivity and FFA handling), rosiglitazone caused no significant 
effects on fasting and postprandial triglycerides,123-126 and even showed a marked increase 
in postprandial remnant like cholesterol particles in patients with HIV-lipodystrophy.126 
In contrast, pioglitazone has been shown to decrease insulin sensitivity and favorably 
modify fasting and postprandial triglycerides, FFAs and HDL cholesterol in overweight 
and obese non-diabetic patients with coronary artery disease and T2DM patients.80,115,128 
In addition, pioglitazone has been proven to improve NAFLD and hitherto has beneficial 
effects on postprandial lipidemia and glycemia.80,128
Insulins
Clinical studies have shown that insulin treatment in patients with T2DM is associated 
with a less (postprandial) atherogenic lipid profile, an effect independently of blood glucose 
control.129-133 Rapid acting insulin analogues have been shown to have more favorable 
effects on postprandial lipemia than longer acting insulins.132,133 
Incretin-based therapies
The short-acting GLP-1 receptor agonist exenatide (administered twice daily before 
breakfast and dinner) significantly lowered postprandial lipidemia in metformin-treated 
patients with T2DM, as compared to insulin glargine or placebo.88,89,134 
Initially, the postprandial lipid-lowering effects were attributed to the concomitant slowing 
of gastric emptying, but recent studies in humans and animals have shown that the incretin 
hormones may directly interfere with lipoprotein metabolism, independently of the 
effects on gastric emptying.135-137 Thus, short time treatment (4 weeks) with the DPP-4i 
vildagliptin, which does not affect gut motility, improved postprandial plasma triglyceride 
and apolipoprotein B-48-containing triglyceride-rich lipoprotein particle metabolism in 
T2DM patients after a fat-rich meal.136 Similar results were obtained in a 6-week study 
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of sitagliptin versus placebo.137 The direct effects of GLP-1 on lipoprotein assembly were 
demonstrated in a series of elegant preclinical experiments, in which, among others, the 
GLP-1R agonist exendin-4 directly reduced Apo48 secretion in enterocyte cultures from 
fructose-fed hamsters.135 Taken together, these novel agents are regarded as very promising, 
as they not only reduce blood glucose, but also have a potential to lower the cardiovascular 
risk profile in patients with T2DM.
Interventions lowering postprandial oxidative stress
Oxidative stress, in particular the increased superoxide production at the mitochondrial 
level, has been suggested as the key link between postprandial dysmetabolism and diabetes 
complications.138 Not only do postprandial hyperglycemia and hyperlipidemia separately 
increase oxidative stress, also evidence for a cumulative effect of both is present.139 Both 
acute and chronic exercise may aid in attenuating postprandial oxidative stress by improving 
blood glucose and triglyceride clearance, and by stimulating an increase in endogenous 
antioxidant enzyme activity.91-93,140 The effect of blood-glucose lowering drugs, including 
metformin, sulfonylureas, acarbose and insulin, on the amelioration of postprandial 
oxidative stress and endothelial function are not consistent.83,84,129,141,142 The effect may be 
mainly due to their long-term glucose-lowering actions and the concomitant alleviation 
of oxidative stress.138Aside their lipid lowering potency, statins have been shown to 
reduce postprandial oxidative stress and improve endothelial function.96,105,106,139,143,144 Also 
fibrates showed postprandial oxidative stress reduction, although to a lesser extent than 
statins.97,105 Previously, in a small intervention study, a attenuating effect of pioglitazone on 
oxidative stress following a meal test was described.115 Not only did exenatide (administered 
twice daily before breakfast and dinner) significantly lowered postprandial glycemia and 
lipidemia in metformin-treated patients with T2DM, these effects were related to changes 
in the oxidative stress markers as compared to insulin glargine88 and placebo.89 The use 
of anti-oxidants and vitamins show promising results in short-term postprandial studies 
assessing the effect on endothelial function and markers of oxidative stress.145-147
Interventions interfering with (postprandial) MP formation
Various anti-platelet drugs, including the GPIIb/IIIa receptor antagonist abciximab148 and 
the cAMP phosphodiesterase inhibitor cilostazol,149 offer therapeutic possibilities, as they 
reduce excessive platelet-derived MP formation. Most notably, there was no influence of 
prior exercise on postprandial circulating levels of presumed endothelial MP (CD31+/42b-), 
despite considerable reduction in lipemia.150 Recently, it was demonstrated that mitiglide 
lowers baseline levels of platelet-derived MP.151 From the same group, a comparable effect of 
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acarbose was shown in T2DM patients following three months of treatment.152 In contrast, 
previously we showed in vitro that simvastatin facilitated the release of MP by endothelial 
cells.153 In a small pilot study, pioglitazone decreased the number of circulating endothelial 
MP independently of plasma glucose and lipid concentrations in subjects with the MetS.154 
The effect of pioglitazone or GLP-1 treatment on postprandial MP levels is not known. 
Short-term administration of vitamin C at a high dose reduced the number of circulating 
endothelial-cell-derived MP in patients with congestive heart failure.155 Moreover, the 
possible beneficial effect of anti-oxidants was previously demonstrated by an anecdotal 
observation, in which consumption of a flavinoid-rich cocoa beverage reduced circulating 
numbers of platelet-derived MP in healthy subjects.156
What is the evidence of these interventions to reduce CVD risk?
The cheapest and probably best intervention to reduce CVD and other chronic disease 
risk is change of life style and additional weight loss.61-64,157-161 However, since most of the 
adults have adapted their life style for several years, a beneficial change in their habits for 
a longer period of time seems far too difficult without cognitive behavioral therapy.161
The fastest, most effective and durable therapy to lose a large amount of weight within 
hours is by bariatric surgery. Although this is accompanied by serious postoperative 
complications, it leads to reduction, or even remission, of T2DM and CVD risk.162,163
Several controlled, prospective, and randomized clinical trials, e.g. the STOP-NIDDM 
trial, the NAVIGATOR trial, and the HEART2D trial have not proofed that targeting 
postprandial hyperglycemia results in a more beneficial outcome of CVD complications in 
IGT subjects or overt type 2 diabetic patients.164-167 A possible explanation is the inclusion of 
patients with a high CVD risk and long-term T2DM duration, who had already accumulated 
considerable cardiovascular compromise. The use of anti-oxidants and vitamins may show 
promising acute effect on postprandial endothelial dysfunction and markers of oxidative 
stress.145-147 However, so far, the use of anti-oxidants and vitamins has not yielded the 
expected benefit in long-term prospective trials.168,169
The role of statins in lowering CVD risk seems undisputable. Large studies demonstrated 
lowering of LDL cholesterol and C-reactive protein concentrations, and increase of LDL size 
and HDL cholesterol concentration, accompanied with a reduction of CVD events.102-104,170 
Of interest, however, a meta-analysis of mega trials suggested that, with the exception of 
pravastatin, the statins appear to modestly increase the risk of new diabetes.171 In prospective 
placebo-controlled studies of T2DM patients, fibrates have been shown to be inconsistent 
in their ability to decrease cardiac events.172-174 In the Helsinki Heart study, cardiac events 
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were decreased by 71% in the group of patients who had all the characteristics of the 
MetS, compared to controls.172 In a subgroup analysis of the VA-HIT trial, treatment with 
gemfibrozil resulted in a more than 30% reduction of cardiac events in patients with T2DM 
and in those with insulin resistance.173 In contrast, daily administration of fenofibrate did 
not change the primary endpoint of fatal myocardial infarction or death related to CVD in 
the FIELD study. However, there was a significant 24% reduction in non-fatal myocardial 
infarction and 11% decrease in CVD events.174 
Recently, rosiglitazone was associated with a significant increase in the risk of myocardial 
infarction and has been withdrawn from the market.175 In contrast, the PROactive trial of 
the thiazolidinedione, pioglitazone, found no benefit with regard to its primary aggregate 
cardiovascular outcome, but it did find a 16% decrease in its secondary end point – death, 
myocardial infarction, and stroke – after three years of treatment.176 However, recently 
an association of pioglitazone use and a higher risk of developing bladder cancer has 
been described.177,178 Presently, several long-term outcome studies for both GLP-1RA 
and DPP-4i are underway that will hopefully demonstrate their added value in the 
treatment of T2DM and its (CVD) complications.179-181 Initial meta-analysis of phase 2 
and 3 studies of these agents are promising and at least did not show any indication of 
harm.182-184 Moreover, treatment with exenatide showed a hazard ratio of 0.81 [95%CI 
0.68-0.95] for CVD events.182 
FUTURE PERSPECTIVES
Realizing that today the role of fasting versus postprandial hyperglycemia and hyperli-
pidemia as CVD risk factors (versus risk markers) remains unresolved, we need future 
studies to establish a causal relationship between oscillating versus more stable glucose, 
lipid levels and their physiochemical properties, and cardiovascular damage. Subsequently, 
the mechanisms that could explain the causal link need to be addressed. The role of MP 
numbers, their cellular origin, composition and their role in cell survival and coping with 
(meal-induced) stress, and eventually atherogenesis has become less clear, their presence 
being not solely deleterious. Furthermore, assuming that oxidative stress appears to be 
the key mechanism underlying all the phenomena reported above, long-term therapeutic 
options that reduce the associated CVD are still lacking. GLP-1 receptor agonists show pro-
mising results in recent studies, although cardiovascular outcome studies are still underway. 
A noteworthy recent development is the increasing interest in a role for non-digestible 
carbohydrates, short-chain fatty acids, prebiotics and antibiotics in manipulation of gut 
microbiota, affecting energy harvesting from gut, obesity, incretin levels, glucose intolerance 
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and the proinflammatory response.185,186 Of interest could be the role of gut microbiota, 
nutrients and functional foods as well as the above-mentioned pharmaceutical treatments 
in postprandial dysmetabolism, MP, oxidative stress and the risk of developing CVD. As 
described, many options are open, which warrants substantial future improvement in 
treatment of MetS, T2DM and ultimately avoidance of CVD.
REFERENCES
1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes, estimates for the year 
2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
2. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607
3. Diamant M, Tushuizen ME. The metabolic syndrome and endothelial dysfunction: common highway 
to type 2 diabetes and CVD. Curr Diab Rep 2006;6:279-86.
4. Pratley RE. Metabolic syndrome: why the controversy? Curr Diab Rep 2007;7:56-9.
5. Simmons RK, Alberti KG, Gale EA, et al. The metabolic syndrome: useful concept or clinical tool? 
Report of a WHO Expert Consultation. Diabetologia 2010;53:600-5.
6. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107:1058-70.
7. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. 
Nature 2006;444:875-80.
8. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. 
Arch Intern Med 2003;163:1306-16.
9. Tushuizen ME, Diamant M, Heine RJ. Postprandial dysmetabolism and cardiovascular disease in 
type 2 diabetes. Postgrad Med J 2005;81:1-6.
10. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of 
insulin resistance. Nature 2006;440:944-8.
11. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010:107:1058-70.
12. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 
2010;72:219-46.
13. Lee WL, Cheung AM, Cape D, Zinman B. Impact of diabetes on coronary artery disease in women 
and men: a meta-analysis of prospective studies. Diabetes Care 2000;23:962-8.
14. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes 
in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006;332:73-8.
15. Miller VT. Lipids, lipoproteins, women and cardiovascular disease. Atherosclerosis 1994;108 
Suppl:S73-82.
16. Juutilainen A, Kortelainen S, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Gender difference in the 
impact of type 2 diabetes on coronary heart disease risk. Diabetes Care 2004;27:2898-904.
185
G
eneral discussion and future perspectives
Chapter 10
10
17. Van Beek AP, Ruijter-Heijstek FC, Erkelens DW, De Bruin TW. Menopause is associated with reduced 
protection from postprandial lipemia. Arterioscler Thromb Vasc Biol 1999;19:2737-41.
18. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler 
Thromb Vasc Biol 2008:28:27-38.
19. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the 
metabolic syndrome to NALFD or vice versa? Dig Liver Dis 2010;42:320-30.
20. Matikainen N, Mänttäri S, Westerbacka J, et al. Postprandial lipemia associates with liver fat content. 
J Clin Endocrinol Metab 2007;92:3052-9.
21. Patel S, Puranik R, Nakhla S, et al. Acute hypertriglyceridaemia in humans increases the triglyceride 
content and decreases the anti-inflammatory capacity of high density lipoproteins. Atherosclerosis 
2009;204:424-8.
22. Diwadkar VA, Anderson JW, Bridges SR, Gowri MS, Oelgten PR. Postprandial low-density lipoproteins 
in type 2 diabetes are oxidized more extensively than fasting diabetes and control samples. Proc Soc 
Exp Biol Med 1999:222;178-84.
23. Nicholls SJ, Lundman P, Harmer JA, et al. Consumption of saturated fat impairs the anti-inflammatory 
properties of high-density lipoproteins and endothelial function. J Am Coll Cardiol 2006:48;715-20.
24. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase 
as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular 
disease. Diabetes Metab Res Rev 2006;22:437-43.
25. Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase predicts coronary heart 
disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007;191:391-6.
26. Diamant M, Tushuizen ME, Sturk A, Nieuwland R. Microparticles: New players in the field of vascular 
disease? Eur J Clin Invest 2004;34:392-401.
27. Boulanger CM, Amabile N, Tedgui A. Circulating microparticles: a potential prognostic marker for 
atherosclerotic vascular disease. Hypertension 2006;48:180-6.
28. Nomura S, Ozaki Y, Ikeda Y. Function and role of microparticles in various clinical settings. Thromb 
Res 2008;123:8-23.
29. Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JW, Radder JK. Elevated numbers of tissue-factor 
exposing microparticles correlate with components of the metabolic syndrome in uncomplicated 
type 2 diabetes mellitus. Circulation 2002;106:2442-7.
30. Bae JH, Bassenge E, Kim KB, et al. Postprandial hypertriglyceridemia impairs endothelial function 
by enhanced oxidant stress. Atherosclerosis 2001;155:517-23.
31. Gaenzer H, Sturm W, Neumayr G, et al. Pronounced postprandial lipemia impairs endothelium-
dependent dilation of the brachial artery in men. Cardiovasc Res 2001;52:509-16.
32. Vogel RA, Corretti MC, Plotnick GD. Effect of a single high-fat meal on endothelial function in 
healthy subjects. Am J Cardiol 1997;79:350-4.
General discussion and future perspectivesChapter 10
186
33. Anderson RA, Evans ML, Ellis GR, et al. The relationships between post-prandial lipaemia, endothelial 
function and oxidative stress in healthy individuals and patients with type 2 diabetes. Atherosclerosis 
2001;154:475-83.
34. Tsai WC, Li YH, Lin CC, Chao TH, Chen JH. Effects of oxidative stress on endothelial function after 
a high-fat meal. Clin Sci (Lond) 2004;106:315-9.
35. Ferreira AC, Peter AA, Mendez AJ, et al. Postprandial hypertriglyceridemia increases circulating 
levels of endothelial cell microparticles. Circulation 2004;110:3599-603.
36. Abid-Hussein MN, Meesters EW, Osmanovic N, Romijn FP, Nieuwland R, Sturk A. Antigenic 
characterization of endothelial cell-derived microparticles and their detection ex vivo. Thromb 
Haemost 2003;1:2434-43.
37. Nieuwland R, Berckmans RJ, McGregor S, et al. Cellular origin and procoagulant properties of 
microparticles in meningococcal sepsis. Blood 2000;95:930-5.
38. Toth B, Nieuwland R, Kern M, et al. Systemic changes in haemostatic balance are not associated 
with increased levels of circulating microparticles in women with recurrent spontaneous abortion. 
Am J Reprod Immunol 2008;59:159-66.
39. Abid Hussein MN, Böing AN, Biró E, et al. Phospholipid composition of in vitro endothelial 
microparticles and their in vivo thrombogenic properties. Thromb Res 2008;121:865-71.
40. Sandberg H, Andersson LO, Hoglund S. Isolation and characterization of lipid-protein particles 
containing platelet factor 3 released from human platelets. Biochem J 1982;203:303-11.
41. Biro E, Akkerman JW, Hoek FJ, et al. The phospholipid composition and cholesterol content of 
platelet-derived microparticles: a comparison with platelet membrane fractions. J Thromb Haemost 
2005;3:2754-63.
42. Wang JM, Huang YJ, Wang Y, et al. Increased circulating CD31+/CD42- microparticles are associated 
with impaired systemic artery elasticity in healthy subjects. Am J Hypertens 2007;20:957-64.
43. Amabili N, Guérin AP, Leroyer A, et al. Circulating endothelial microparticles are associated with 
vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol 2005;16:3381-8.
44. Koga H, Sugiyama S, Kugiyama K, et al. Elevated levels of VE-cadherin-positive endothelial 
microparticles in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll 
Cardiol 2005;45:1622-30.
45. Bernard S, Loffroy R, Sérusclat A, et al. Increased levels of endothelial microparticles CD144 (VE-
Cadherin) positives in type 2 diabetic patients with coronary noncalcified plaques evaluated by 
multidetector computed tomography (MDCT). Atherosclerosis 2009;203:429-35.
46. Tsimerman G, Roguin A, Bachar A, Melamed E, Brenner B, Aharon A. Involvement of microparticles 
in diabetic vascular complications. Thromb Haemost 2011;106:310-21.
47. Nozaki T, Sugiyama S, Koga H, et al. Significance of a multiple biomarkers strategy including 
endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high 
risk for coronary heart disease. J Am Coll Cardiol 2009;54:601-8.
48. Standl E, Schnell O, Ceriello A. Postprandial hyperglycemia and glycemic variability: should we 
care? Diabetes Care 2011;34:S120-7.
187
G
eneral discussion and future perspectives
Chapter 10
10
49. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased 
by hyperglycemia in humans: role of oxidative stress. Circulation 2002;106:2067-72.
50. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared 
with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-7.
51. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 
2005;54:1615-25.
52. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular 
complications in type 1 diabetes. Diabetes Care 2006;29:1486-90.
53. Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular complications in type 
1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 2008;31:2198-202. 
54. Kilpatrick ES, Rigby AS, Atkin SL. Mean blood glucose compared with HbA1c in the prediction of 
cardiovascular disease in patients with type 1 diabetes. Diabetologia 2008;51:365-71.
55. Wentholt IM, Kulik W, Michels RP, Hoekstra JB, DeVries JH. Glucose fluctuations and activation of 
oxidative stress in patients with type 1 diabetes. Diabetologia 2008;51:183-90. 
56. Raz I, Wilson PWF, Strojek K, et al. Effects of prandial versus fasting glycemia on cardiovascular 
outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32:381-6.
57. Siegelaar SE, Kerr L, Jacober SJ, Devries JH.A decrease in glucose variability does not reduce 
cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis 
of the HEART2D study. Diabetes Care 2011;34:855-7.
58. Kilpatrick ES. Arguments for and against the role of glucose variability in the development of diabetes 
complications. J Diabetes Sci Technol 2009;3:649-55.
59. Ceriello A, Colaquiri S. International Diabetes Federation guideline for management of postmeal 
glucose: a review of recommendations. Diabet Med 2008;25:1151-6.
60. Edelstein SL, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance 
to NIDDM: an analysis of six prospective studies. Diabetes 1997;46:701-10.
61. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with 
impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-44.
62. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in 
lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
63. Roumen C, Corpeleijn E, Feskens EJ, Mensink M, Saris WH, Blaak EE. Impact of 3-year lifestyle 
intervention on postprandial glucose metabolism: the SLIM study. Diabet Med 2008;25:597-605.
64. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with 
lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
65. Hostmark AT, Ekeland GS, Beckstrom AC, Meen HD. Postprandial light physical activity blunts the 
blood glucose increase. Prev Med 2006;42:369-71.
66. Nygaard H, Tomten SE, Hostmark AT. Slow postmeal walking reduces postprandial glycemia in 
middle-aged women. Appl Physiol Nutr Metab 2009;34:1087-92.
General discussion and future perspectivesChapter 10
188
67. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose 
control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
68. United Kingdom Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose 
control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). 
Lancet 1998;352:854-65.
69. Lund SS, Tarnow L, Frandsen M, et al. Impact of metformin versus the prandial insulin secretagogue, 
repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 
2 diabetes. Eur J Endocrinol 2008;158:35-46.
70. Ratziu V, Caldwell S, Neuschwander-Tetri BA. Therapeutic trials in nonalcoholic steatohepatitis: 
insulin sensitizers and related methodological issues. Hepatology 2010;52:2206-15.
71. Groop L. Sulfonylureas in NIDDM. Diabetes Care 1992;15:737-47.
72. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with 
sulphonylureas or insulin compared with conventional treatment and risk of complication in patients 
with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
73. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose 
control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
74. Landgraf R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs & Ageing 
2000;17:411-25.
75. Dornhurst A. Insulinotrophic meglitinide analogues. Lancet 2001;358:1709-16.
76. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-
NIDDM randomised trial. Lancet 2002;359:2072-7.
77. Nijpels G, Boorsma W, Dekker JM, Kostense PJ, Bouter LM, Heine RJ. A study of the effects of 
acarbose on glucose metabolism in patients predisposed to developing diabetes: the Dutch acarbose 
intervention study in persons with impaired glucose tolerance (DAISI). Diabetes Metab Res Rev 
2008:24:611-6.
78. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. 
Drugs 2003;63:1373-1405.
79. Glass LC, Cusi K, Berria R, et al. Pioglitazone improvement of fasting and postprandial hyperglycaemia 
in Mexican-American patients with type 2 diabetes: a double tracer OGTT study. Clin Endocrinol 
(Oxf) 2010;73:339-45.
80. Ravikumar B, Gerrard J, Dalla Man C, et al. Pioglitazone decreases fasting and postprandial 
endogenous glucose production in proportion to decrease in hepatic triglyceride content. Diabetes 
2008;57:2288-95.
81. Holman RR, Thorne KI, Farmer AJ, et al; 4-T Study Group. Addition of biphasic, prandial, or basal 
insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30.
82. Koda JE, Fineman M, Rink TJ, et al. Amylin concentrations and glucose control. Lancet 1992;339:1179-
80.
189
G
eneral discussion and future perspectives
Chapter 10
10
83. Ceriello A, Piconi L, Quagliaro L, et al. Effects of pramlintide on postprandial glucose excursions 
and measures of oxidative stress in patients with type 1 diabetes. Diabetes Care 2005;28:632-7.
84. Ceriello A, Lush CW, Darsow T, et al. Pramlintide reduced markers of oxidative stress in the 
postprandial period in patients with type 2 diabetes. Diabetes Metab Res Rev 2008;24:103-8.
85. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3:153-65.
86. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on 
glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. 
Lancet 2002;359:824-30.
87. Ahren B. The future of incretin-based therapy: novel avenues--novel targets. Diabetes Obes Metab 
2011;13 suppl 1:158-66.
88. Bunck MC, Corner A, Eliasson B, et al. One-year treatment with exenatide vs. insulin glargine: effects 
on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 2010;212:223-9.
89. Wu JD, Xu XH, Zhu J, et al. Effect of exenatide on inflammatory and oxidative stress markers in 
patients with type 2 diabetes mellitus. Diab Tech Ther 2011;13:143-8.
90. Farah NM, Malkova D, Gill JM. Effects of exercise on postprandial responses to ad libitum feeding 
in overweight men. Med Sci Sports Exerc 2010;42:2015-22.
91. Silvestre R, Kraemer WJ, Quann EE, et al. Effects of exercise at different times on postprandial 
lipemia and endothelial function. Med Sci Sports Exerc 2008;40:264-74.
92. Clegg M, McClean CM, Davison WG, et al. Exercise and postprandial lipaemia: effects on peripheral 
vascular function, oxidative stress and gastrointestinal transit. Lipids Health Dis 2007;6:30-5.
93. Gill JMR, Caslake MJ, McAllister C, et al. Effects of short-term detraining on postprandial metabolism, 
endothelial function, and inflammation in endurance-trained men: dissociation between changes 
in triglyceride metabolism and endothelial function. J Clin Endocrinol Metab 2003;88:4328-35. 
94. Johnson BD, Padilla J, Harris RA, Wallace JP. Vascular consequences of a high-fat meal in physically 
active and inactive adults. Appl Physiol Nutr Metab 2011;36:368-75.
95. Zhang JQ, Ji LL, Fogt DL, Fretwell VS. Effect of exercise duration on postprandial hypertriglyceridemia 
in men with metabolic syndrome. J Appl Physiol 2007;103:1339-45.
96. Karpe F. Postprandial lipemia: effect of lipid lowering drugs. Atheroscler Suppl 2002;3:41-6.
97. Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW. Fenofibrate therapy ameliorates 
fasting and postprandial lipoproteinemia, oxidative stress, and inflammatory response in subjects 
with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 2007;30:1945-51.
98. Rosenson RS, Helenowski IB, Tangney CC. Heterogeneous postprandial lipoprotein responses in the 
metabolic syndrome, and response to fenofibrate therapy. Cardiovasc Drugs Ther 2010;24:439-47.
99. Ooi TC, Cousins M, Ooi DS, Nakajima K, Edwards AL. Effect of fibrates on postprandial remnant-
like particles in patients with combined hyperlipidemia. Atherosclerosis 2004;172:375-82.
100. Iovine C, Lilli S, Gentile A, et al. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 
diabetic patients with hyperlipidaemia. Eur J Clin Invest 2006;36:560-5.
General discussion and future perspectivesChapter 10
190
101. Uchida A, Slipchenko MN, Cheng JX, Buhman KK. Fenofibrate, a peroxisome proliferator-activated 
receptor α agonist, alters triglyceride metabolism in enterocytes of mice. Biochim Biophys Acta 
2011;1811:170-6.
102. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart protection study of cholesterol-
lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. 
Lancet 2003;361:2005-16.
103. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with 
atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre 
randomised placebo-controlled trial. Lancet 2004;364:685-96.
104. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins 
after coronary syndromes. N Engl J Med 2004;350:1495-1504.
105. Wilmink HW, Twickler MB, Banga JD, et al. Effect of statin versus fibrate on postprandial endothelial 
dysfunction: role of remnant-like particles. Cardiovasc Res 2001;50:577-82.
106. Ceriello A, Quagliaro L, Piconi L, et al. Effect of postprandial hypertriglyceridemia and hyperglycemia 
on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin 
treatment. Diabetes 2004;53:701-10.
107. Hajer GR, Dallinga-Thie GM, Van Vark-Van der Zee LC, Visseren FL. The effect of statin alone or in 
combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome 
patients. Atherosclerosis 2009;202:216-24.
108. Weintraub MS, Charach G, Grosskopf I. Effects of fibric acid derivatives and metformin on 
postprandial lipemia. Atherosclerosis 1998;141(Suppl 1):S71-5.
109. James AP, Watts GF, Mamo JC. The effect of metformin and rosiglitazone on postprandial lipid 
metabolism in obese insulin-resistant subjects. Diabetes Obes Metab 2005;7:381-9.
110. Lund SS, Tarnow L, Frandsen M, et al. Impact of metformin versus the prandial insulin secretagogue 
repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 
2 diabetes. Eur J Endocrinol 2008;158:35-46.
111. Greenfield MS, Doberne L, Rosenthal M, Vreman HJ, Reaven GM. Lipid metabolism in non-insulin-
dependent diabetes mellitus: effect of glipizide therapy. Arch Intern Med 1982;142:1498-500.
112. Baynes C, Elkeles RS, Henderson AD, Richmond W, Johnston DG. The effects of glibenclamide on 
glucose homeostasis and lipoprotein metabolism in poorly controlled type 2 diabetes. Horm Metab 
Res 1993;25:96-101.
113. Jeppesen J, Zhou MY, Chen YD, Reaven GM. Effect of glipizide treatment on postprandial lipaemia 
in patients with NIDDM. Diabetologia 1994;37;781-7.
114. Skrapari I, Perrea D, Ioannidis I, et al. Glibenclamide improves postprandial hypertriglyceridaemia 
in type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein 
subfraction levels. Diabet Med 2001;18:781-5.
115. Mori Y, Itoh Y, Obata T, Tajima N. Effects of pioglitazone vs glibenclamide on postprandial increases 
in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes. 
Endocrine 2006;29:143-8.
191
G
eneral discussion and future perspectives
Chapter 10
10
116. Vakkilainen J, Mero N, Schweizer A, Foley JE, Taskinen MR. Effects of nateglinide and glibenclamide 
on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes Metab Res Rev 2002;18:484-
90.
117. Mohanlal BH, Holman R. The effect of nateglinide stimulated insulin secretion on post challenge 
glucose and lipid metabolism in type 2 diabetes mellitus. Diabetologia 2002;45:A768.
118. Tentolouris N, Kolia M, Tselepsis AD, et al. Lack of effect of acute repaglinide administration on 
postprandial lipaemia in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 
2003;111:370-3.
119. Hillebrand I, Boehme K, Frank G, Fink H, Berchtold P. The effects of the alpha-glucosidase inhibitor 
BAY g 5421 (Acarbose) on postprandial blood glucose, serum insulin, and triglyceride levels: dose-
time-response relationships in man. Res Exp Med (Berl) 1979;175:87-94.
120. Hanefeld M, Fischer S, Schulze J, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM 
insufficiently treated with diet alone. Diabetes Care 1991;14:732-7.
121. Ogawa S, Takeuchi K, Ito S. Acarbose lowers serum triglyceride and postprandial lipid metabolism 
in type 2 diabetes. Diabetes Obes Metab 2004;6:384-90.
122. Kado S, Murakami T, Aoki A, et al. Effect of acarbose on postprandial lipid metabolism in type 2 
diabetes mellitus. Diabetes Res Clin Pract 1998;41:49-55.
123. Raskin P, Rappaport EB, Cole ST, et al. Rosiglitazone short-term monotherapy lowers fasting and 
postprandial glucose in patients with type II diabetes. Diabetologia 2000;43:278-84.
124. Tan GD, Fielding BA, Currie JM, et al. The effects of rosiglitazone on fatty acid and triglyceride 
metabolism in type 2 diabetes. Diabetologia 2005;48:83-95.
125. Van Wijk JP, De Koning EJ, Castro Cabezas M, Rabelink TJ. Rosiglitazone improves postprandial 
triglyceride and free fatty acid metabolism in type 2 diabetes. Diabetes Care 2005;28:844-9.
126. Van Wijk JP, Hoepelman AI, De Koning EJ, Dallinga-Thie G, Rabelink TJ, Cabezas MC. Differential 
effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy. 
Arterioscler Thromb Vasc Biol 2011;31:228-33.
127. Mieszczanska H, Kaba NK, Francis CW, et al. Effects of pioglitazone on fasting and postprandial 
levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery 
disease. J Thromb Haemost 2007;5:942-9.
128. Jonker JT, Wang Y, de Haan W, et al. Pioglitazone decreases plasma cholesteryl ester transfer protein 
mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabetes. 
Diabetes Care 2010;33:1625-8.
129. Evans M, Anderson RA, Smith JC, et al. Effects of insulin lispro and chronic vitamin C therapy on 
postprandial lipaemia, oxidative stress and endothelial function in patients with type 2 diabetes 
mellitus. Eur J Clin Invest 2003;33:231-8.
130. Gallagher A, Home PD. The effect of improved post-prandial blood glucose control on post-prandial 
metabolism and markers of vascular risk in people with type 2 diabetes. Diabetes Res Clin Pract 
2005;67:196-203.
General discussion and future perspectivesChapter 10
192
131. Schmoelzer I, De Campo A, Pressl H, et al. Biphasic insulin aspart compared to biphasic insulin 
reduces postprandial hyperlipidemia in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 
2005;113:176-81.
132. Ceriello A, Del Prato S, Bue-Valleskey J, et al. Premeal insulin lispro plus bedtime NPH or twice-daily 
NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control 
and cardiovascular risk factors. J Diabetes Complications 2007;21:20-7.
133. Sourij H, Schmoelzer I, De Campo A, et al. Non-glycemic effects of insulin therapy: a comparison 
between insulin aspart and regular human insulin during two consecutive meals in patients with 
type 2 diabetes. Eur J Endocrinol 2011;165:269-74.
134. Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD. Exenatide suppresses 
postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance 
and recent onset type 2 diabetes mellitus. Atherosclerosis 2010;212:217-22.
135. Hsieh J, Longuet C, Baker CL, et al. The glucagon-like peptide 1 receptor is essential for postprandial 
lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 2010;53:552-61.
136. Matikainen N, Manttari S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal 
triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006;49:2049-57.
137. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on 
postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 2011;13:366-73.
138. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 
2005;54:1615-25.
139. Ceriello A, Taboga C, Tonutti L, et al. Evidence for an independent and cumulative effect of 
postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative 
stress generation: effects of short- and long-term simvastatin treatment. Circulation 2002;106:1211-8.
140. Tucker PS, Fisher-Wellman K, Bloomer RJ. Can exercise minimize postprandial oxidative stress in 
patients with type 2 diabetes? Curr Diabetes Rev 2008;4:309-19.
141. Assaloni R, Da Ros R, Quagliaro L, et al. Effects of S21403 (mitiglinide) on postprandial generation 
of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia 2005;48:1919-24.
142. Stephens JW, Bodvarsdottir TB, Wareham K, et al. Effects of short-term therapy with glibenclamide and 
repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia 
in subjects with type 2 diabetes mellitus. Diabetes Res Clin Pract 2011 Aug 9. [Epub ahead of print]
143. Ceriello A, Quagliaro L, Piconi L, et al. Effect of postprandial hypertriglyceridemia and hyperglycemia 
on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin 
treatment. Diabetes 2004;53:701-10.
144. Ceriello A, Assaloni R, Da Ros R, et al. Effect of atorvastatin and irbesartan, alone and in combination, 
on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. 
Circulation 2005;111:2518-24.
145. Plotnick GD, Corretti MC, Vogel R. Effect of antioxidant vitamins on the transient impairment 
of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA 
1997;278:1682-6.
193
G
eneral discussion and future perspectives
Chapter 10
10
146. Beckman JA, Goldfine AB, Gordon MB, Creager MA. Ascorbate restores endothelium-dependent 
vasodilation impaired by acute hyperglycemia in humans. Circulation 2001;103:1618-23.
147. Neri S, Signorelli SS, Torrisi B, et al. Effects of antioxidant supplementation on postprandial oxidative 
stress and endothelial function: a single-blind, 15 day clinical trial in patients with untreated type 2 
diabetes, subjects with impaired glucose tolerance, and healthy controls. Clin Ther 2005;27:1764-73.
148. Goto S, Tamura N, Li M, et al. Different effects of various anti-GPIIb-IIIa agents on shear-induced 
platelet activation and expression of procoagulant activity. J Thromb Haemost 2003;1:2022-30.
149. Nomura S, Shouzu A, Omoto S, et al. Effect of cilostazol on soluble adhesion molecules and platelet-
derived microparticles in patients with diabetes. Thromb Haemost 1998;80:388-92.
150. Harrison M, Murphy RP, O’Connor PL, et al. The endothelial microparticle response to a high fat 
meal is not attenuated by prior exercise. Eur J Appl Physiol 2009;106:555-62.
151. Nomura S, Omoto S, Yokoi T, et al. Effects of miglitol in platelet-derived microparticle, adiponectin, 
and selectin level in patients with type 2 diabetes mellitus. Int J Gen Med 2011;4:539-45.
152. Shimazu T, Inami N, Satoh D, et al. Effect of acarbose on platelet-derived microparticles, soluble 
selectins, and adiponectin in diabetic patients. J Thromb Thrombolysis 2009;28:429-35.
153. Diamant M, Tushuizen ME, Abid-Hussein MN, Hau CM, Boing AN, Sturk A, Nieuwland R. 
Simvastatin-induced endothelial cell detachment and microparticle release are prenylation dependent. 
Thromb Haemost 2008;100:489-97.
154. Esposito K, Ciotola M, Giugliano D. Pioglitazone reduces endothelial microparticles in the metabolic 
syndrome. Arterioscl Thromb Vasc Biol 2006;26:1926.
155. Rössig L, Hoffmann J, Hugel B, et al. Vitamin C inhibits endothelial cell apoptosis in congestive heart 
failure. Circulation 2001;104:2182-7.
156. Rein D, Paglieroni TG, Wun T, et al. Cocoa inhibits platelet activation and function. Am J Clin Nutr 
2000;72:30-5.
157. Reddigan JI, Riddell MC, Kuk JL. The joint association of physical activity and glycaemic control 
in predicting cardiovascular death and all-cause mortality in the US population. Diabetologia 2011 
Nov 13. [Epub ahead of print]
158. Dunstan DW, Barr EL, Healy GN, et al. Television viewing time and mortality: the Australian Diabetes, 
Obesity and Lifestyle Study (AusDiab). Circulation 2010;121:384-91.
159. Look AHEAD Research Group, Wing RR. Long-term effects of a lifestyle intervention on weight 
and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the 
Look AHEAD trial. Arch Intern Med 2010;170:1566-75.
160. Schwandt P, Haas GM, Liepold E. Lifestyle and cardiovascular risk factors in 2001 child-parent pairs: 
the PEP Family Heart Study. Atherosclerosis 2010;213:642-8.
161. Gulliksson M, Burell G, Vessby B, Lundin L, Toss H, Svardsudd K. Randomized controlled trial of 
cognitive behavioral therapy vs standard treatment to prevent recurrent cardiovascular events in 
patients with coronary heart disease: secondary prevention in Uppsala primary health care project 
(SUPRIM). Arch Intern Med 2011;17:134-40.
General discussion and future perspectivesChapter 10
194
162. Sjostrom L, Narbro K, Sjostrom D, et al. Effects of bariatric surgery on mortality in Swedish obese 
subjects. New Engl J Med 2007;357:741-52.
163. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J 
Med 2007;357:753-61.
164. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the 
risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the 
STOP-NIDDM trial. JAMA 2003;290:486-94.
165. Holman RR, Haffner SM, McMurray JJ, et al: NAVIGATOR Study Group. Effect of nateglinide on 
the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1463-76.
166. Raz I, Wilson PWF, Strojek K, et al. Effects of prandial versus fasting glycemia on cardiovascular 
outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32:381-6.
167. Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S. Meglitinide analogues for type 
2 diabetes mellitus. Cochrane Database Syst Rev 2007:CD004654.
168. Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular 
events and cancer: a randomized controlled trial. JAMA 2005, 293:1338-47.
169. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant 
vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. 
Lancet 2002;360:23-33.
170. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people 
with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25.
171. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-
analysis of randomized statin trials. Lancet 2010;375:735-42.
172. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol 
and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. 
Implications for treatment. Circulation 1992;85:37-45.
173. Rubins Hb, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart 
disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density 
lipoprotein cholesterol intervention trial study group. N Engl J Med 1999;341:410-8.
174. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events 
in 9795 people with type 2 diabetes mellitus (the FIELD-study): randomized controlled trial. Lancet 
2005;366:1849-61.
175. Nissen SE, Wolski KW. Effect of rosiglitazone on the risk of myocardial infarction and death from 
cardiovascular causes. N Engl J Med 2007;356:2457-71.
176. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in 
patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In 
macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
177. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with 
pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011;34:916-22.
195
G
eneral discussion and future perspectives
Chapter 10
10
178. Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and 
bladder cancer through drug adverse event reporting. Diabetes Care 2011;34:1369-71.
179. EXCEL outcome trial exenatide once weekly: http://clinicaltrials.gov/ct2/show/NCT01144338
180. TECOS outcome trial sitagliptin: http://clinicaltrials.gov/ct2/show/NCT00790205
181. LEADER outcome trial liraglitude: http://clinicaltrials.gov/ct2/show/NCT01179048
182. Best JH, Hoogwerf BJ, Herman WH, et al. Risk of cardiovascular disease events in patients with type 
2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or 
other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 
2011;34:90-5.
183. Schweizer A, DeJager S, Foley JE, Couturier M, Ligueros-Saylan M, Kothny W. Assessing the cardio-
cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 
2 diabetes population. DOM 2010;12:485-94.
184. Marso SP, Lindsey JB, Stolker JM, et al. Cardiovascular safety of liraglutide assessed in a patient-level 
pooled analysis of phase 2—3 liraglutide clinical development studies. Diabetes Vasc Dis Res 2011 
8: 237-40.
185. Kootte RS, Vrieze A, Holleman F, et al. The therapeutic potential of manipulating gut microbiotica 
in obesity and type 2 diabetes mellitus. Diabetes Obes Metab 2011 Aug 3. [epub ahead of print]
186. Diamant M, Blaak EE, De Vos WM. Do nutrient-gut-microbiota interactions play a role in human 
obesity, insulin resistance and type 2 diabetes? Obes Rev 2010;12:272-81.
General discussion and future perspectivesChapter 10
196
11
Samenvatting voor de 
geïnteresseerde leek
SamenvattingChapter 11
198
Het voorkomen  van (ernstig) overgewicht of obesitas neemt wereldwijd ernstige vormen 
aan, met name door het overnemen van de zogenaamde Westerse leefstijl, dat wil zeggen 
hoge calorie-inname en weinig lichamelijke beweging. Deze verandering in leefstijl met 
bijkomend overgewicht leidt tot ongevoeligheid voor het hormoon insuline, een hormoon 
dat onder andere een belangrijke rol speelt bij de suiker- en vetstofwisseling. Door deze 
ongevoeligheid of resistentie kan insuline, dat dus wel aanwezig is, niet goed zijn werking 
hebben. Dit leidt tot hoge concentraties van insuline in het bloed, verhoogde bloeddruk 
en een gestoord vet- of lipidenmetabolisme, allemaal bekende risicofactoren voor het 
ontwikkelen van hart- en vaatziekten. Deze combinatie van factoren wordt het metabool 
syndroom genoemd en dit syndroom speelt een belangrijke rol bij het ontwikkelen van type 
2 diabetes mellitus, (voorheen ook wel ‘ouderdomssuikerziekte’ genoemd). Bij personen die 
hier namelijk een genetische aanleg voor hebben, kan de voortdurende vraag naar insuline 
resulteren in het tekort schieten van de insuline-producerende cellen in de alvleesklier, 
of te wel de betacellen. Hierdoor ontstaat onder andere een (te) hoge bloedsuiker en dus 
type 2 diabetes mellitus. 
Bij mensen die insuline-ongevoelig zijn en type 2 diabetes mellitus hebben, zullen de 
stofwisselingsstoornissen meer uitgesproken worden wanneer zij een maaltijd eten. 
Hierdoor ontstaan tijdelijk nog hogere concentraties van suiker (glucose), vetdeeltjes 
(triglyceriden en vrije vetzuren) en insuline in het bloed. Omdat het langer duurt 
voordat deze verstoringen verwerkt zijn en men meerdere maaltijden per dag eet, zijn de 
bloedvaten bijna 24 uur per dag blootgesteld aan een milieu waarin gemakkelijk ontsteking, 
bloedstolling en (daardoor) aderverkalking (atherosclerose) ontstaan. 
Patiënten met type 2 diabetes hebben een sterk verhoogd risico op het ontwikkelen van 
hart- en vaatziekten. De zogenaamde ‘klassieke’ risicofactoren hiervoor zijn roken, hoge 
bloeddruk en hoog cholesterolgehalte. Deze factoren kunnen echter het hoge risico 
voor hart- en vaatziekten bij patiënten met type 2 diabetes maar deels verklaren. Het 
is niet ondenkbaar dat de stofwisselingsstoornissen die optreden na de maaltijd, ofwel 
postprandiaal, leiden tot verstoringen aan de bloedvatwand en bijdragen aan het ontstaan 
van hart- en vaatziekten. Aanwijzingen voor deze relatie worden in Hoofdstuk 1a uitgebreid 
besproken en samengevat aan de hand van de literatuur.  
In dit proefschrift hebben we de relatie tussen postprandiale verstoringen in onder andere 
glucose, insuline en vetdeeltjes, en het risico op het ontstaan van hart- en vaatziekten 
bestudeerd  bij mensen met een verhoogd risico hierop. Verder hebben we mogelijke 
onderliggende mechanismen, zoals toename van oxidatieve stress, verstoring van functie 
van de vaatwandbekleding (endotheel) en veranderingen in aantallen en samenstelling 
van zogenaamde micropartikels, na het nuttigen van maaltijden bestudeerd. 
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Micropartikels zijn blaasjes die afgesnoerd worden door diverse cellen in lichaamsvloeistoffen, 
zoals bloed en speeksel, tijdens activatie en celdood (apoptose). Deze micropartikels 
vormen een heterogene populatie en hun aantal, cellulaire herkomst, samenstelling en 
functionele eigenschappen hangen nauw samen met de omstandigheden die tot hun 
ontstaan hebben geleid. In het bloed van gezonde personen zijn micropartikels aanwezig 
die met name afkomstig zijn van bloedplaatjes (trombocyten), maar in geringere mate 
ook van witte bloedcellen (lymfocyten, leukocyten), rode bloedcellen (erytrocyten) en 
endotheelcellen. De stolling, veruit de bekendste eigenschap van micropartikels, wordt 
gefaciliteerd door de aanwezigheid van negatief geladen fosfolipiden op het micropartikel-
oppervlak en, soms, door de expositie van weefselfactor. Daarnaast zijn micropartikels ook 
betrokken bij ontstekingsreacties, het moduleren van endotheelfuncties, het bevorderen van 
celgroei, chemotaxis, apoptose en het uitgroeien van getransplanteerde hematopoëtische 
stamcellen. Op grond van hun functionele eigenschappen vormen micropartikels mogelijk 
de ontbrekende schakel tussen de verschillende processen die ten grondslag liggen aan het 
ontstaan van atherosclerotische vaatschade. In Hoofdstuk 1b bespreken we uitgebreid de 
mogelijke rol van micropartikels bij het ontstaan van hart- en vaatziekten.
Voorgaande onderzoeken waarbij het effect van een maaltijd op risicofactoren voor het 
ontstaan van hart- en vaatziekten werd gemeten, maakten gebruik van slechts 1 maaltijd, 
vaak vloeibaar van samenstelling, waarna vervolgens tot 8 uur allerlei metingen werden 
verricht. Dit terwijl men in het dagelijks leven meerdere (vaste) maaltijden per dag 
nuttigt. Om eerder genoemde mogelijke relatie tussen verschillende componenten van 
postprandiale metabole verstoringen en risicofactoren voor het ontwikkelen van hart- en 
vaatziekten te bestuderen, kozen wij vervolgens  voor een uitgebreide onderzoeksopzet. 
Om de rol van hoge bloedglucosewaarden te ontrafelen, hebben we metingen verricht 
bij mannen met het metabool syndroom (overgewicht, verhoogde bloeddruk, gestoorde 
vetstofwisseling) zonder gestoorde bloedglucosewaarden en bij mannen die dat wel 
hadden, dus type 2 diabetes mellitus. Om vervolgens de bijdrage van het metabool 
syndroom te meten, hebben we beide groepen vergeleken met gezonde mannen van 
gelijke leeftijd. Door deze mannen gedurende 24 uur te observeren, waarbij zij 3 vaste 
gestandaardiseerde maaltijden kregen voorgeschoteld als ontbijt, lunch en avondeten op 
vaste tijdstippen, konden wij diverse aspecten van onder andere het vetmetabolisme bij 
deze groepen deelnemers bestuderen. Het is mogelijk dat de hoeveelheid vet in de lever 
hierbij een belangrijke rol speelt omdat de lever van belang is voor de vetstofwisseling 
en een vervette lever, de zogenaamde Non-Alcoholic Fatty Liver Disease (NAFLD), vaak 
voorkomt bij mensen met het metabool syndroom en type 2 diabetes. In Hoofdstuk 2 
laten we zien dat meerdere  maaltijden, genuttigd als ontbijt, lunch en avondeten, bij 
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mannen met het metabool syndroom en met type 2 diabetes, inderdaad leidt tot hogere 
concentraties van vetdeeltjes in het bloed, vergeleken met gezonde mannen. De hoeveelheid 
vet in de lever blijkt hierin van belang te zijn: hoe meer levervet, hoe hoger de verstoringen 
waren. Daarnaast beschrijven we in Hoofdstuk 4 dat de hoeveelheid levervet effect heeft 
op de verzadiging van HDL-cholesteroldeeltjes (het zogenaamde ‘goede cholesterol’) 
met vetdeeltjes na 3 maaltijden, waardoor deze HDL-cholesteroldeeltjes minder goed 
functioneren. Niet alleen vonden we dat de functie van het HDL-cholesterol verstoord 
raakte, ook een functie van de binnenbekleding van de vaatwand, het endotheel, werd 
gestoord na het nuttigen van de 3 maaltijden, vooral bij de mannen met type 2 diabetes.
De postprandiale veranderingen in HDL- en LDL (het ‘slechte’ cholesterol)-cholesteroldeel-
tjes hebben we nader bestudeerd. De resultaten hiervan staan beschreven in Hoofdstuk 
3. We laten zien dat de (langdurig) verhoogde concentraties van vetdeeltjes in het bloed 
na de maaltijd, zoals we zien bij het metabool syndroom en type 2 diabetes, resulteert 
in verzadiging van de HDL- en LDL-deeltjes, waardoor deze ontvankelijk worden voor 
oxidatie en hierdoor kunnen bijdragen aan het ontstaan van hart- en vaatziekten. 
Ten tijde van het opstarten van het onderzoek was nog niet bekend wat het effect is van 
postprandiale veranderingen op de vorming en samenstelling van micropartikels. Daarom 
hebben wij allereerst bij gezonde jonge mannen uitgezocht wat het effect is van 2 gestan-
daardiseerde, vaste en opeenvolgende maaltijden (ontbijt en lunch) op deze celblaasjes in 
combinatie met eerdergenoemde risicofactoren, en vergeleken we dit met de resultaten 
van een dag waarop de deelnemers nuchter bleven. In Hoofdstuk 5 beschrijven we dat 
bij deze gezonde jonge mannen de veranderingen die optreden in de concentraties van 
glucose, vetdeeltjes en insuline in het bloed na inname van 2 vetrijke maaltijden,  al leiden 
tot verhoogde oxidatieve stress, disfunctioneren van het endotheel en verhoogde aantallen 
micropartikels, in vergelijking met de nuchtere dag. 
Omdat de postprandiale periode en micropartikels beiden in relatie worden gebracht 
met de bloedstolling, hebben we bestudeerd of de gevonden veranderingen in aantallen 
micropartikels gerelateerd waren aan bloedstolling. Deze resultaten worden beschreven 
in Hoofdstuk 6. Niet alleen bestudeerden we de aantallen micropartikels, maar ook hun 
cellulaire herkomst, samenstelling en eigenschap om bloedstolling in het laboratorium 
te bevorderen. Hierbij vonden we dat in de postprandiale periode vooral het aantal 
micropartikels afkomstig van rode bloedcellen verhoogd raakt. Daarnaast zagen we dat er 
veranderingen optraden in de samenstelling van de wand van de micropartikels, namelijk 
van de zogenaamde fosfolipiden, waaruit de wand voor een groot deel bestaat. Ondanks 
de verhoogde aantallen en veranderingen in de fosfolipidensamenstelling zagen we geen 
verandering in de bloedstolling, zowel in het bloed van de deelnemers tijdens de testdagen 
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als bij het bestuderen van de stollingsbevorderende eigenschappen van de micropartikels 
in het laboratorium. 
In Hoofdstuk 7 beschrijven we het effect van de metabole verstoringen die ontstaan na 
het nuttigen van 3 maaltijden (ontbijt, lunch en avondeten) op aantallen en herkomst 
van micropartikels bij mannen van middelbare leeftijd met en zonder het metabool 
syndroom. Verder onderzochten we of deze eventuele veranderingen gerelateerd waren 
aan de stijfheid van de bloedvaten. De stijfheid van de bloedvaten is een risicofactor voor 
het ontstaan van hart- en vaatziekten: hoe stijver de bloedvatwand, hoe hoger het risico. 
We laten zien dat er veranderingen in de aantallen micropartikels van rode bloedcellen 
en van geactiveerde witte bloedcellen en bloedplaatjes optraden bij de mannen met het 
metabool syndroom. Opvallend is dat deze bepaalde subpopulaties zowel positief als 
negatief gerelateerd waren aan de stijfheid van de bloedvaten. Zo waren hogere aantallen 
van bloedplaatjes afkomstige micropartikels gerelateerd aan een verminderde stijfheid 
van de bloedvaten. Deze bevindingen passen bij de gedachte dat micropartikels niet alleen 
nadelige gevolgen hebben.   
Bij mannen met type 2 diabetes vonden we dat de metabole verstoringen die optraden na 
het eten van de 3 maaltijden leidden tot verhoogde aantallen van micropartikels afkomstig 
van de binnenbekleding van bloedvaten (endotheel). Niet alleen waren deze aantallen 
gerelateerd aan de hoogte van de vetdeeltjes-, glucose- en insulineconcentraties, ook 
hingen deze aantallen micropartikels samen met een functie van het endotheel, namelijk 
het zogenaamde vaatverwijdende vermogen hiervan. Deze resultaten staan beschreven 
in Hoofdstuk 8. 
In Hoofdstuk 9 gaan we uitvoerig in op de rol die micropartikels zouden kunnen spelen 
in het ontstaan van hart- en vaatziekten. We beschrijven dat micropartikels niet alleen 
nadelige gevolgen kunnen hebben, maar zelfs ook gunstige gevolgen. Het afsnoeren van 
micropartikels door cellen zou beschouwd kunnen worden als het afgeven van vuilniszakjes 
waardoor de cel gevrijwaard blijft van schadelijke prikkels afkomstig van zowel binnen als 
van buiten de cel. Hierdoor draagt de afsnoering van micropartikels bij aan de vitaliteit 
en overleving van de cel.
Samenvattend, bij mannen met het metabool syndroom en mannen met type 2 diabetes 
wordt de postprandiale staat gekarakteriseerd door verhoogde concentraties van schadelijke 
vetdeeltjes in het bloed, die vervolgens ook daarin langer blijven circuleren vergeleken met 
gezonde mannen. Dit wordt voor een deel verklaard door de verhoogde hoeveelheid vet in 
de lever, voor een ander deel door verhoogde glucoseconcentraties bij type 2 diabetes. Deze 
postprandiale metabole verstoringen leiden tot verhoogde oxidatieve stress, verstoringen 
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van de functie van het endotheel en de afsnoering van micropartikels door verschillende 
cellen. Hierdoor zouden verstoringen in het postprandiale metabolisme bij kunnen dragen 
aan het ontstaan van hart- en vaatziekten, vooral bij populaties met een verhoogd risico 
hierop zoals mensen met het metabool syndroom en type 2 diabetes.
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Martinus Everardus (‘Maarten’) Tushuizen was born on September 3rd, 1974 at the Free 
University Hospital in Amsterdam, The Netherlands. After graduation from secondary 
school (pre-university education, Geert Groote School, Amsterdam) in 1993, he did not 
pass the numerus clausus for Medicine and started studying Medical Biology at the Free 
University, Amsterdam and obtained his propaedeutic diploma in 1994. After a year 
he could switch to medicine at the Free University and graduated as a medical doctor 
(MD) in July 2001. From September 2001 until December 2006, he was a PhD student 
at the Diabetes Center at the Department of Internal Medicine (than Department of 
Endocrinology) of the VU University Medical Center in Amsterdam, under supervision 
of Prof. Michaela Diamant, in collaboration with the Laboratory of Experimental Clinical 
Chemistry of the Academic Medical Center in Amsterdam, under supervision of Prof. 
Auguest Sturk and Dr. Rienk Nieuwland. Most of the results of these years of research are 
described in this thesis. He started his training in Internal Medicine in January 2007 at 
the Rijnland Hospital in Leiderdorp, under supervision of Dr. Frans Cluitmans and Dr. 
Martien Janssen, affiliated with Leiden University Medical Center, Leiden, The Netherlands. 
In January 2009 he switched specialty training and started training in Gastroenterology 
and Hepatology at Medical Center Alkmaar in Alkmaar under supervision of Dr. Hans 
Tuynman, affiliated with the VU University Medical Center. In 2010 he continued his 
training at the Department of Gastroenterology and Hepatology at the VU University 
Medical Center, supervised by Prof. Chris Mulder. During his training he was visiting 
fellow/specialty registrar Hepatology at the Erasmus Medical Center, Rotterdam, The 
Netherlands and the Queen Elizabeth University Medical Centre, Birmingham, United 
Kingdom. Maarten is married with Fleur and together they have two children (Tom and 
Julianne) and are expecting a third.
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Martinus Everardus (‘Maarten’) Tushuizen werd geboren op 3 september 1974 in het VU 
Ziekenhuis te Amsterdam. Na het afronden van de middelbare school in 1993 (VWO, Vrije 
School Geert Groote te Amsterdam), werd hij uitgeloot voor de studie Geneeskunde en 
ging hij Medische Biologie studeren aan de Vrije Universiteit te Amsterdam. Na het behalen 
van zijn propedeuse in 1994 werd hij ingeloot voor de studie Geneeskunde aan dezelfde 
universiteit en behaalde in juli 2001 zijn artsexamen. Van september 2001 tot januari 2007 
was hij arts-onderzoeker bij het Diabetescentrum van de afdeling Interne Geneeskunde 
(aanvankelijk afdeling Endocrinologie) van het VU medisch centrum, onder leiding van 
Prof. Dr. M. Diamant en in samenwerking met het Laboratorium van Experimentele 
Klinische Chemie van het Academisch Medisch Centrum te Amsterdam, onder leiding 
van Prof. Dr. A. Sturk en Dr. R. Nieuwland. Een groot deel van het verrichte onderzoek 
is beschreven in dit proefschrift. In januari 2007 begon hij als internist in opleiding in 
het Rijnland Ziekenhuis te Leiderdorp met als opleiders Dr. F.H. Cluitmans en Dr. M.J. 
Janssen, geaffilieerd aan het Leids Universitair Medisch Centrum te Leiden. In januari 2009 
wisselde hij van opleiding en begon als maag-, darm- en lever(MDL)-arts in opleiding in 
het Medisch Centrum Alkmaar te Alkmaar, met als opleider H.A. Tuynman, geaffilieerd 
aan het VU medisch centrum te Amsterdam. In 2010 vervolgde hij zijn opleiding in het 
VU medisch centrum met als opleider Prof. Dr. C.J. Mulder. Gedurende zijn opleiding 
volgde hij stages Hepatologie in het Erasmus Medisch Centrum te Rotterdam en het 
Queen Elizabeth University Medical Centre te Birmingham, Verenigd Koninkrijk. Maarten 
is getrouwd met Fleur en zij hebben samen twee kinderen (Tom en Julianne) en zijn in 
verwachting van een derde. 
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